Europe PMC Funders Group Author Manuscript *Cochrane Database Syst Rev.* Author manuscript; available in PMC 2014 September 18.

Published in final edited form as: Cochrane Database Syst Rev.; (3): CD007076. doi:10.1002/14651858.CD007076.pub2.

Pregabalin for acute and chronic pain in adults

R Andrew Moore¹, Sebastian Straube², Philip J Wiffen³, Sheena Derry¹, and Henry J McQuay¹

¹Pain Research and Nuffield Department of Anaesthetics, University of Oxford, Oxford, UK

²Department of Occupational and Social Medicine, University of Göttingen, Göttingen, Germany

³UK Cochrane Centre, Oxford, UK

Abstract

Background—Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is a recently developed antiepileptic drug also used in management of chronic neuropathic pain conditions.

Objectives—To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain.

Search methods—We searched MEDLINE, EMBASE, and CENTRAL to May 2009 for randomised controlled trials (RCTs). Additional studies were identified from the reference lists of retrieved papers and on-line clinical trial databases.

Selection criteria—Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome.

Data collection and analysis—Two independent review authors extracted data and assessed trial quality. Numbers-needed-to-treat-to-benefit (NNTs) were calculated, where possible, from dichotomous data for effectiveness, adverse events and study withdrawals.

DECLARATIONS OF INTEREST

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Contact address: Maura Moore, Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, OX3 9DU, UK. maura.moore@pru.ox.ac.uk.

CONTRIBUTIONS OF AUTHORS

PW registered the title and wrote the protocol. SS, SD, RAM, and HJM contributed to the final draft and approved the published version.

RAM and SS carried out searching, identified studies for inclusion, and carried out data extraction. All authors were involved with analysis and writing.

SD will be responsible for the update of this review.

Editorial group: Cochrane Pain, Palliative and Supportive Care Group.

Publication status and date: Edited (no change to conclusions), published in Issue 11, 2010.

Review content assessed as up-to-date: 10 May 2009.

SD, RAM and HJM have received research support from charities, government and industry sources at various times. RAM and HJM have consulted for various pharmaceutical companies. RAM, and HJM have received lecture fees from pharmaceutical companies related to analgesics and other healthcare interventions. PW is a full time employee of the UK Cochrane Centre funded by the UK National Institute of Health Research. SS: no conflicts known.

Main results—There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain. No studies evaluated pregabalin in chronic nociceptive pain, like arthritis.

Pregabalin at doses of 300 mg, 450 mg, and 600 mg daily was effective in patients with postherpetic neuralgia, painful diabetic neuropathy, central neuropathic pain, and fibromyalgia (19 studies, 7003 participants). Pregabalin at 150 mg daily was generally ineffective. Efficacy was demonstrated for dichotomous outcomes equating to moderate or substantial pain relief, alongside lower rates for lack of efficacy discontinuations with increasing dose. The best (lowest) NNT for each condition for at least 50% pain relief over baseline (substantial benefit) for 600 mg pregabalin daily compared with placebo were 3.9 (95% confidence interval 3.1 to 5.1) for postherpetic neuralgia, 5.0 (4.0 to 6.6) for painful diabetic neuropathy, 5.6 (3.5 to 14) for central neuropathic pain, and 11 (7.1 to 21) for fibromyalgia.

With 600 mg pregabalin daily somnolence typically occurred in 15% to 25% and dizziness occurred in 27% to 46%. Treatment was discontinued due to adverse events in 18 to 28%. The proportion of participants reporting at least one adverse event was not affected by dose, nor was the number with a serious adverse event, which was not more than with placebo.

Higher rates of substantial benefit were found in postherpetic neuralgia and painful diabetic neuropathy than in central neuropathic pain and fibromyalgia. For moderate and substantial benefit on any outcome NNTs for the former were generally six and below for 300 mg and 600 mg daily; for fibromyalgia NNTs were much higher, and generally seven and above.

Authors' conclusions—Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia. A minority of patients will have substantial benefit with pregabalin, and more will have moderate benefit. Many will have no or trivial benefit, or will discontinue because of adverse events. Individualisation of treatment is needed to maximise pain relief and minimise adverse events. There is no evidence to support the use of pregabalin in acute pain scenarios.

Medical Subject Headings (MeSH)

Acute Disease; Analgesics [administration & dosage; *therapeutic use]; Chronic Disease; Diabetic Neuropathies [drug therapy]; Fibromyalgia [drug therapy]; Neuralgia, Postherpetic [drug therapy]; Pain [*drug therapy]; Randomized Controlled Trials as Topic; gamma-Aminobutyric Acid [administration & dosage; *analogs & derivatives; therapeutic use]

MeSH check words

Adult; Humans

BACKGROUND

Chronic pain is usually defined as pain experienced for a period of about three to six months during which it is felt every day or almost every day. Any pain that is not chronic is acute, though there are always special circumstances, using these definitions, where either or neither are entirely satisfactory.

Moore et al.

Chronic pain is a major health problem affecting one in five people in Europe (Fricker 2004), though data for the incidence of neuropathic pain (pain resulting from a disturbance of the central or peripheral nervous system) is more difficult to obtain. Antiepileptic drugs have been used in pain management since the 1960s, very soon after they were first used generally in medicine. The clinical impression is that they are useful for neuropathic pain (e.g. painful diabetic neuropathy, post herpetic neuralgia), especially when the pain is lancinating or burning (Jacox 1994). Although these neuropathic pain disorders are not common (with the incidence of trigeminal neuralgia being four in 100,000 per year (Rappaport 1994)), they can be very disabling.

There is evidence for the effectiveness of a number of antiepileptics including carbamazepine, gabapentin, phenytoin and valproate; these are considered in other reviews published by the Cochrane Pain, Palliative and Supportive Care review group (Wiffen 2005a; Wiffen 2005b; Wiffen 2005c). Antiepileptics are sometimes prescribed in combination with antidepressants, as in the treatment of post-herpetic neuralgia (PHN) (Monks 1994). In the UK carbamazepine and phenytoin are licensed for the treatment of pain associated with trigeminal neuralgia, and gabapentin and pregabalin for the treatment of neuropathic pain.

The use of antiepileptic drugs in chronic pain has tended to be confined to neuropathic pain (like painful diabetic neuropathy, PDN), rather than nociceptive pain (like arthritis). However, some trials have examined the utility of this class of drugs in acute pain conditions. It is therefore probably useful to extend the scope of this first Cochrane review of pregabalin to seek studies that have been conducted in acute pain conditions. Acute pain is generally as poorly treated as chronic pain.

Pregabalin has a mechanism of action similar to gabapentin, binding to calcium channels and modulating calcium influx as well as influencing GABergic neurotransmission. This mode of action confers anti-epileptic, analgesic, and anxiolytic effects. It is more potent than gabapentin and therefore used at lower doses. Pregabalin, as LyricaTM, is licensed for the treatment of peripheral and central neuropathic pain in adults. Guidance suggests that pregabalin treatment can be started at a dose of 150 mg per day for treating neuropathic pain. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after an interval of three to seven days, and if needed, to a maximum dose of 600 mg per day after an additional seven-day interval (EMC 2007). European approval for marketing was granted in 2004 and US approval in 2005.

This review is an extension to the published review in *The Cochrane Library* on 'Anticonvulsants in acute and chronic pain' (Wiffen 2005a). Because pregabalin has been introduced within the last few years, with a number of trial reports now becoming available, a review specific to this drug is appropriate at this time.

A particular issue with pregabalin is that of dose and dose escalation with different upper limits used in different trials. In standard clinical trials there is known to be a significant dose-response (Straube 2008). Another is the possible impact of enriched enrolment on the efficacy reported in trials, although the rather small amount of partial enrichment that could

occur in most trials is without any significant effect (Straube 2008). More interesting is the publication of the results of a trial with complete enrichment, randomised withdrawal (EERW) design (Crofford 2008). This is the largest, longest, and best example of this trial design in pain (McQuay 2008a), and offers a potential challenge to interpretation of clinical trial data. Dose, but not degree of enrichment, has been shown to be important for pregabalin (Straube 2008).

OBJECTIVES

- 1. To assess the analgesic efficacy of pregabalin for acute pain and for chronic pain in adults.
- 2. To assess the adverse events associated with the clinical use of pregabalin for pain.

METHODS

Criteria for considering studies for this review

Types of studies—Studies were included in this review if they were randomised controlled trials (RCTs), reported to be double-blind, and investigating the analgesic effects of pregabalin, with pain assessment as either the primary or secondary outcome. Full journal publication or summary clinical trial reports were required, with brief abstracts not included. For chronic pain, participants were required to have had a diagnosed condition for at least three months.

Studies that were non-randomised, studies of experimental pain, case reports, clinical observations or studies of pregabalin used to treat pain produced by other drugs were excluded.

Types of participants—Adults aged 18 years or more, who:

- reported pain in the acute pain setting or were studied in situations (postoperative, for example) where pain was anticipated; or
- had one or more of a wide range of chronic or neuropathic pains including diabetic neuropathy, post herpetic neuralgia (PHN), phantom limb pain, Guillain Barré, and spinal cord injury;
- had any other chronic painful condition.

For chronic pain the predominant presenting neuropathic pain conditions were analysed separately.

Types of interventions—Administration of pregabalin, in any dose, by any route to achieve analgesia. Studies had to include placebo control or any active control as comparisons.

Types of outcome measures—A variety of outcome measures were used in the studies. For acute pain studies we expected to identify assessment at 6 hours post-treatment. For

Moore et al.

In chronic pain the majority of studies were expected to use standard subjective scales for pain intensity or pain relief, or both. A hierarchy of pain-related outcome measures in chronic pain was agreed as follows:

- 1. patient reported pain relief of 30% or greater;
- 2. patient reported pain relief of 50% or greater;
- 3. patient reported global impression of clinical change (PGIC);
- 4. pain on movement;
- 5. pain on rest;
- 6. any other pain related measure;
- 7. adverse effects with a sub group analysis of older people if data were available.

Particular attention was paid to IMMPACT definitions for moderate and substantial benefit in chronic pain studies (Dworkin 2008). These were defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on PGIC (moderate), and very much improved on PGIC (substantial).

In acute pain the most likely outcome measure anticipated was analgesic consumption in perioperative use of pregabalin.

For both chronic and acute pain situations, various adverse event outcomes were sought:

- number of participants with at least one adverse event;
- number of participants with at least one serious adverse event;
- number of participants experiencing particular adverse events (somnolence and dizziness);
- all-cause withdrawals;
- lack of efficacy withdrawals;
- adverse event withdrawals.

Search methods for identification of studies

Studies were identified by several methods. RCTs of pregabalin (and key brand name: Lyrica) in acute, chronic or cancer pain were identified using:

- MEDLINE (PubMed) from 1990 to May 2009;
- EMBASE (Ovid) from 1990 to May 2009;
- Cochrane CENTRAL, Issue 2, 2009.

Additional studies were sought from reference lists of the retrieved papers, and by searching the Internet for summary clinical trial reports not available as full publications. Given the

limited literature in this area, a general search strategy was undertaken. See Appendix 1, Appendix 2, and Appendix 3 for the MEDLINE, EMBASE and CENTRAL search strategies. The PhRMA clinical study results database (www.clinicalstudyresults.org/) was interrogated for trial results of pregabalin (Lyrica) in painful conditions.

Data collection and analysis

Eligibility was determined by reading each study identified by the search. All studies were read independently by two review authors and agreement reached by discussion. The studies were not anonymised before assessment.

Information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), study duration and follow-up, analgesic outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event, or serious adverse event) were extracted from each study and recorded on a data extraction sheet.

QUOROM guidelines were followed (Moher 1999). For efficacy analyses we used the number of participants in each treatment group who were randomised, received medication, and provided at least one post-baseline assessment. For safety analyses we used the number of participants who received study medication in each treatment group.

Number needed to treat to benefit (NNT) was calculated as the reciprocal of the absolute risk reduction (ARR) (McQuay 1998). For unwanted events, the NNT becomes the number needed to treat to harm (NNH), and is calculated in the same manner. Dichotomous data was used to calculate relative risk (RR) with 95% confidence intervals (CIs) using a fixed-effect model. Continuous data (if available) would be entered into RevMan 5.0 using the appropriate statistic. Studies were assessed for quality using the Oxford Quality Scale (Jadad 1996). Sub group analysis was undertaken for dose of pregabalin and type of painful condition. Risk of bias tables were also completed.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search—Pregabalin is a relatively new drug, and therefore searching produced a relatively modest number of titles for examination.

Included studies—Twenty five studies were included in total for this review as follows:

- Six studies (649 participants; Agarwal 2008; Hill 2001; Jokela 2008a; Jokela 2008b; Mathiesen 2009; Paech 2007) studied the effects of pregabalin at various doses in perioperative situations over about 24 hours, in comparisons with placebo or an active drug (diazepam).
- Nineteen studies (7003 participants) studied the effects of pregabalin in: post herpetic neuralgia (A0081120 2008; Dworkin 2003; Sabatowski 2004; Stacey

2008; van Seventer 2006), painful diabetic neuropathy (A0081071 2007; Arezzo 2008; Freynhagen 2005; Lesser 2004; Richter 2005; Rosenstock 2004; Tolle 2008), central neuropathic pain (Siddall 2006; Vranken 2008), or fibromyalgia (A0081100 2008; Arnold 2008; Crofford 2005; Crofford 2008; Mease 2008). A further study was a duplicate report in German of Freynhagen 2005. All of these compared various doses of pregabalin, using various fixed-dose or titration strategies, with placebo. Study duration was mainly between four and 14 weeks, with the exception of a longer EERW trial that lasted 26 weeks (Crofford 2008). Full details are in the 'Characteristics of included studies' table.

Excluded studies—One study (Reuben 2006) was included initially. However, due to allegations of data fabrication from the publishing journal, we chose to exclude the data.

Risk of bias in included studies

The studies all had Oxford quality scores of three or more out of the maximum of five, indicating little likelihood of methodological bias. Eleven studies scored five, eight scored four, and six scored three points. Details are in the 'Characteristics of included studies' table. Risk of bias tables are presented (Figure 1 and Figure 2) and show risk of bias based on sequence generation, allocation concealment, and blinding.

Effects of interventions

Acute pain—The six studies of pregabalin in acute pain (Agarwal 2008; Hill 2001; Jokela 2008a; Jokela 2008b; Mathiesen 2009; Paech 2007) did not present a sufficiently homogeneous group of trials to allow a pooled analysis. There were differences in types of surgery, dose of pregabalin, and whether it was used preoperatively to prevent pain or postoperatively to reduce established pain. One study was sponsored by Pfizer or Parke Davies (Hill 2001), and two were funded by a foundation (Jokela 2008a; Jokela 2008b).

Hill 2001 used a standard postoperative pain model (single dose oral therapy with pain measurements over 6 hours in participants with established moderate or severe pain) to compare single oral doses of pregabalin 50 mg and 300 mg with placebo and ibuprofen 400 mg. Participants with only mild pain were included, reducing the validity of the results because it is difficult to demonstrate pain relief if there is little pain to begin with (McQuay 2008b). Pregabalin 300 mg had similar efficacy to ibuprofen 400 mg, possibly with a slightly longer duration of action, in groups of about 50 participants each. The reported adverse event rate was much higher (68%) with pregabalin 300 mg than any other group, and two participants (4%) had serious adverse events, which is unusual for this type of study.

Paech 2007 found that 100 mg pregabalin given 1 hour before minor gynaecological surgery made no difference to postoperative pain, although most women had no pain even with placebo. Results for perioperative pregabalin given at various doses were no different from diazepam 5 mg or 10 mg over 24 hours in women undergoing laparoscopic surgery (Jokela 2008a; Jokela 2008b), although again average pain scores were generally below the level of moderate pain for most of the time. In another study, pregabalin 300 mg preoperatively with

Moore et al.

or without dexamethasone made no difference to pain scores over 24 hours; a statistically lower 24-hour morphine consumption was compromised by enormous variability in the placebo group where the 95% CI range for morphine consumption ranged from 0 mg to over 100 mg (Mathiesen 2009). One study of preoperative pregabalin (150 mg) found consistent benefit for pregabalin compared with placebo over 24 hours, in terms of measured pain at rest and on activity, together with a 26% reduction in postoperative fentanyl consumption (Agarwal 2008).

Chronic pain—Studies investigating the efficacy and safety of pregabalin compared with placebo in chronic pain were found in four neuropathic pain conditions: five studies (1417 participants) in PHN (A0081120 2008; Dworkin 2003; Sabatowski 2004; Stacey 2008; van Seventer 2006), seven studies (2086 participants) in painful diabetic neuropathy (PDN; A0081071 2007; Arezzo 2008; Freynhagen 2005; Lesser 2004; Richter 2005; Rosenstock 2004; Tolle 2008), two studies (177 participants) in central neuropathic pain (CP; Siddall 2006; Vranken 2008), and five studies (3323 participants) in fibromyalgia (A0081100 2008; Arnold 2008; Crofford 2005; Crofford 2008; Mease 2008). The total number of participants in the neuropathic pain studies and fibromyalgia was 7003. Studies were all sponsored by Pfizer or Parke Davies, except one study where no sponsorship was mentioned (Vranken 2008).

One study included both PDN and PHN; as 74% of participants had PDN, this study was classified and analysed as PDN (Freynhagen 2005). One study in fibromyalgia used complete enriched enrolment randomised withdrawal (EERW) design (Crofford 2008). This design is very different from classic randomised design which is used for the rest of the studies so its results are discussed separately (McQuay 2008a). Some studies used partial enriched enrolment, in which some patients may have been excluded by failure to respond to treatments similar to pregabalin, or included because they had responded to treatments like pregabalin. The effects of partial enriched enrolment in this circumstance has been adequately explored, and shown not to have had any effect on results (Straube 2008).

Study duration was four weeks in one study (Stacey 2008), five weeks in one study (Lesser 2004), and six weeks in another (Richter 2005). In all other studies duration was 8 to 14 weeks, with the exception of the EERW study of over 26 weeks (Crofford 2008). Results were combined irrespective of trial duration, but results of the EERW study were not included in the combined analysis. Results for pregabalin at different daily doses were compared with placebo; there were no active controlled trials. Most studies used a short titration period of one week to a fixed daily dose of pregabalin. Some (Stacey 2008, for example) used a more flexible dosing regimen, with pregabalin flexible dosing including a maximum daily dose. In the latter case, the maximum daily dose was considered the dose used. No separate analysis was undertaken for flexible versus fixed dose regimens because this would fragment the data and leave too little for sensible comparison.

The analysis conducted has concentrated on each condition separately, on efficacy or adverse event outcomes, and by dose (150 mg, 300 mg, 450 mg, and 600 mg daily). The format of results is to examine efficacy and adverse events separately, by condition. Analyses at the end of the document show the same data by dose, outcome, and condition,

Moore et al.

with analyses 1 to 4 containing data on pregabalin 150 mg, 300 mg, 450 mg, and 600 mg daily.

The five efficacy outcomes consistently reported were participants with:

- 1. at least 30% pain relief over baseline;
- 2. at least 50% pain relief over baseline;
- 3. much or very much improved on patient global impression of change (PGIC);
- 4. very much improved on PGIC;
- 5. lack of efficacy discontinuation.

Adverse event outcomes were participants with:

- **1.** at least one adverse event;
- 2. at least one serious adverse event;
- 3. somnolence;
- 4. dizziness;
- 5. adverse event discontinuation.

Adverse event reporting was typically not comprehensive, with only those events occurring in 3% to 5% of participants reported. Common adverse events consistently reported were somnolence and dizziness.

1. Postherpetic neuralgia efficacy: Summary of results A shows results for the four main efficacy outcomes for which data were available. In each case there was a greater response with higher dose, with more participants achieving the outcomes, and with lower (better) NNT values. For lack of efficacy discontinuations there were increasingly fewer discontinuations with higher doses, but with a number needed to treat to prevent (NNTp) one discontinuation about the same for 300 mg and 600 mg daily. At least 30% pain relief (moderate benefit) tended to produce higher response rates and lower NNT values than did at least 50% pain relief (substantial benefit). No studies reported a measure of substantial benefit (very much improved) on the PGIC scale.

Limiting analyses to studies of 8 weeks duration or more made no appreciable difference to the results.

Summary of results A: Efficacy outcomes with different doses of pregabalin in postherpetic neuralgia:

	Number	of	Percent with outcome			
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative benefit (95% CI)	NNT (95% CI)
At least 30% pain	relief					

	Number of		Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative benefit (95% CI)	NNT (95% CI)
150 mg	1	180	39	17	2.3 (1.4 to 3.8)	4.6 (2.9 to 11)
300 mg	2	369	49	24	2.1 (1.5 to 2.7)	4.0 (2.9 to 6.5)
300 mg (8 weeks)	1	191	41	17	2.4 (1.4 to 3.9)	4.2 (2.8 to 8.9)
600 mg	3	537	62	24	2.5 (2.0 to 3.2)	2.7 (2.2 to 3.4)
600 mg (8 weeks)	2	356	58	21	2.8 (2.0 to 3.8)	2.7 (2.2 to 3.7)
At least 50% pain	relief					
150 mg	3	527	25	11	2.3 (1.6 to 3.4	6.9 (4.8 to 13)
300 mg	4	713	32	13	2.5 (1.9 to 3.4)	5.1 (3.9 to 7.4)
300 mg (8 weeks)	3	535	30	11	2.7 (1.9 to 4.0)	5.3 (3.9 to 8.1)
600 mg	4	732	41	15	2.7 (2.1 to 3.5)	3.9 (3.1 to 5.1)
600 mg (8 weeks)	3	551	39	14	2.8 (2.0 to 3.9)	4.0 (3.1 to 5.5)
PGIC much or ver	ry much im	proved				
150 mg	2	342	27	15	1.8 (1.2 to 2.8)	8.4 (4.9 to 30)
300 mg	2	348	32	15	2.2 (1.4 to 3.3)	5.8 (3.9 to 12)
600 mg	1	183	37	16	2.3 (1.3 to 3.9)	4.9 (3.0 to 12)
Lack of efficacy di	iscontinuati	on				NNTp (95% CI
150 mg	3	527	8	13	0.6 (0.3 to 1.0)	not calculated
300 mg	4	713	4	11	0.4 (0.2 to 0.7)	15 (9 to 34)
300 mg (8 weeks)	3	535	6	13	0.4 (0.2 to 0.7)	13 (7.9 to 35)
600 mg	4	732	3	11	0.3 (0.1 to 0.5)	13 (9 to 24)
600 mg (8 weeks)	3	551	3	13	0.3 (0.1 to 0.6)	11 (7.4 to 22)

2. Painful diabetic neuropathy efficacy: Summary of results B shows results for the four main efficacy outcomes for which data were available. In each case there was a greater response with a higher dose, with more participants having the outcomes, and with lower (better) NNT values. For lack of efficacy discontinuations there were no fewer discontinuations with higher doses, but with a measurable NNTp because of a higher discontinuation rate with placebo. At least 30% pain relief (moderate benefit) tended to produce higher response rates and lower NNT values than did at least 50% pain relief (substantial benefit). No trials reported a measure of substantial benefit (very much improved) on the PGIC scale.

Limiting analyses to studies of 8 weeks duration or more made no appreciable difference to results.

Summary of results B: Efficacy outcomes with different doses of pregabalin in painful diabetic neuropathy:

	Number	of	Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative benefit (95% CI)	NNT (95% CI)
At least 30% pain	relief					
150 mg	no data					
300 mg	2	482	59	45	1.3 (1.1 to 1.6)	6.8 (4.3 to 17)
300 mg (8 weeks)	1	304	58	52	1.1 (0.9 to 1.4)	not calculated
600 mg	3	819	63	43	1.5 (1.3 to 1.7)	5.1 (3.8 to 7.8)
600 mg (8 weeks)	2	641	62	48	1.3 (1.1 to 1.5)	6.8 (4.4 to 15)
At least 50% pain	relief					
150 mg	2	359	27	23	1.1 (0.8 to 1.6)	not calculated
150 mg (8 weeks)	1	195	34	30	1.1 (0.8 to 1.7)	not calculated
300 mg	4	823	40	26	1.5 (1.2 to 1.8)	7.5 (5.1 to 14)
300 mg (8 weeks)	3	645	38	29	1.3 (1.1 to 1.6)	11 (6.1 to 54)
600 mg	6	1360	45	25	1.7 (1.5 to 2.0)	5.0 (4.0 to 6.6)
600 mg (8 weeks)	4	1005	46	30	1.5 (1.3 to 1.8)	6.3 (4.6 to 10)
PGIC much or ver	ry much imp	proved				
150 mg	1	195	45	34	1.4 (0.96 to 2.0)	not calculated
300 mg	2	359	48	30	1.6 (1.2 to 2.1)	5.6 (3.6 to 13)
300 mg (8 weeks)	1	195	42	33	1.3 (0.9 to 1.8)	not calculated
600 mg	4	875	56	33	1.8 (1.5 to 2.1)	4.2 (3.3 to 5.8)
600 mg (8 weeks)	3	702	54	36	1.5 (1.3 to 1.8)	5.4 (3.9 to 9.2)
Lack of efficacy di	iscontinuatio	on				NNTp (95% CI
150 mg	2	359	4	7	0.7 (0.3 to 1.5)	not calculated
150 mg (8 weeks)	1	195	8	11	0.7 (0.3 to 1.7)	not calculated
300 mg	2	341	3	8	0.4 (0.2 to 1.0)	not calculated
600 mg	4	869	4	11	0.3 (0.2 to 0.5)	14 (9 to 31)
600 mg (8 weeks)	3	702	4	14	0.3 (0.2 to 0.5)	10 (6.9 to 20)

<u>3. Central neuropathic pain efficacy:</u> There was relatively little data from two studies on central neuropathic pain, where only 600 mg daily was used. The results are in Summary of results C. Using substantial benefit produced lower response rates, and a higher (worse) NNT, than moderate benefit. There were fewer 'lack of efficacy' discontinuations with pregabalin compared with placebo.

Summary of results C: Efficacy outcomes with different doses of pregabalin in central neuropathic pain:

	Number	Number of		Percent with outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative benefit (95% CI)	NNT (95% CI)
At least 30% pain	relief					
600 mg	1	136	42	13	3.1 (1.6 to 6.1)	3.5 (2.3 to 7.0)
At least 50% pain	relief					
600 mg	2	176	25	7	3.6 (1.5 to 8.4)	5.6 (3.5 to 14)
Lack of efficacy di	scontinuatio	on				NNTp (95% CI)
600 mg	2	177	6	24	0.3 (0.1 to 0.6)	5.4 (3.5 to 12)

<u>4. Fibromyalgia efficacy:</u> The four classic trials of pregabalin in fibromyalgia (not including that using EERW (Crofford 2008)) provided the most consistent information in terms of efficacy results and dose range.

Summary of results D shows results for the five main efficacy outcomes. In each case there tended to be a greater response with a higher dose of up to 450 mg, with more participants achieving the outcomes, and with lower (better) NNT values; 600 mg seemed to produce no better results than 450 mg for any outcome. For lack of efficacy discontinuations there were fewer discontinuations with higher doses. A daily dose of 150 mg pregabalin was not significantly different from placebo on any measure.

Both measures of moderate benefit produced higher rates of response with pregabalin, and lower (better) values for NNT than measures of substantial benefit, but with overlap of confidence intervals.

The EERW trial (Crofford 2008) used a six-week open titration to allow participants to obtain a substantial benefit (at least 50% pain relief and much or very much improved on PGIC) and have tolerable adverse events. Participants who achieved this outcome then entered a randomised, double blind, 26-week withdrawal phase in which either the established dose or placebo was used. The outcome was loss of therapeutic response, defined as having less than 30% reduction in pain from baseline or worsening, as judged by the investigator, of fibromyalgia symptoms such that alternative treatment was necessary.

During the open label phase, 54% had at least 50% pain relief on a visual analogue scale (VAS) over baseline and a PGIC of much or very much improved and so were able to enter the randomised double-blind phase. During the double blind treatment phase time to loss of therapeutic response was significantly longer for participants receiving pregabalin than for the placebo group. For pregabalin, 90/279 (32%) experienced loss of therapeutic response over 26 weeks, compared with 174/287 (61%) with placebo. The NNT to prevent one patient experiencing a loss of treatment response for fibromyalgia was 3.5 (95% CI 2.8 to 4.9).

Summary of results D: Efficacy outcomes with different doses of pregabalin in fibromyalgia (classic trial design only):

	Number	of	Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative benefit (95% CI)	NNT (95% CI)
At least 30% pair	ı relief					
150 mg	1	263	31	27	1.1 (0.8 to 1.7)	not calculated
300 mg	4	1374	39	28	1.4 (1.2 to 1.6)	9.2 (6.3 to 17)
450 mg	4	1376	43	28	1.5 (1.3 to 1.8)	6.6 (5.0 to 9.8)
600 mg	3	1122	39	28	1.4 (1.2 to 1.6)	9.1 (6.1 to 18)
At least 50% pair	ı relief					
150 mg	1	263	13	13	1.0 (0.5 to 1.9)	not calculated
300 mg	4	1374	21	14	1.5 (1.2 to 1.9)	14 (9.0 to 33)
450 mg	4	1376	25	14	1.7 (1.4 to 2.1)	9.8 (7.0 to 16)
600 mg	3	1122	24	15	1.6 (1.3 to 2.1)	11 (7.1 to 21)
PGIC much or ve	ery much in	nproved				
150 mg	1	263	32	27	1.2 (0.8 to 1.8)	not calculated
300 mg	4	1374	36	28	1.5 (1.2 to 1.9)	11 (7.3 to 26)
450 mg	4	1376	42	28	1.5 (1.3 to 1.8)	6.8 (5.1 to 10)
600 mg	3	1122	41	28	1.5 (1.2 to 1.7)	7.7 (5.4 to 13)
PGIC very much	improved					
150 mg	no data					
300 mg	4	1352	17	11	1.7 (1.2 to 2.9)	16 (9.9 to 37)
450 mg	4	1354	19	11	1.8 (1.4 to 2.4)	11 (7.9 to 20)
600 mg	3	1095	12	7	1.7 (1.1 to 2.4)	21 (12 to 83)
Lack of efficacy d	liscontinua	tion				NNTp (95% Cl
150 mg	1	263	9	14	0.7 (0.3 to 1.3)	not calculated
300 mg	4	1374	4	10	0.4 (0.3 to 0.7)	18 (12 to 34)
450 mg	4	1376	3	10	0.3 (0.2 to 0.5)	15 (11 to 25)
600 mg	3	1122	2	9	0.3 (0.2 to 0.5)	15 (11 to 26)

5. Participants experiencing at least one adverse event or serious adverse event: Results

for participants experiencing at least one adverse event or serious adverse event were not reported in all studies. Consequently, the analysis in Summary of results E is by dose only, and not by dose and condition. Most participants with pregabalin and placebo reported at least one adverse event over the period, with no indication of a dose-response relationship. A small proportion reported at least one adverse event considered serious (almost certainly using pre-set criteria of seriousness). There was no difference in the incidence of adverse events between pregabalin and placebo, and no indication of any dose response. Summary of results E: Participants experiencing at least one adverse event or serious adverse event:

	Number	of	Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative risk (95% CI)	NNH (95% CI)
At least one advers	se event					
150 mg	2	449	77	71	1.2 (0.97 to 1.4)	not calculated
300 mg	8	2190	82	67	1.2 (1.17 to 1.29)	6.6 (5.4 to 8.7)
450 mg	4	1379	90	74	1.2 (1.15 to 1.27)	6.3 (5.1 to 8.5)
600 mg	9	2540	83	67	1.3 (1.25 to 1.37)	6.1 (5.1 to 7.7)
At least one seriou	s adverse ev	vent				
150 mg	3	542	4.1	4.0	1.0 (0.5 to 2.3)	not calculated
300 mg	8	1566	3.6	2.9	1.2 (0.7 to 2.1)	not calculated
450 mg	2	740	2.7	1.6	1.7 (0.6 to 4.5)	not calculated
600 mg	9	2101	3.7	3.2	1.2 (0.7 to 1.8)	not calculated

<u>6. Adverse events in postherpetic neuralgia:</u> Results for somnolence, dizziness and adverse event discontinuation are shown in Summary of results F. Higher doses produced higher adverse event rates with pregabalin, and lower (worse) NNH values. Between one participant in 10 and one in five discontinued because of an adverse event. Only for somnolence did 150 mg produce higher adverse event rates than placebo</u>.

Summary of results F: Somnolence, dizziness, and adverse event discontinuation in postherpetic neuralgia:

	Number	of	Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative risk (95% CI)	NNH (95% CI)
Somnolence						
150 mg	3	527	15	7	2.2 (1.3 to 3.7)	12 (7.3 to 34)
300 mg	4	713	19	6	3.0 (2.1 to 5.3)	7.4 (5.5 to 11)
600 mg	4	732	25	6	4.4 (2.8 to 6.8)	5.2 (4.1 to 7.0)
Dizziness						
150 mg	3	527	13	10	1.3 (0.8 to 2.1)	not calculated
300 mg	4	713	30	9	3.2 (2.3 to 4.6)	4.7 (3.7 to 6.5)
600 mg	4	732	35	9	4.0 (2.8 to 5.7)	3.8 (3.2 to 4.9)
Adverse event disc	ontinuation	l				
150 mg	3	527	9	7	1.3 (0.7 to 2.3)	not calculated
300 mg	4	713	17	6	2.7 (1.7 to 4.3)	9.3 (6.5 to 16)
600 mg	4	732	19	5	3.7 (2.3 to 6.0)	7.1 (5.3 to 11)

7. Adverse events in painful diabetic neuropathy: Results for somnolence, dizziness and adverse event discontinuation are shown in Summary of results G. Higher doses produced higher adverse event rates with pregabalin, and lower (worse) NNH values. Between one participant in 20 and one in five discontinued because of an adverse event. Pregabalin 150 mg produced adverse event rates no different from placebo.

Summary of results G: Somnolence, dizziness, and adverse event discontinuation in painful diabetic neuropathy:

	Number	of	Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative risk (95% CI)	NNH (95% CI)
Somnolence						
150 mg	2	359	5	2	2.3 (0.7 to 7.5)	not calculated
300 mg	4	823	16	4	4.6 (2.7 to 7.9)	7.8 (6.0 to 11)
600 mg	6	1351	15	2	4.6 (2.9 to 7.3)	8.8 (7.0 to 12)
Dizziness						
150 mg	2	359	6	2	2.8 (0.9 to 8.7)	not calculated
300 mg	4	823	23	5	4.7 (3.0 to 7.5)	5.5 (4.4 to 7.4)
600 mg	3	1122	46	10	4.4 (3.4 to 5.8)	2.8 (2.5 to 3.2)
Adverse event disc	ontinuation	l				
150 mg	2	359	4	4	1.0 (0.4 to 2.9)	not calculated
300 mg	4	823	11	5	2.3 (1.4 to 3.8)	16 (9.9 to 37)
600 mg	6	1351	18	6	2.6 (1.8 to 3.7)	8.8 (6.8 to 12)

8. Adverse events in central neuropathic pain: Results for somnolence, dizziness and adverse event discontinuation are shown in Summary of results H. Pregabalin 600 mg produced significantly more somnolence and dizziness, but no higher rate of adverse event discontinuation.

Summary of results H: Somnolence, dizziness, and adverse event discontinuation in central neuropathic pain:

	Number of		Percent with outcome			
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative risk (95% CI)	NNH (95% CI)
Somnolence						
600 mg	2	177	42	17	2.5 (1.5 to 4.1)	4.0 (2.6 to 8.3)
Dizziness						
600 mg	2	177	27	14	2.0 (1.1 to 3.6)	7.8 (4.1 to 82)
Adverse event disc	ontinuation	l				

	Number	of	Percent with outcome			
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative risk (95% CI)	NNH (95% CI)
600 mg	2	177	20	14	1.5 (0.7 to 2.8)	not calculated

9. Adverse events in fibromyalgia: Results for somnolence, dizziness and adverse event discontinuation are shown in Summary of results H. Higher doses produced higher adverse event rates with pregabalin, and lower (worse) NNH values. Between one participant in 10 and one in three discontinued because of an adverse event. Only for somnolence did 150 mg produce higher adverse event rates than placebo.

In the EERW study (Crofford 2008) 863 of 1051 participants (82%) entering the open label phase experienced at least one adverse event. The most common adverse events during this phase were dizziness and somnolence. One hundred and ninety-six participants (19%) withdrew during the open label phase because of adverse events. Of the participants entering the double blind phase, 129/287 (45%) of participants in the placebo group, 37/63 (59%) of participants taking 300 mg, 46/73 (63%) taking 450 mg, and 89/143 (62%) participants taking 600 mg pregabalin experienced an adverse event. During the open label phase, serious adverse events occurred in 8/1051 participants (0.8%).

Summary of results H: Somnolence, dizziness, and adverse event discontinuation in fibromyalgia:

	Number	of	Percent with	outcome		
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative risk (95% CI)	NNH (95% CI)
Somnolence						
150 mg	1	263	16	5	3.5 (1.5 to 8.3)	8.8 (5.4 to 24)
300 mg	4	1374	20	5	4.0 (2.8 to 5.8)	6.7 (5.5 to 8.7)
450 mg	4	1376	21	5	4.2 (2.9 to 6.0)	6.4 (5.2 to 8.1)
600 mg	3	1122	23	5	4.5 (3.1 to 6.7)	5.7 (4.6 to 7.3)
Dizziness						
150 mg	3	527	13	10	1.3 (0.8 to 2.1)	not calculated
300 mg	4	1374	32	10	3.1 (2.4 to 3.9)	4.6 (3.9 to 5.7)
450 mg	4	1376	43	10	4.1 (3.2 to 5.2)	3.1 (2.8 to 3.6)
600 mg	3	1122	46	10	4.4 (3.4 to 5.8)	2.8 (2.5 to 3.2)
Adverse event disc	ontinuation	1				
150 mg	1	263	8	8	1.1 (0.5 to 2.5)	not calculated
300 mg	4	1374	16	10	1.6 (1.2 to 2.1)	17 (11 to 43)
450 mg	4	1377	20	10	1.9 (1.5 to 2.5)	11 (7.6 to 18)
600 mg	3	1122	28	11	2.5 (1.9 to 3.3)	5.9 (4.6 to 8.0)

For details of risk of bias see Figure 2.

For efficacy see Analysis 1.1; Analysis 1.2; Analysis 1.3; Analysis 1.4; Analysis 1.5; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5; Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis 3.4; Analysis 3.5; Analysis 4.1; Analysis 4.2; Analysis 4.3; Analysis 4.4; Analysis 4.5.

For adverse events see Analysis 1.6; Analysis 1.7; Analysis 1.8; Analysis 2.6; Analysis 2.7; Analysis 2.8; Analysis 3.6; Analysis 3.7; Analysis 3.8; Analysis 4.6; Analysis 4.7; Analysis 4.8; Analysis 5.1; Analysis 6.1.

DISCUSSION

Conventional assessment of the analgesic effect of drugs involves measuring pain intensity reduction or pain relief in participants with established moderate or severe pain, in order for studies to be sensitive. The assessment of perioperative use of combination therapies to reduce postoperative pain is more difficult because participants often have low levels of pain. There are a number of complexities, and no definitive method that clearly delivers a correct answer, as a methodological review of perioperative gabapentin studies showed (McQuay 2008b). This review has no clear message about pregabalin in acute painful conditions because there was only a single study of proven classic design in postoperative pain.

By contrast, the review has examined what is arguably the largest data set of high quality, longer-duration studies in four chronic painful conditions with neuropathic involvement. Anti-epileptic drugs have been used before for chronic pain with neuropathic involvement, and for prophylaxis of migraine (McQuay 1995; Wiffen 2005a; Wiffen 2005b; Wiffen 2005c). Information on the analgesic effects of antiepileptics in acute and chronic nociceptive conditions is very limited, but these drugs are not generally effective in acute painful conditions like postoperative pain or chronic nociceptive conditions like arthritis (Wiffen 2005c).

Summary of main results

There is no clear evidence of any beneficial effects of pregabalin in acute postoperative pain. No studies were found of pregabalin in chronic nociceptive pain conditions like arthritis.

Pregabalin at doses of 300 mg, 450 mg, and 600 mg daily produced useful benefits in patients with PHN, PDN, CNP and fibromyalgia. Pregabalin at 150 mg daily was generally ineffective except in PHN. This was the case for several dichotomous outcomes equating to moderate or substantial pain relief as defined by the IMMPACT group (Dworkin 2008), alongside lower rates of lack of efficacy discontinuations with increasing dose.

With increasing daily dose also came increasing rates of adverse events like somnolence and dizziness, as well as more discontinuations because of adverse events. The proportion of participants reporting at least one adverse event was not affected by dose, nor was the number of participants with a serious adverse event, which was not more than with placebo.

Moore et al.

There were obvious differences in pregabalin efficacy between the four painful conditions, as measured by response rate and NNT. For example, Figure 3 shows the rates of substantial benefit with pregabalin 150 mg to 600 mg for the four conditions using the outcome of at least 50% pain relief over baseline. Much higher rates were found with PHN and PDN than with CNP and fibromyalgia. NNTs for the former for moderate and substantial benefit on any outcome were generally six and below for 300 mg and 600 mg daily; for fibromyalgia NNTs were much higher, and generally seven and above. CNP, with an NNT of 5.6 for 600 mg daily, had a low response rate and low placebo response. The low number of participants (177) limits how far this interpretation can be taken.

Overall completeness and applicability of evidence

It is likely that all of the completed clinical trials have been found, because summaries of completed but unpublished trials are now available on the Internet, though not necessarily easy to find. In this review we had information from six studies (649 participants) for acute perioperative use. This is not a large amount for acute pain, and only one of the studies (Hill 2001) was a classic study design in established postoperative pain designed to show analgesic efficacy.

For four conditions in chronic pain with neuropathic involvement there were 19 studies with 7003 participants. This is a large amount of information, both in terms of studies and numbers of participants. Studies were all of four weeks duration or longer, and most were of 8 to 14 weeks. This very large amount of information can be compared to fewer than 600 participants for individual antidepressants in neuropathic pain, (Sultan 2008), with 404 participants for carbamazepine (Wiffen 2005b), and 1468 for gabapentin for acute and chronic pain combined (Wiffen 2005c).

There remained the problem of consistent reporting of outcomes, especially dichotomous outcomes of efficacy. The number of participants with at least 30% pain relief, and the number with PGIC very much improved were frequently not reported. For adverse events the number with at least one adverse event, and at least one serious adverse event was not reported in all studies. Reporting of particular adverse events was typically curtailed, so that only adverse events affecting 5% or so of participants was reported. To adequately access this information, data from clinical trial reports is usually needed (Edwards 2004; Moore 2005). The problem of reporting of adverse events has been commented on before (Edwards 1999; Ioannidis 2001; Loke 2001).

Quality of the evidence

All the studies in the review were described as randomised and double blind, and scored at least three out of five points on a validated scale (Jadad 1996). Chronic pain studies were predominantly of six weeks duration or longer and generally reported clinically useful outcomes, making them valid. Studies also tended to be large, with reasonable group sizes, making the random play of chance less of a problem, and the total numbers of participants and events was larger than needed to minimise chance effects (Moore 1998). Diagnostic criteria for inclusion were reasonable using appropriate definitions and duration of pain, and participants in chronic pain studies all had to have pain of 40% of maximum, indicating that

they had pain of at least moderate intensity. This means that studies would be sensitive enough to measure any analgesic effect.

Potential biases in the review process

Study quality was such as to minimise any bias. There was nothing obvious in study design that might lead to bias, and the one aspect that has been questioned, that of partial enrichment in some studies, has been shown already not to have had any measurable effect (Straube 2008). One study had complete enriched enrolment, but its results are reviewed separately and not combined with other studies in any analyses. In any event, the results from this enriched EERW study in fibromyalgia (Crofford 2008) were not strikingly different from those of a classic study design.

In the four trials in fibromyalgia of classical study design, about 40% of participants taking pregabalin 300 to 600 mg daily had a PGIC rating of much or very much improvement over 8 to 14 weeks. In the EERW study, 54% of those participants who entered the open label phase had at least 50% pain relief on a VAS over baseline and a PGIC of much or very much improved after six weeks and so continued into the double-blind phase. Comparing these two response rates, the larger size of effect observed in the EERW study was obtained during an open label phase, without a placebo group, and in participants titrated to an optimal dose of pregabalin rather than a fixed dose. The smaller effect size (about 40%) occurred in double-blind, placebo-controlled trials, in which participants were largely randomised to different doses of pregabalin irrespective of which dose might suit them best. Given these differences in trial design, the difference in response rates was not surprising.

Not all outcomes were available for all studies. It is possible that results could change if all outcomes were available for all studies. It is possible that trial duration may have an effect on efficacy, with studies shorter than eight weeks over-estimating efficacy compared with studies of eight weeks or longer (Moore 2009). Study duration was four weeks in one study in PHN (Stacey 2008), and five weeks (Lesser 2004), and six weeks (Richter 2005) in two in PDN. The largest contribution of studies of less than eight weeks duration was for at least 50% pain relief in PDN. Omission of these two studies would have made the calculated NNT 6.3 (4.6 to 10) rather than 5.0 (4.0 to 6.6); though larger, the difference was not significant. Eighteen of the 19 chronic pain studies were sponsored by Pfizer or Parke-Davis; the single study not mentioning sponsorship had only 40 participants (Vranken 2008). All were published since 2004. Three extensive abstracts, containing details of the design and results of unpublished trials, with about 1600 participants were identified in the PhRMA clinical study results database, so that almost a quarter of participant data came from studies unpublished in February 2009. It not likely that there is a substantial additional body of completed but unpublished studies in neuropathic pain. For example, it would require about three times as many participants in trials with zero treatment effect to increase the NNT of 600 mg to above 12 in studies of PHN or PDN (Moore 2008).

Agreements and disagreements with other studies or reviews

Several previous systematic reviews and meta-analyses mention pregabalin.

A systematic review of gabapentin and similar drugs in perioperative pain (Dahl 2004) found only the study of Hill 2001, though it and a second, similar, review (Tiippana 2007) were generally favourable to the use of gabapentin or pregabalin in the perioperative period. We find the evidence for pregabalin use during the perioperative period less than compelling. Only one of six studies had a positive outcome in favour of pregabalin, while five were negative. It may be that the previous reviews have incorrectly assumed that gabapentin and pregabalin have the same effects in acute pain.

Based on two studies, a systematic review of treatment for PHN concluded that pregabalin was effective, using several different efficacy outcomes (Hempenstall 2005). Evidencebased guidelines, backed by systematic searching and analysis, concluded that pregabalin provided level A evidence for use in neuropathic pain (Attal 2006), and a second set of consensus guidelines based on systematic reviews indicated that pregabalin should be considered as first line treatment for neuropathic pain (Moulin 2007). A systematic review that combined different neuropathic pain conditions and fibromyalgia, but with only about 2400 participants in all, came to broadly similar conclusions about dichotomous efficacy and adverse events as this review (Straube 2008), though NNTs were understandably numerically different. A review of central nervous system adverse events of new antiepileptic drugs with 938 participants in four studies not involved with pain identified dizziness and somnolence as major adverse events, with some differences in ataxia and fatigue (Zaccara 2008).

AUTHORS' CONCLUSIONS

Implications for practice

Pregabalin at daily oral doses of 300 to 600 mg provides high levels of benefit for a minority of patients experiencing neuropathic pain (painful diabetic neuropathy, postherpetic neuralgia, central neuropathic pain) and fibromyalgia, conditions that are difficult to treat and carry a substantial health burden. The quality of the evidence is good, from studies at low risk of bias, of long duration, with clinically useful outcomes, and with large numbers of participants. An important finding is that some patients will not have a useful benefit with pregabalin, and for those individuals another therapeutic intervention should be tried. There is no evidence to support the use of pregabalin in acute pain scenarios.

Implications for research

While the quality and weight of evidence supporting pregabalin in these conditions probably surpasses that available for other interventions, it has largely been generated for regulatory purposes. We need more information about which patients are likely to benefit most with this drug, how best to titrate dose to effect to minimise adverse effects, and whether patients who failed on other drugs can still benefit from pregabalin.

Acknowledgments

SOURCES OF SUPPORT

Internal sources

Moore et al.

• Oxford Pain Research Funds, UK.

External sources

- NHS Cochrane Collaboration Grant, UK.
- NIHR Biomedical Research Centre Programme, UK.

Funding for RAM

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

A0081071 2007

Methods	Randomised, double blind, parallel group, no obvious enriched enrolment. Initial dose titration before fixed dose (13 weeks in total)			
Participants	Painful diabetic neuropathy for at least 3 months, with average daily pain score of at least 40 mm/100 mm. Mean age 59 years, 57% male, majority white			
Interventions	Pregabalin 300 mg daily, $n = 153$ Pregabalin 600 mg daily, $n = 152$ Placebo daily, $n = 151$			
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes			
Notes	Oxford quality score: R1, D2, W1 = 4/5 Pfizer sponsored			
Risk of bias				
Item	Authors' judgement	Description		
Adequate sequence generation?	Unclear	Stated to be randomised		
Allocation concealment?	Unclear	Not described		
Blinding? All outcomes	Yes	"matching placebo"		

A0081100 2008

Methods	Randomised, double blind, parallel group, no obvious enriched enrolment. Initial dose titration before fixed dose (14 weeks in total)	
Participants	Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before randomisation. Mean age 49 years, 91% female, 76% white	
Interventions	Pregabalin 300 mg daily, $n = 183$ Pregabalin 450 mg daily, $n = 182$ Pregabalin 600 mg daily, $n = 186$ Placebo daily, $n = 184$	
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised

Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Yes	"matching placebo"

A0081120 2008

Methods	Randomised, double blind, parallel group, no obvious enriched enrolment. Initial dose titration before fixed dose (13 weeks in total)	
Participants	Pain persisting for at least 3 months after healing of herpes zoster skin rash, with average daily pain score of at least 40 mm/100 mm. Mean age 70 years, 54% male	
Interventions	Pregabalin 150 mg daily, $n = 86$ Pregabalin 300 mg daily, $n = 89$ Pregabalin 600 mg daily, $n = 97$ Placebo daily, $n = 97$	
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised
Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Unclear	Stated to be double blind

Agarwal 2008

Methods	Randomised, double blind, parallel group. Single oral dose	
Participants	Adults undergoing elective laparoscopic cholecystectomy. Mean age 46 years	
Interventions	Pregabalin 150 mg preoperatively, n = 30 Placebo, n = 30	
Outcomes	Pain at rest and on activity, and postoperative opioid consumption	
Notes	Oxford quality score: R2, D2, W1 = 5/5 No sponsorship mentioned	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated table of random numbers"
Allocation concealment?	Yes	Administered by independent nurse
Blinding? All outcomes	Yes	"identical placebo"

Arezzo 2008

Methods	Randomised, double blind, parallel group, no enriched enrolment. Initial dose titration before fixed dose (13 weeks in total)	
Participants	Painful diabetic neuropathy for at least 3 months, with average daily pain score of at least 40 mm/100 mm over seven days. Mean age 58 years, 60% male, 73% white	
Interventions	Pregabalin 600 mg daily, $n = 82$ Placebo daily, $n = 85$	
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated random code"
Allocation concealment?	Yes	Remote administration
Blinding? All outcomes	Yes	"identical capsules"

Arnold 2008

Methods	Randomised, double blind, parallel group, no enriched enrolment. Initial dose titration before fixed dose (14 weeks in total)	
Participants	Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before randomisation. Mean age 50 years, 95% female, 91% white	
Interventions	Pregabalin 300 mg daily, $n = 183$ Pregabalin 450 mg daily, $n = 190$ Pregabalin 600 mg daily, $n = 188$ Placebo daily, $n = 184$	
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated random code"
Allocation concealment?	Yes	Remote administration
Blinding? All outcomes	Unclear	"identical in appearance and taste"

Crofford 2005

Methods	Randomised, double blind, parallel group, partial enriched enrolment. Initial dose titration before fixed dose for 450 mg only (8 weeks in total)
Participants	Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before randomisation. Mean age 49 years, 92% female, 93% white
Interventions	Pregabalin 150 mg daily, n = 132

Europ
ĕ
PN
IC
H
unders
Author
$\mathbf{<}$
Ianus
n.
ipt
Ś

	Pregabalin 300 mg daily, n = 134 Pregabalin 450 mg daily, n = 132 Placebo daily, n = 131	
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R2, D1, W1 = 4/: Pfizer sponsored	5
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated code"
Allocation concealment?	Unclear	Not described
Blinding?	Unclear	Stated to be double blind

Crofford 2008

Methods	Randomised, double blind, parallel group, complete enriched enrolment with randomised withdrawal. Participants initially screened for response (50% decrease in pain and PGIC of much or very much improved). Responders to initial titration selected for randomisation to placebo or continued use of tolerated effective dose	
Participants	Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before randomisation, with six months of follow up. Mean age 49 years, 95% female, 91% white	
Interventions	1051 entered open label phase; 566 randomised to double blind phase Pregabalin titrated to a maximum of 600 mg daily, $n = 279$ Placebo daily, $n = 287$	
Outcomes	Loss of therapeutic response	
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised
Allocation concealment?	Yes	Remote administration
Blinding? All outcomes	Yes	"matching placebo"

Dworkin 2003

Methods	Randomised, double blind, parallel group, partial enriched enrolment. Titration of over 1 week (9 weeks in total)	
Participants	Painful postherpetic neuralgia 3 months after healing of herpes zoster skin rash and pain of at least 40/100 mm or numerical rating of at least 4/11 at baseline. Mean age 71 years, 53% female, 95% white	
Interventions	Pregabalin 600 mg daily, n = 89 Placebo daily, n = 84	
Outcomes	Proportion of patients with 30% or 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R2, D2, $W1 = 5/5$	

	Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	Random number generator
Allocation concealment?	Yes	Protocol for concealment
Blinding? All outcomes	Yes	"identical in appearance"

Freynhagen 2005

Methods	Randomised, double blind, parallel group, no enriched enrolment Fixed and flexible dosing regimens		
Participants		Chronic neuropathic pain (diabetic neuropathy, post herpetic neuralgia) of more than 3 months, and pain at least 40/100 mm. Mean age 62 years, 46% female, 98% white	
Interventions	Flexible regimen of pregabalin 150, 300, 450, or 600 mg daily daily based on individual response, $n = 141$ Fixed 300 mg/day for 1 week followed by 600 mg daily (12 weeks in total), $n = 132$ Placebo, $n = 65$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R1, D2, W1 = 4/5 Pfizer sponsored		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear	Stated to be randomised	
Allocation concealment?	Unclear	Not described	
Blinding? All outcomes	Yes	"matching placebo capsules"	

Hill 2001

Methods	Randomised, double blind, parallel group. Single oral dose.	
Participants	Oral surgery for removal of one or more third molars. Initial pain mild in 17%, and moderate or severe in others. Mean age 24 years, 59% female, 92% white	
Interventions	Pregabalin 50 mg, $n = 49$ Pregabalin 300 mg, $n = 50$ Ibuprofen 400 mg, $n = 49$ Placebo, $n = 50$	
Outcomes	Pain intensity difference, time to remedication	
Notes	Oxford quality score: R1, D1, W1 = 3/5 Parke-Davis/Warner-Lambert sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised
Allocation concealment?	Unclear	Not described

Blinding? Unclear Stated to be blinded	
--	--

Jokela 2008a

Methods	Randomised, double blind, parallel group	
Participants	Women undergoing laparoscopic hystere	ectomy. Mean age 50 years
Interventions	Diazepam 10 mg, $n = 30$ pregabalin 150 mg, $n = 30$ pregabalin 300 mg, $n = 30$ All given 1 hour preoperatively, and 12 hours later, when placebo was given to those initially given diazepam, and pregabalin 150 mg or 300 mg to those initially given pregabalin 150 mg or 300 mg (24 hr study)	
Outcomes	Postoperative pain using 11-point numerical rating scale	
Notes	Oxford quality score: R2, D2, W1 = 5/5 HUCH-EVO Committee and Paulo Foundation sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated random number table"
Allocation concealment?	Yes	"opaque containers"
Blinding? All outcomes	Yes	"identical capsules"

Jokela 2008b

Methods	Randomised, double blind, parallel group. Single oral dose	
Participants	Laparoscopic gynaecological surgery. Mean age 36 years	
Interventions	Pregabalin 75 mg, $n = 30$ Pregabalin 150 mg, $n = 30$ Diazepam 5 mg, $n = 30$ all in addition to ibuprofen 800 mg	
Outcomes	Postoperative pain using 11-point numerical rating scale	
Notes	Oxford quality score: R2, D2, W1 = 5/5 HUCH-EVO Committee and Paulo Foundation sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated random number table"
Allocation concealment?	Yes	"opaque containers"
Blinding? All outcomes	Yes	"identical capsules"

Lesser 2004

Methods	Randomised, double blind, parallel group, partial enriched enrolment. 5-day titration (5 weeks in total)	
Participants	Painful diabetic neuropathy for 1-5 years, and pain at least 40/100 mm. Mean age 60 years, 40% female, 95% white	
Interventions	Pregabalin 75 mg daily, $n = 77$ Pregabalin 300 mg daily, $n = 81$ Pregabalin 600 mg daily, $n = 82$, Placebo daily, $n = 97$	
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes	
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"random number table"
Allocation concealment?	Yes	Remote administration
Blinding? All outcomes	Yes	double dummy technique

Mathiesen 2009

Methods	Randomised, double blind, parallel group. Single oral dose	
Participants	Adult patients undergoing hip	arthroplasty. Mean age 68 years
Interventions	Pregabalin 300 mg, $n = 42$ Pregabalin 300 mg + dexamethasone 8 mg, $n = 42$ Placebo, $n = 42$	
Outcomes	24-hour postoperative morphine consumption, with pain scores at rest and on activity	
Notes	Oxford quality score: R2, D2, W1 = 5/5 No pregabalin-related sponsorship mentioned	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer generated block randomisation"
Allocation concealment?	Yes	"no person was aware of assignment"
Blinding? All outcomes	Yes	"identical capsules"

Mease 2008

Methods	Randomised, double blind, parallel group, partial enriched enrolment. 1-week titration for 600 mg dose (13 weeks in total)
Participants	Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before randomisation. Mean age 49 years, 94% female, 91% white
Interventions	Pregabalin 300 mg daily, n = 185 Pregabalin 450 mg daily, n = 183 Pregabalin 600 mg daily, n = 190

	Placebo daily, n = 190	
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored	
Notes		
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised
Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Unclear	Stated to be double blind

Paech 2007

Methods	Randomised, double blind, parallel group. Single oral dose	
Participants	Minor gynaecological surgery involving cervix and uterus, but without incision (dilation and curettage, hysteroscopy). Mean age 44 years	
Interventions	Pregabalin 100 mg given orally 1 hour before surgical intervention (24 hour study), n = 45 Placebo, n = 45	
Outcomes	Pain scores and opioid use over 24 hours	
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description
Adequate sequence generation?	Yes	"computer derived random number sequence"
Allocation concealment?	Yes	"sealed opaque envelopes"
Blinding? All outcomes	Yes	"identical capsules"

Richter 2005

Methods	Randomised, double blind, parallel group, no enriched enrolment. 2-week titration. (6 weeks in total)	
Participants	Painful diabetic neuropathy for 1-5 years, and pain at least $40/100$ mm. Mean age 57 years, 60% female, 84% white	
Interventions	Pregabalin 150 mg daily, n = 79 Pregabalin 600 mg daily, n = 82 Placebo daily, n = 85	
Outcomes	Proportion of patients with 50% decrease baseline, and other outcomes	e in mean pain score between endpoint and
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored	
Risk of bias		
Item	Authors' judgement	Description

_	Adequate sequence generation?	Yes	"computer generated"
	Allocation concealment?	Unclear	Not described
-	Blinding? All outcomes	Yes	double dummy technique

Rosenstock 2004

Methods	Randomised, double blind, parallel group, partial enriched enrolment. No titration (8 weeks in total)		
Participants	Painful diabetic neuropathy for 1-5 years, and pain at least 40/100 mm. Mean age 60 years, 56% female, 88% white		
Interventions	Pregabalin 300 mg daily, $n = 76$ Placebo daily, $n = 70$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R2, D1, W1 = 4/5 Pfizer sponsored		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Yes	"randomisation schedule"	
Allocation concealment?	Unclear Not described		
Blinding? All outcomes	Unclear Not adequately described		

Sabatowski 2004

Methods	Randomised, double blind, parallel group, partial enriched enrolment. 1-week fixed titration (8 weeks in total)		
Participants	Painful postherpetic neuralgia 6 months after healing of herpes zoster skin rash and pain of at least 40/100 mm or numerical rating of at least 4/11 at baseline. Mean age 72 years, 45% female, 99% white		
Interventions	Pregabalin 150 mg daily, $n = 81$ Pregabalin 300 mg daily, $n = 76$ Placebo daily, $n = 81$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R2, D2, W1 = 5/5 Parke-Davis Pfizer sponsored		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Yes	"computer generated code"	
Allocation concealment?	Unclear Not described		
Blinding? All outcomes	Yes	"identical capsules"	

Siddall 2006

Methods	Randomised, double blind, parallel group, no enriched enrolment		
Participants	Spinal cord injury (paraplegia or tetraplegia) at least 1 year previously, non progressive 6 months, with chronic pain at least 3 months at least 40/100 mm. Mean age 50 years, 17% female, 97% white		
Interventions	Pregabalin up to 600 mg daily, with variable titration (12 weeks in total), $n = 70$ Placebo, $n = 67$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R2, D2, W1 = 5/5 Pfizer sponsored		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Yes	"computer generated"	
Allocation concealment?	Unclear Not described		
Blinding? All outcomes	Yes "identical size colour taste and smell"		

Stacey 2008

Methods	Randomised, double blind, parallel group, no enriched enrolment. Double blind phase 4 weeks, with at least two weeks of escalation allowed in flexible dose phase		
Participants	Pain persisting for at least 3 months after healing of herpes zoster skin rash, with average daily pain score of at least 40 mm/100 mm. Mean age 67 years, 50% male, 96% white		
Interventions	Pregabalin flexible dose (150-600 mg daily), $n = 91$ Fixed dose pregabalin 300 mg, $n = 88$ Placebo, $n = 90$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R1, D2, W1 = 4/5 Pfizer sponsored		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear Stated to be randomised		
Allocation concealment?	Unclear Not described		
Blinding? All outcomes	Yes "matching placebo"		

Tolle 2008

Methods	Randomised, double blind, parallel group, no enriched enrolment. 1-week titration for 300/600 mg (withdrawing those not able to reach target dose) (12 weeks total)
Participants	Painful diabetic neuropathy for more than 1 year, and pain at least 40/100 mm. Mean age 59 years, 44% female, 96% white
Interventions	Pregabalin 150 mg daily, n = 99

Europe
PM
\mathbf{C}
Funders
Author
Manuscrip
ste

	Pregabalin 300 mg daily, n = 99 Pregabalin 600 mg daily, n = 101 Placebo daily, n = 96			
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes			
Notes	Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored			
Risk of bias				
Item	Authors' judgement	Description		
Adequate sequence generation?	Unclear Stated to be randomised			
Allocation concealment?	Unclear Not described			
Blinding? All outcomes	Unclear	Stated to be double blind		

van Seventer 2006

Methods	Randomised, double blind, parallel group, no enriched enrolment. 1-week titration for 300/600 mg (withdrawing those not able to reach target dose) (12 weeks total)		
Participants	Painful postherpetic neuralgia 6 months after healing of herpes zoster skin rash and pain of at least 40/100 mm or numerical rating of at least 4/11 at baseline. Mean age 71 years, 54% female, 99% white		
Interventions	Pregabalin 150 mg daily, $n = 87$ Pregablin 300 mg daily, $n = 98$ Pregablin 600 mg daily, $n = 90$ Placebo daily, $n = 93$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored		
Risk of bias			
Item	Authors' judgement	Description	
Adequate sequence generation?	Unclear Stated to be randomised		
Allocation concealment?	Unclear Not described		
Blinding? All outcomes	Unclear Stated to be double blind		

Vranken 2008

Methods	Randomised, double blind, parallel group, no enriched enrolment. Flexible dosing regimen		
Participants	Severe central neuropathic pain lasting longer than 6 months, VAS more than 60/100 mm. Mean age 54 years, 48% female		
Interventions	Pregabalin to a maximum of 600 mg, $n = 20$ Placebo, $n = 20$		
Outcomes	Proportion of patients with 50% decrease in mean pain score between endpoint and baseline, and other outcomes		
Notes	Oxford quality score: R2, D2, $W1 = 3/5$		

Risk of bias				
Item	Authors' judgement	Description		
Adequate sequence generation?	Yes	"automated assignment system"		
Allocation concealment?	Unclear	"blinded treating physician"		
Blinding? All outcomes	Yes	"identical capsules"		

D - double blind; n - number of participants; R - randomisation; W - withdrawals

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion	
Reuben 2006	Excluded because of fabrication of data acknowledged by journal	

DATA AND ANALYSES

Comparison 1 Pregabalin 150 mg daily versus placebo

No. of studies	No. of participants	Statistical method	Effect size
2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1	180	Risk Ratio (M-H, Fixed, 95% CI)	2.27 [1.35, 3.81]
1	263	Risk Ratio (M-H, Fixed, 95% CI)	1.13 [0.78, 1.65]
6		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3	701	Risk Ratio (M-H, Fixed, 95% CI)	2.61 [1.80, 3.80]
2	359	Risk Ratio (M-H, Fixed, 95% CI)	1.14 [0.80, 1.63]
1	263	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.53, 1.86]
4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2	342	Risk Ratio (M-H, Fixed, 95% CI)	1.79 [1.16, 2.77]
1	195	Risk Ratio (M-H, Fixed, 95% CI)	1.36 [0.96, 1.95]
1	263	Risk Ratio (M-H, Fixed, 95% CI)	1.23 [0.84, 1.80]
1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1	263	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [0.83, 1.85]
6		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3	527	Risk Ratio (M-H, Fixed, 95% CI)	0.62 [0.38, 1.02]
	2 1 1 6 3 2 1 4 2 1 4 2 1 1 1 1 1 1 5	2 1 180 1 263 6 3 701 2 359 1 263 4 2 342 1 195 1 263 1 263 1 263 6	2 Risk Ratio (M-H, Fixed, 95% CI) 1 180 Risk Ratio (M-H, Fixed, 95% CI) 1 263 Risk Ratio (M-H, Fixed, 95% CI) 6 Risk Ratio (M-H, Fixed, 95% CI) 3 701 Risk Ratio (M-H, Fixed, 95% CI) 2 359 Risk Ratio (M-H, Fixed, 95% CI) 1 263 Risk Ratio (M-H, Fixed, 95% CI) 2 359 Risk Ratio (M-H, Fixed, 95% CI) 1 263 Risk Ratio (M-H, Fixed, 95% CI) 2 342 Risk Ratio (M-H, Fixed, 95% CI) 1 195 Risk Ratio (M-H, Fixed, 95% CI) 1 263 Risk Ratio (M-H, Fixed, 95% CI) 1

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.2 Painful diabetic neuropathy	2	359	Risk Ratio (M-H, Fixed, 95% CI)	0.67 [0.29, 1.53]
5.3 Fibromyalgia	1	263	Risk Ratio (M-H, Fixed, 95% CI)	0.66 [0.33, 1.32]
6 Somnolence	6	1149	Risk Ratio (M-H, Fixed, 95% CI)	2.49 [1.64, 3.77]
6.1 Postherpetic neuralgia	3	527	Risk Ratio (M-H, Fixed, 95% CI)	2.20 [1.31, 3.70]
6.2 Painful diabetic neuropathy	2	359	Risk Ratio (M-H, Fixed, 95% CI)	2.32 [0.72, 7.47]
6.3 Fibromyalgia	1	263	Risk Ratio (M-H, Fixed, 95% CI)	3.47 [1.45, 8.33]
7 Dizziness	6	1149	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [1.19, 2.37]
7.1 Postherpetic neuralgia	3	527	Risk Ratio (M-H, Fixed, 95% CI)	1.29 [0.80, 2.05]
7.2 Painful diabetic neuropathy	2	359	Risk Ratio (M-H, Fixed, 95% CI)	2.84 [0.93, 8.69]
7.3 Fibromyalgia	1	263	Risk Ratio (M-H, Fixed, 95% CI)	2.13 [1.18, 3.82]
8 Withdrawal - adverse event	6	1149	Risk Ratio (M-H, Fixed, 95% CI)	1.18 [0.76, 1.82]
8.1 Postherpetic neuralgia	3	527	Risk Ratio (M-H, Fixed, 95% CI)	1.29 [0.71, 2.34]
8.2 Painful diabetic neuropathy	2	359	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.36, 2.86]
8.3 Fibromyalgia	1	263	Risk Ratio (M-H, Fixed, 95% CI)	1.09 [0.48, 2.48]

Comparison 2 Pregabalin 300 mg daily versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 At least 30% pain relief	8		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Postherpetic neuralgia	2	369	Risk Ratio (M-H, Fixed, 95% CI)	2.05 [1.53, 2.75]
1.2 Painful diabetic neuropathy	2	482	Risk Ratio (M-H, Fixed, 95% CI)	1.32 [1.11, 1.56]
1.3 Fibromyalgia	4	1368	Risk Ratio (M-H, Fixed, 95% CI)	1.66 [1.41, 1.95]
2 At least 50% pain relief	12		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Postherpetic neuralgia	4	713	Risk Ratio (M-H, Fixed, 95% CI)	2.52 [1.86, 3.42]
2.2 Painful diabetic neuropathy	4	823	Risk Ratio (M-H, Fixed, 95% CI)	1.50 [1.23, 1.83]
2.3 Fibromyalgia	4	1374	Risk Ratio (M-H, Fixed, 95% CI)	1.50 [1.19, 1.89]
3 Much or very much improved	8		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

Moore et al.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Postherpetic neuralgia	2	348	Risk Ratio (M-H, Fixed, 95% CI)	2.16 [1.43, 3.27]
3.2 Painful diabetic neuropathy	2	359	Risk Ratio (M-H, Fixed, 95% CI)	1.59 [1.22, 2.08]
3.3 Fibromyalgia	4	1374	Risk Ratio (M-H, Fixed, 95% CI)	1.32 [1.13, 1.54]
4 Very much improved	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
4.1 Fibromyalgia	4	1352	Risk Ratio (M-H, Fixed, 95% CI)	1.59 [1.22, 2.07]
5 Withdrawal - lack of efficacy	10	2437	Risk Ratio (M-H, Fixed, 95% CI)	0.41 [0.30, 0.57]
5.1 Postherpetic neuralgia	4	722	Risk Ratio (M-H, Fixed, 95% CI)	0.39 [0.23, 0.67]
5.2 Painful diabetic neuropathy	2	341	Risk Ratio (M-H, Fixed, 95% CI)	0.41 [0.16, 1.04]
5.3 Fibromyalgia	4	1374	Risk Ratio (M-H, Fixed, 95% CI)	0.43 [0.28, 0.65]
6 Somnolence	12	2910	Risk Ratio (M-H, Fixed, 95% CI)	3.96 [3.08, 5.09]
6.1 Postherpetic neuralgia	4	713	Risk Ratio (M-H, Fixed, 95% CI)	3.40 [2.13, 5.41]
6.2 Painful diabetic neuropathy	4	823	Risk Ratio (M-H, Fixed, 95% CI)	4.59 [2.67, 7.87]
6.3 Fibromyalgia	4	1374	Risk Ratio (M-H, Fixed, 95% CI)	4.02 [2.80, 5.77]
7 Dizziness	11	2910	Risk Ratio (M-H, Fixed, 95% CI)	3.39 [2.82, 4.08]
7.1 Postherpetic neuralgia	4	713	Risk Ratio (M-H, Fixed, 95% CI)	3.24 [2.27, 4.64]
7.2 Painful diabetic neuropathy	4	823	Risk Ratio (M-H, Fixed, 95% CI)	4.74 [3.00, 7.49]
7.3 Fibromyalgia	4	1374	Risk Ratio (M-H, Fixed, 95% CI)	3.09 [2.42, 3.94]
8 Withdrawal - adverse event	12	2910	Risk Ratio (M-H, Fixed, 95% CI)	1.92 [1.55, 2.37]
8.1 Postherpetic neuralgia	4	713	Risk Ratio (M-H, Fixed, 95% CI)	2.70 [1.71, 4.27]
8.2 Painful diabetic neuropathy	4	823	Risk Ratio (M-H, Fixed, 95% CI)	2.29 [1.38, 3.80]
8.3 Fibromyalgia	4	1374	Risk Ratio (M-H, Fixed, 95% CI)	1.57 [1.19, 2.07]

Comparison 3 Pregabalin 450 mg daily versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 At least 30% pain relief	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Fibromyalgia	4	1376	Risk Ratio (M-H, Fixed, 95% CI)	1.54 [1.33, 1.79]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 At least 50% pain relief	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Fibromyalgia	4	1376	Risk Ratio (M-H, Fixed, 95% CI)	1.71 [1.37, 2.14]
3 Much or very much improved	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Fibromyalgia	4	1376	Risk Ratio (M-H, Fixed, 95% CI)	1.53 [1.32, 1.78]
4 Very much improved	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
4.1 Fibromyalgia	4	1354	Risk Ratio (M-H, Fixed, 95% CI)	1.83 [1.42, 2.37]
5 Withdrawal - lack of efficacy	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5.1 Fibromyalgia	4	1376	Risk Ratio (M-H, Fixed, 95% CI)	0.34 [0.21, 0.54]
6 Somnolence	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
6.1 Fibromyalgia	4	1383	Risk Ratio (M-H, Fixed, 95% CI)	4.97 [3.47, 7.12]
7 Dizziness	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
7.1 Fibromyalgia	4	1376	Risk Ratio (M-H, Fixed, 95% CI)	4.07 [3.22, 5.15]
8 Withdrawal - adverse event	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
8.1 Fibromyalgia	4	1377	Risk Ratio (M-H, Fixed, 95% CI)	1.91 [1.46, 2.48]

Comparison 4 Pregabalin 600 mg daily versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 At least 30% pain relief	10		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Postherpetic neuralgia	3	537	Risk Ratio (M-H, Fixed, 95% CI)	2.53 [2.01, 3.18]
1.2 Painful diabetic neuropathy	3	819	Risk Ratio (M-H, Fixed, 95% CI)	1.48 [1.27, 1.72]
1.3 Central neuropathic pain	1	136	Risk Ratio (M-H, Fixed, 95% CI)	3.13 [1.60, 6.10]
1.4 Fibromyalgia	3	1122	Risk Ratio (M-H, Fixed, 95% CI)	1.39 [1.18, 1.64]
2 At least 50% pain relief	15		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Postherpetic neuralgia	4	732	Risk Ratio (M-H, Fixed, 95% CI)	2.66 [2.04, 3.48]
2.2 Painful diabetic neuropathy	6	1425	Risk Ratio (M-H, Fixed, 95% CI)	1.76 [1.51, 2.06]
2.3 Central neuropathic pain	2	176	Risk Ratio (M-H, Fixed, 95% CI)	3.59 [1.53, 8.42]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.4 Fibromyalgia	3	1122	Risk Ratio (M-H, Fixed, 95% CI)	1.64 [1.28, 2.10]
3 Much or very much improved	8		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Postherpetic neuralgia	1	183	Risk Ratio (M-H, Fixed, 95% CI)	2.27 [1.33, 3.89]
3.2 Painful diabetic neuropathy	4	940	Risk Ratio (M-H, Fixed, 95% CI)	1.78 [1.52, 2.09]
3.3 Fibromyalgia	3	1133	Risk Ratio (M-H, Fixed, 95% CI)	1.33 [1.13, 1.56]
4 Very much improved	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
4.1 Fibromyalgia	3	1095	Risk Ratio (M-H, Fixed, 95% CI)	1.65 [1.13, 2.39]
5 Withdrawal - lack of efficacy	13	2965	Risk Ratio (M-H, Fixed, 95% CI)	0.26 [0.19, 0.35]
5.1 Postherpetic neuralgia	4	732	Risk Ratio (M-H, Fixed, 95% CI)	0.28 [0.14, 0.53]
5.2 Painful diabetic neuropathy	4	934	Risk Ratio (M-H, Fixed, 95% CI)	0.24 [0.15, 0.38]
5.3 Central neuropathic pain	2	177	Risk Ratio (M-H, Fixed, 95% CI)	0.25 [0.10, 0.59]
5.4 Fibromyalgia	3	1122	Risk Ratio (M-H, Fixed, 95% CI)	0.28 [0.15, 0.50]
6 Somnolence	15	3457	Risk Ratio (M-H, Fixed, 95% CI)	4.53 [3.62, 5.67]
6.1 Postherpetic neuralgia	4	732	Risk Ratio (M-H, Fixed, 95% CI)	4.36 [2.79, 6.82]
6.2 Painful diabetic neuropathy	6	1416	Risk Ratio (M-H, Fixed, 95% CI)	5.04 [3.18, 8.00]
6.3 Central neuropathic pain	2	177	Risk Ratio (M-H, Fixed, 95% CI)	2.47 [1.47,4.15]
6.4 Fibromyalgia	3	1132	Risk Ratio (M-H, Fixed, 95% CI)	5.41 [3.65, 8.02]
7 Dizziness	15	3447	Risk Ratio (M-H, Fixed, 95% CI)	4.76 [3.99, 5.69]
7.1 Postherpetic neuralgia	4	732	Risk Ratio (M-H, Fixed, 95% CI)	3.98 [2.78, 5.70]
7.2 Painful diabetic neuropathy	6	1416	Risk Ratio (M-H, Fixed, 95% CI)	7.70 [5.17, 11.45
7.3 Central neuropathic pain	2	177	Risk Ratio (M-H, Fixed, 95% CI)	1.95 [1.05, 3.63]
7.4 Fibromyalgia	3	1122	Risk Ratio (M-H, Fixed, 95% CI)	4.44 [3.42, 5.75]
8 Withdrawal - adverse event	15	3447	Risk Ratio (M-H, Fixed, 95% CI)	2.62 [2.18, 3.16]
8.1 Postherpetic neuralgia	4	732	Risk Ratio (M-H, Fixed, 95% CI)	3.71 [2.28, 6.03]
8.2 Painful diabetic neuropathy	6	1416	Risk Ratio (M-H, Fixed, 95% CI)	2.60 [1.86, 3.63]
8.3 Central neuropathic pain	2	177	Risk Ratio (M-H, Fixed, 95% CI)	1.45 [0.74, 2.83]
8.4 Fibromyalgia	3	1122	Risk Ratio (M-H, Fixed, 95% CI)	2.54 [1.94, 3.32]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 At least one adverse event	10		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Pregabalin 150 mg	2	449	Risk Ratio (M-H, Fixed, 95% CI)	1.08 [0.97, 1.20]
1.2 Pregabalin 300 mg	7	2012	Risk Ratio (M-H, Fixed, 95% CI)	1.22 [1.16, 1.28]
1.3 Pregabalin 450 mg	4	1379	Risk Ratio (M-H, Fixed, 95% CI)	1.21 [1.15, 1.28]
1.4 Pregabalin 600 mg	9	2540	Risk Ratio (M-H, Fixed, 95% CI)	1.31 [1.25, 1.38]

Comparison 5 Participants with at least one adverse event

Comparison 6 Participants with at least one serious adverse event

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 At least one serious adverse event	10		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Pregabalin 150 mg	3	542	Risk Ratio (M-H, Fixed, 95% CI)	1.03 [0.45, 2.38]
1.2 Pregabalin 300 mg	8	1933	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [0.66, 1.85]
1.3 Pregabalin 450 mg	2	740	Risk Ratio (M-H, Fixed, 95% CI)	1.67 [0.61, 4.52]
1.4 Pregabalin 600 mg	9	2101	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [0.74, 1.83]

Analysis 1.1 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 1 At least 30% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 1 At least 30% pain relief

Study or subgroup	Pregabalin 150 mg n/N	Placebo n/N	Risk Ratio M-H.Fixed,95% Cl	Weight	Risk Ratio M-H.Fixed,95% C
I Postherpetic neuralgia					
van Seventer 2006	34/87	16/93		100.0 %	2.27 [1.35, 3.81
Subtotal (95% CI)	87	93	-	100.0 %	2.27 [1.35, 3.81]
Total events: 34 (Pregabalin I	50 mg), 16 (Placebo)				
Heterogeneity: not applicable	1				
Test for overall effect: $Z = 3$.	II (P = 0.0019)				
2 Fibromyalgia					
Crofford 2005	41/132	36/131	-	100.0 %	1.13 [0.78, 1.65
Subtotal (95% CI)	132	131	+	100.0 %	1.13 [0.78, 1.65
Total events: 41 (Pregabalin I	50 mg), 36 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	64 (P = 0.52)				
			0.1 0.2 0.5 1 2 5 10		
			Favours placebo Favours pregabalir	1	

Analysis 1.2 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 2 At least 50% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 2 At least 50% pain relief

Risk Ratio		Weight	Risk Ratio	Placebo	Pregabalin 150 mg	Study or subgroup
xed,95% C	M-H,Fix		M-H,Fixed,95% CI	n/N	n/N	
						I Postherpetic neuralgia
1.32, 3.62	2.19[1	49.6 %		30/272	21/87	A0081120 2008
1.24, 5.58	2.63 [1	27.3 %		8/81	21/81	Sabatowski 2004
1.59, 7.77	3.51[1	23.1 %		7/93	23/87	van Seventer 2006
0, 3.80]	2.61 [1.80	100.0 %	•	446	255	Subtotal (95% CI)
					0 mg), 45 (Placebo)	Total events: 65 (Pregabalin 150
					= 2 (P = 0.60); l ² =0.0%	Heterogeneity: Chi ² = 1.01, df =
					(P < 0.00001)	Test for overall effect: $Z = 5.04$
						2 Painful diabetic neuropathy
0.58, 2.31	1.16[0	29.8 %		13/85	14/79	Richter 2005
0.76, 1.71	1.14[0	70.2 %	-	29/96	34/99	Tolle 2008
0, 1.63	1.14 [0.80	100.0 %	•	181	178	Subtotal (95% CI)
					0 mg), 42 (Placebo)	Total events: 48 (Pregabalin 150
					= 1 (P = 0.96); l ² =0.0%	Heterogeneity: Chi ² = 0.00, df =
					(P = 0.46)	Test for overall effect: $Z = 0.74$
						3 Fibromyalgia
0.53, 1.86	0.99 [0	100.0 %		17/131	17/132	Crofford 2005
3, 1.86	0.99 [0.53	100.0 %	+	131	132	Subtotal (95% CI)
					0 mg), 17 (Placebo)	Total events: 17 (Pregabalin 150
						Heterogeneity: not applicable
					(P = 0.98)	Test for overall effect: $Z \approx 0.02$
			0.1 0.2 0.5 1 2 5 10			
			Favours placebo Favours pregabalin			

Analysis 1.3 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 3 Much or very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 3 Much or very much improved

Study or subgroup	Pregabalin 150 mg	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
1 Postherpetic neuralgia					
Sabatowski 2004	25/81	11/81		43.1 %	2.27 [1.20, 4.30]
van Seventer 2006	20/87	15/93		56.9 %	1.43 [0.78, 2.60]
Subtotal (95% CI)	168	174	+	100.0 %	1.79 [1.16, 2.77]
Total events: 45 (Pregabalin I	150 mg), 26 (Placebo)				
Heterogeneity: Chi ² = 1.09,	df = 1 (P = 0.30); 1 ² =8%				
Test for overall effect: Z = 2.	62 (P = 0.0087)				
2 Painful diabetic neuropathy					
Tolle 2008	45/99	32/96	-	100.0 %	1.36 [0.96, 1.95]
Subtotal (95% CI)	99	96	•	100.0 %	1.36 [0.96, 1.95]
Total events: 45 (Pregabalin	50 mg), 32 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1$.	71 (P = 0.088)				
3 Fibromyalgia					
Crofford 2005	42/132	34/131	•	100.0 %	1.23 [0.84, 1.80
Subtotal (95% CI)	132	131	+	100.0 %	1.23 [0.84, 1.80]
Total events: 42 (Pregabalin I	50 mg), 34 (Placebo)				
Heterogeneity: not applicable	e				
Test for overall effect: Z = 1.	04 (P = 0.30)				
			0.1 0.2 0.5 1 2 5 10		
			Favours placebo Favours pregabali	n	

Analysis 1.4 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 4 Very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 4 Very much improved

Study or subgroup	Pregabalin 150 mg n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% C
I Fibromyalgia					
Crofford 2005	40/132	32/131	-	100.0 %	1.24 [0.83, 1.85]
Subtotal (95% CI)	132	131	•	100.0 %	1.24 [0.83, 1.85]
Total events: 40 (Pregabalin 1	50 mg), 32 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.0$	06 (P = 0.29)				
			0.1 0.2 0.5 1 2 5 10		
			Favours placebo Favours pregabalin		

Analysis 1.5 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 5Withdrawal - lack of efficacy

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 5 Withdrawal - lack of efficacy

Study or subgroup	Pregabalin 150 mg	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
I Postherpetic neuralgia					
A0081120 2008	4/87	6/98		16.4 %	0.75 [0.22, 2.57
Sabatowski 2004	0/81	7/81	•	21.8 %	0.07 [0.00, 1.15
van Seventer 2006	16/87	22/93		61.8 %	0.78 [0.44, 1.38
Subtotal (95% CI)	255	272	-	100.0 %	0.62 [0.38, 1.02
Total events: 20 (Pregabalin 1)	50 mg), 35 (Placebo)				
Heterogeneity: $Chi^2 = 3.06$, d	If = 2 (P = 0.22); I ² =35%				
Test for overall effect: $Z = 1.8$	19 (P = 0.059)				
2 Painful diabetic neuropathy					
Richter 2005	0/79	1/85	•	11.5 %	0.36 [0.01, 8.67
Tolle 2008	8/99	11/96		88.5 %	0.71 [0.30, 1.68
Subtotal (95% CI)	178	181	-	100.0 %	0.67 [0.29, 1.53
Total events: 8 (Pregabalin 15	0 mg), 12 (Placebo)				
Heterogeneity: $Chi^2 = 0.16$, d	$ff = 1 (P = 0.69); I^2 = 0.0\%$				
Test for overall effect: $Z = 0.9$	96 (P = 0.34)				
3 Fibromyalgia					
Crofford 2005	12/132	18/131		100.0 %	0.66 [0.33, 1.32
Subtotal (95% CI)	132	131	-	100.0 %	0.66 [0.33, 1.32
Total events: 12 (Pregabalin 1)	50 mg), 18 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.1$	7 (P = 0.24)				
			0.1 0.2 0.5 1 2 5 10		
			Favours pregabalin Favours placebo		

Analysis 1.6 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 6 Somnolence

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 6 Somnolence

Study or subgroup	Pregabalin 150 mg n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% C
I Postherpetic neuralgia					
A0081120 2008	19/87	9/98		30.0 %	2.38 [1.14, 4.98
Sabatowski 2004	12/81	6/81		21.2 %	2.00 [0.79, 5.07
van Seventer 2006	8/87	4/93		13.7 %	2.14 [0.67, 6.85
Subtotal (95% CI)	255	272	•	64.9 %	2.20 [1.31, 3.70
Total events: 39 (Pregabalin 1	50 mg), 19 (Placebo)				
Heterogeneity: Chi ² = 0.09, o					
Test for overall effect: Z = 2.9					
2 Painful diabetic neuropathy					
Richter 2005	4/79	3/85		10.2 %	1.43 [0.33, 6.21
Tolle 2008	5/99	1/96		3.6 %	4.85 [0.58, 40.74
Subtotal (95% CI)	178	181		13.8 %	2.32 [0.72, 7.47
Total events: 9 (Pregabalin 15	0 mg), 4 (Placebo)				
Heterogeneity: Chi ² = 0.87, d	df = 1 (P = 0.35); 1 ² =0.0%				
Test for overall effect: Z = 1.4	41 (P = 0.16)				
3 Fibromyalgia					
Crofford 2005	21/132	6/131		21.3 %	3.47 [1.45, 8.33
Subtotal (95% CI)	132	131	-	21.3 %	3.47 [1.45, 8.33
Total events: 21 (Pregabalin 1	50 mg), 6 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 2.7$	79 (P = 0.0053)				
Total (95% CI)	565	584	+	100.0 %	2.49 [1.64, 3.77
Total events: 69 (Pregabalin 1	50 mg), 29 (Placebo)				
Heterogeneity: Chi ² = 1.77, o	$df = 5 (P = 0.88); t^2 = 0.0\%$				
Test for overall effect: $Z = 4.3$	30 (P = 0.000017)				
			0.1 0.2 0.5 1 2 5 10		
			Favours pregabalin Favours placebo		

Analysis 1.7 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 7 Dizziness

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 7 Dizziness

Study or subgroup	Pregabalin 150 mg	Placebo n/N	Risk Ratio M-H.Fixed.95% Cl	Weight	Risk Ratio M-H.Fixed.95% C
I Postherpetic neuralgia					
A0081120 2008	10/87	7/98		14.5 %	1.61 [0.64, 4.04
Sabatowski 2004	10/81	12/81		26.5 %	0.83 [0.38, 1.82
van Seventer 2006	14/87	9/93		19.2 %	1.66 [0.76, 3.64
Subtotal (95% CI)	255	272	-	60.2 %	1.29 [0.80, 2.05]
Total events: 34 (Pregabalin 1		2/2		0012 /0	112) (0100, 210) ;
Heterogeneity: Chi ² = 1.83, o					
Test for overall effect: $Z = 1.0$	· /·				
2 Painful diabetic neuropathy					
Richter 2005	8/79	2/85	· · · ·	4.3 %	4.30 [0.94, 19.66
Tolle 2008	3/99	2/96		4.5 %	1.45 [0.25, 8.51
Subtotal (95% CI)	178	181		8.7 %	2.84 [0.93, 8.69]
Total events: 11 (Pregabalin 1	50 mg), 4 (Placebo)				
Heterogeneity: Chi ² = 0.84, d	$df = 1 (P = 0.36); I^2 = 0.0\%$				
Test for overall effect: Z = 1.8	B3 (P = 0.067)				
3 Fibromyalgia					
Crofford 2005	30/132	14/131		31.0 %	2.13 [1.18, 3.82
Subtotal (95% CI)	132	131	-	31.0 %	2.13 [1.18, 3.82
Total events: 30 (Pregabalin 1	50 mg), 14 (Placebo)				
Heterogeneity: not applicable	2				
Test for overall effect: Z = 2.5	52 (P = 0.012)				
Total (95% CI)	565	584	+	100.0 %	1.68 [1.19, 2.37]
Total events: 75 (Pregabalin 1	50 mg), 46 (Placebo)				
Heterogeneity: Chi ² = 5.23, a	df = 5 (P = 0.39); $I^2 = 4\%$				
Test for overall effect: $Z = 2.9$					
Test for subgroup differences	: Chi ² = 0.0, df = 2 (P = 0.0)	, l ² =0.0%			
			<u></u>		
			0.1 0.2 0.5 1 2 5 10		

Analysis 1.8 Comparison 1 Pregabalin 150 mg daily versus placebo, Outcome 8Withdrawal - adverse event

Review: Pregabalin for acute and chronic pain in adults Comparison: 1 Pregabalin 150 mg daily versus placebo Outcome: 8 Withdrawal - adverse event

A0081120 2008 6487 5498 136 (1.35 [0.43, 427 Sabatowski 2004 9181 8181 23.2 % 11.3 [0.46, 2.77 van Seventer 2006 7187 5493 140 % 1.50 [0.49, 454 chocal (95% CI) 255 272 50.9 % 1.29 [0.71, 2.34 al events Z (Pregabalin 150 mg). 18 (Placebo) terogeneity: Chi ² = 0.18, df = 2 (P = 0.92); P = 0.0% is for overall effect Z = 0.83 (P = 0.32); P = 0.0% is for overall effect Z = 0.03 (P = 0.32); P = 0.0% is for overall effect Z = 0.03 (P = 0.32); P = 0.0% is for overall effect Z = 0.03 (P = 0.32); P = 0.0% is for overall effect Z = 0.03 (P = 0.32); P = 0.0% is for overall effect Z = 0.03 (P = 0.32); P = 0.0% is for overall effect Z = 0.03 (P = 0.33); P = 0.0% is for overall effect Z = 0.01 (P = 0.83); P = 0.0% is for overall effect Z = 0.01 (P = 0.83); P = 0.0% is for overall effect Z = 0.01 (P = 0.83); P = 0.0% is for overall effect Z = 0.01 (P = 0.83); P = 0.0% is for overall effect Z = 0.01 (P = 0.83); P = 0.0%; P = 0.00%; P = 0.0%; P = 0.0%	Study or subgroup	Pregabalin 150 mg n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% C
A0081120 2008 687 598 136 135 [0.43, 427 Sabatowski 2004 981 8/81 23.2 % 11.3 [0.45, 2.77 van Seventer 2006 7/87 5/93 140 % 1.50 [0.49, 454 bboal (95% CI) 255 272 50.9 % 1.29 [0.71, 2.34 all events 22 (Pregabalin 150 mg). 18 (Placebo) terogeneity: Chi ² = 0.16, df = 2 (P = 0.92); l ² = 0.0% at for overall effect Z = 0.83 (P = 0.41) Taihi di dateitic neuropathy Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86 abtool (95% CI) 178 181 al events 7 (Pregabalin 150 mg). 7 (Placebo) terogeneity: Chi ² = 0.98, df = 1 (P = 0.32); l ² = 0.0% at for overall effect Z = 0.03 (P = 0.98) timornalgia Crofford 2005 11/132 10/131 29.1 % 10.9 [0.48, 2.48 bal events 11 (Pregabalin 150 mg). 10 (Placebo) terogeneity: Chi ² = 0.92, df = 1 (P = 0.32); l ² = 0.0% at al events 11 (Pregabalin 150 mg). 35 (Placebo) terogeneity: Chi ² = 0.21 (P = 0.83) tatal events 11 (Pregabalin 150 mg). 35 (Placebo) terogeneity: Chi ² = 0.21 (P = 0.83) tatal events 21 (Pregabalin 150 mg). 35 (Placebo) terogeneity: Chi ² = 1.32, df = 5 (P = 0.93); l ² = 0.0%	I Postherpetic neuralgia					
Van Sevents 2006 7/87 5/93 14.0 % 1.50 [0.49, 454 Michotal (95% CI) 255 272 50.9 % 1.29 [0.71, 2.34 tereogeneity: Ch ² = 0.16, df = 2 (P = 0.32); l ² = 0.0% is for overall effect: Z = 0.83 (P = 0.41) 11.2 % 0.54 [0.10, 2.86 valid dabetic neuropathy Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86 abevents (Pegabalin 150 mg), 7 (Placebo) 178 181 20.0 % 1.01 [0.36, 2.86 abevents (Pegabalin 150 mg), 7 (Placebo) terogeneity: Ch ² = 0.98, df = 1 (P = 0.32); l ² = 0.0% 10/131 29.1 % 1.09 [0.48, 2.48 atal events: 11 (Pregabalin 150 mg), 132 131 29.1 % 1.09 [0.48, 2.48 100.0 % 1.18 [0.76, 1.82 atal events: 11 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Ch ² = 1.2, 2.1 (P = 0.83) 565 584 100.0 % 1.18 [0.76, 1.82	A0081120 2008	6/87	5/98		13.6 %	1.35 [0.43, 4.27
abtoral (95% CI) 255 272 50.9 % 1.29 [0.71, 2.34 tai events: 22 (Pregabalin 150 mg), 18 (Placebo) tereogeneity: Ch ² = 0.16, df = 2 (P = 0.32); 1 ² = 0.0% ts 50.9 % 1.29 [0.71, 2.34 tai events: 22 (Pregabalin 150 mg), 18 (Placebo) tereogeneity: Ch ² = 0.16, df = 2 (P = 0.32); 1 ² = 0.0% ts 50.9 % 1.29 [0.71, 2.34 tai events: 22 (Pregabalin 150 mg), 7 (Placebo) tero event effects 2 0.0 % 1.01 [0.36, 2.86 tai events: 47 (Pregabalin 150 mg), 7 (Placebo) teroseneity: Ch ² = 0.98, df = 1 (P = 0.32); 1 ² = 0.0% 1.01 [0.36, 2.86 tai events: 17 (Pregabalin 150 mg), 7 (Placebo) teroseneity: Ch ² = 0.98, df = 1 (P = 0.32); 1 ³ = 0.0% 1.01 [0.36, 2.48 tai events: 11 (Pregabalin 150 mg), 13 [2] 10/131 29.1 % 1.09 [0.48, 2.48 tai events: 11 (Pregabalin 150 mg), 10 (Placebo) teroseneity: not applicable 1.09 [0.48, 2.48 tai events: 10 (Pregabalin 150 mg), 35 (Placebo) teroseneity: not applicable 1.00.0 % 1.18 [0.76, 1.82 tai events: 40 (Pregabalin 150 mg), 35 (Placebo) teroseneity: not applicable 1.00.0 % 1.18 [0.76, 1.82	Sabatowski 2004	9/81	8/81		23.2 %	1.13 [0.46, 2.77
tal events: 22 (Pregabalin 150 mg), 18 (Placebo) terogenety: Ch ² = 016, df = 2 (P = 0.32); l ² = 0.0% tar overall effect: Z = 0.83 (P = 0.41) hinful dabetic neuropathy Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86 hbtoral (95% CI) 178 181 al events: 7 (Pregabalin 150 mg), 7 (Placebo) terogenety: Ch ² = 0.98, df = 1 (P = 0.32); l ² = 0.0% tal events: 11 (Pregabalin 150 mg), 7 (Placebo) terogenety: Ch ² = 0.98, df = 0 = 0.91) hbtoral (95% CI) 132 131 conford 2005 11/132 10/131 29.1 % 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 10 (Placebo) terogenety: not applicable tor overall effect: Z = 0.01 (P = 0.83) tal events: 11 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable tor overall effect: Z = 0.21 (P = 0.83) tal events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable tal events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable tor overall effect: Z = 0.21 (P = 0.83) tal events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable tor overall effect: Z = 0.21 (P = 0.03); kf = 0.0%	van Seventer 2006	7/87	5/93		14.0 %	1.50 [0.49, 4.54
terogeneity: Ch ² = 0.16, df = 2 (P = 0.32); l ² = 0.0% it for overall effect: Z = 0.83 (P = 0.41) hinful diabetic neuropathy Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86 hitoral (95% CI) 178 181 20.0 % 1.01 [0.36, 2.86 hitoral (95% CI) 178 181 20.0 % 1.01 [0.36, 2.86 hitoral effect: Z = 0.03 (P = 0.32); l ² = 0.0% terogeneity: Ch ² = 0.98, df = 1 (P = 0.32); l ² = 0.0% to roverall effect: Z = 0.03 (P = 0.98) hitoral (95% CI) 132 131 29.1 % 1.09 [0.48, 2.48 hitoral (95% CI) 132 131 29.1 % 1.09 [0.48, 2.48 hitoral effect: Z = 0.21 (P = 0.83) hitoral effect: Z = 0.21 (P = 0.83) had events: 0 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Ch ² = 1.32, df = 5 (P = 0.93); l ² = 0.0%	Subtotal (95% CI)	255	272	•	50.9 %	1.29 [0.71, 2.34
at for overall effect: Z = 0.83 (P = 0.41) Tainful dabetic neuropathy Richter 2005 2/79 4/85 Tolle 2008 5/99 3/96 8.8 % 1.62 [0.40, 658 balaevents: 7 (Pregabalin 150 mg), 7 (Placebo) 178 181 20.0 % 1.01 [0.36, 2.86 all events: 7 (Pregabalin 150 mg), 7 (Placebo) 178 181 20.0 % 1.01 [0.36, 2.86 all events: 7 (Pregabalin 150 mg), 7 (Placebo) terogenetry, Chi ² = 0.98, df = 1 (P = 0.32); P = 0.0% 1.07 (Placebo) 1.09 [0.48, 2.48 Crofford 2005 11/132 10/131 29.1 % 1.09 [0.48, 2.48 balaevents: 11 (Pregabalin 150 mg), 10 (Placebo) 132 131 29.1 % 1.09 [0.48, 2.48 all events: 11 (Pregabalin 150 mg), 10 (Placebo) terogenetry, Chi ² = 0.21 (P = 0.83) 1.09 [0.48, 2.48 100.0 % 1.18 [0.76, 1.82 all events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenetry, Chi ² = 1.32, df = 5 (P = 0.93); P = 0.0% 100.0 % 1.18 [0.76, 1.82	· · ·					
Ninful diabetic neuropathy Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86 Tolle 2008 5/99 3/96 8.8 % 1.62 [0.40, 6.58 ubtortal (05% CI) 178 181 20.0 % 1.01 [0.36, 2.86 uterostra; C/P egabalin 150 mg), 7 (Placebo) terogeneity: Ch ² = 0.98, df = 1 (P = 0.32); P = 0.0% 1.01 [0.36, 2.86 thrornal effect; Z = 0.03 (P = 0.98) Thiomyalgia 29.1 % 1.09 [0.48, 2.48 chordal (05% CI) 132 131 29.1 % 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 13 (Placebo) terogeneity: not applicable 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Ch ² = 1.32, df = 5 (P = 0.33); F = 0.0% 100.0 % 1.18 [0.76, 1.82	Heterogeneity: Chi ² = 0.16, df	= 2 (P = 0.92); I ² =0.0%				
Ninful diabetic neuropathy Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86 Tolle 2008 5/99 3/96 8.8 % 1.62 [0.40, 6.58 ubtortal (05% CI) 178 181 20.0 % 1.01 [0.36, 2.86 uterostra; C/P egabalin 150 mg), 7 (Placebo) terogeneity: Ch ² = 0.98, df = 1 (P = 0.32); P = 0.0% 1.01 [0.36, 2.86 thrornal effect; Z = 0.03 (P = 0.98) Thiomyalgia 29.1 % 1.09 [0.48, 2.48 chordal (05% CI) 132 131 29.1 % 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 13 (Placebo) terogeneity: not applicable 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Ch ² = 1.32, df = 5 (P = 0.33); F = 0.0% 100.0 % 1.18 [0.76, 1.82	0 1					
Richter 2005 2/79 4/85 11.2 % 0.54 [0.10, 2.86] Tolle 2008 5/99 3/96 8.8 % 1.62 [0.40, 6.58] shbotal (95% CI) 178 181 20.0 % 1.01 [0.36, 2.86] terogeneity: Ch ² = 0.98, df = 1 (P = 0.32); P = 0.02% tif or overall effect: Z = 0.03 (P = 0.98) 11/132 10/131 29.1 % 1.09 [0.48, 2.48] tal events: 11 (Pregabalin 150 mg), 10 (Placebo) 132 131 29.1 % 1.09 [0.48, 2.48] tal events: 11 (Pregabalin 150 mg), 10 (Placebo) terogeneity: charter 2.9 cl (P = 0.83) 100.0 % 1.18 [0.76, 1.82] tal events: 2.9 cl (Pregabalin 150 mg), 35 (Placebo) 565 584 100.0 % 1.18 [0.76, 1.82]	2 Painful diabetic neuropathy					
bitosal (95% CI) 178 181 al events 7 (Pregabalin 150 mg), 7 (Placebo) 1001 [0.36, 2.86 terogenety, Ch ² = 0.98, df = 1 (P = 0.32); P = 0.0% 1011 [0.36, 2.86 if or overall effects Z = 0.03 (P = 0.98) 11/132 10/131 bitosal (95% CI) 132 131 dal events 11 (Pregabalin 150 mg), 10 (Placebo) 1000 [0.48, 2.48 terogenety, Ch ² = 0.21 (P = 0.83) 1000 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 15 (Placebo) 565 terogenety, Ch ² = 1.32, df = 5 (P = 0.93); P = 0.0% 100.0 %	Richter 2005	2/79	4/85		11.2.%	0.54 [0.10, 2.86
tal events: 7 (Pregabalin 150 mg), 7 (Placebo) terrogenety: Ch ² = 0.98, df = 1 (P = 0.32); l ² = 0.0% tf or overall effect: Z = 0.03 (P = 0.98) ibiromajaga Crofford 2005 11/132 10/131 29.1 % 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 10 (Placebo) terogenety: not applicable at or overall effect: Z = 0.21 (P = 0.83) trad (95% CI) 565 584 100.0 % 1.18 [0.76, 1.82 tal events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable at events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable tal events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable the events: 40 (Pregabalin 150 mg), 35 (Placebo) terogenety: not applicable terogenety: not applicable teroge	Tolle 2008	5/99	3/96		8.8 %	1.62 [0.40, 6.58
terogeneity: Ch ² = 0.98, df = 1 (P = 0.32); P = 0.0% tf: for overall effect: Z = 0.03 (P = 0.98) ibitornal (95% CI) 132 131 29.1 % 1.09 [0.48, 2.48 ibitoral (95% CI) 132 131 29.1 % 1.09 [0.48, 2.48 all events: 11 (Pregabalin 150 mg), 13 (Placebo) terogeneity: rot applicable at for overall effect: Z = 0.21 (P = 0.83) trail (95% CI) 565 584 100.0 % 1.18 [0.76, 1.82 tai events: 40 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Ch ² = 1.32, df = 5 (P = 0.37); P = 0.0%	Subtotal (95% CI)	178	181	+	20.0 %	1.01 [0.36, 2.86
st for overall effect: Z = 0.03 (P = 0.98) ibioornyagia Crofford 2005 11/132 10/131 2.9.1 % 1.09 [0.48, 2.48 ibiotral (95% CI) 132 131 2.9.1 % 1.09 [0.48, 2.48 ati events: 11 (Pregabalin 150 mg), 10 (Placebo) terogeneity: not applicable at for overall effect: Z = 0.21 (P = 0.83) bral (95% CI) 565 584 100.0 % 1.18 [0.76, 1.82 at events: 40 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Ch ² = 1.32, df = 5 (P = 0.93); l ² = 0.0%	Total events: 7 (Pregabalin 150	mg), 7 (Placebo)				
ibromyalgia Crofford 2005 11/132 10/131 29.1 % 1.09 [0.48, 2.48 sbtotal (05% CI) 132 131 29.1 % 1.09 [0.48, 2.48 tal events: 11 (Pregabalin 150 mg), 10 (Placebo) trogeneity, not applicable 1.09 [0.48, 2.48 st for overall effect: Z = 0.21 (P = 0.83) 56 584 100.0 % 1.18 [0.76, 1.82 tal events: 40 (Pregabalin 150 mg), 35 (Placebo) teresgeneity, not al = 1.32, df = 5 (P = 0.93); I ² = 0.0% 100.0 % 1.18 [0.76, 1.82	Heterogeneity: Chi ² = 0.98, df	= 1 (P = 0.32); 1 ² =0.0%				
Crofferd 2005 11/132 10/131 29.1 % 1.09 [0.48, 2.48 abtocal (95% CI) 132 131 29.1 % 1.09 [0.48, 2.48 all events: 11 (Pregabalin 150 mg). 10 (Placebo) terogenetity. rol applicable 1.09 [0.48, 2.68 1.09 [0.48, 2.48 at events: 40 (Pregabalin 150 mg). 35 (Placebo) 565 584 100.0 % 1.18 [0.76, 1.82 at events: 40 (Pregabalin 150 mg). 35 (Placebo) 565 584 100.0 % 1.18 [0.76, 1.82	Test for overall effect: Z = 0.03	(P = 0.98)				
bbtoral (95% CI) 132 131 29.1 % 1.09 [0.48, 2.48 al events: I1 (Pregabalin 150 mg). 10 (Placebo) terogeneity: not applicable 1.09 [0.48, 2.48 1.09 [0.48, 2.48 st for overall effect Z = 0.21 (P = 0.83) 565 584 100.0 % 1.18 [0.76, 1.82 at events: V(Pregabalin 150 mg). 35 (Placebo) terogeneity: Chi ² = 1.32, df = 5 (P = 0.93); l ² = 0.0% 1.09 [0.48, 2.48	3 Fibromyalgia					
tal events: 11 (Pregabalin 150 mg). 10 (Placebo) terogeneity: not applicable st for overall effect Z = 0.21 (P = 0.83) stal (95% CI) 565 584 100.0 % 1.18 [0.76, 1.82 al events: 40 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Chi ² = 1.32, df = 5 (P = 0.93); l ² = 0.0%	Crofford 2005	11/132	10/131		29.1 %	1.09 [0.48, 2.48
terogeneity: not applicable st for overall effect: Z = 0.21 (P = 0.83) srtal (95% CI) 565 584 100.0 % 1.18 [0.76, 1.82 ali events: 40 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Chi ² = 1.32, df = 5 (P = 0.93); I ² = 0.0%	Subtotal (95% CI)	132	131	+	29.1 %	1.09 [0.48, 2.48
tt for overall effect: Z = 0.21 (P = 0.83) stal (05% CI) 565 584 100.0 % 1.18 [0.76, 1.82 tal events: 40 (Pregabalin 150 mg), 35 (Placebo) teregeneity: CH ² = 1.32, df = 5 (P = 0.93); I ² = 0.0%	Total events: 11 (Pregabalin 150) mg), 10 (Placebo)				
tal (95% CI) 565 584 ← 100.0 % 1.18 [0.76, 1.82 tal events: 40 (Pregabalin 150 mg), 35 (Placebo) terogeneity: Chi ² = 1.32, df = 5 (P = 0.93); l ² = 0.0%	Heterogeneity: not applicable					
tal events: 40 (Pregabalin 150 mg), 33 (Placebo) terogeneity: Chi ² = 1.32, df = 5 (P = 0.93); l ² = 0.0%	Test for overall effect: $Z = 0.21$	(P = 0.83)				
terogeneity: $Chi^2 = 1.32$, df = 5 (P = 0.93); $l^2 = 0.0\%$	Total (95% CI)	565	584	•	100.0 %	1.18 [0.76, 1.82
	Total events: 40 (Pregabalin 150) mg), 35 (Placebo)				
st for overall effect: $Z = 0.73$ (P = 0.47)	Heterogeneity: Chi ² = 1.32, df	= 5 (P = 0.93); I ² =0.0%				
		(P = 0.47)				
st for subgroup differences: $Chi^2 = 0.0$, df = 2 (P = 0.0), $l^2 = 0.0\%$	Test for overall effect: $Z = 0.73$					

-

Analysis 2.1 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 1 At least 30% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 1 At least 30% pain relief

	M-H,Fixed,95% CI	n/N	n/N	
				I Postherpetic neuralgia
62.8 %	-	28/90	51/88	Stacey 2008
37.2 %		16/93	40/98	van Seventer 2006
100.0 %	•	183	186	Subtotal (95% CI)
			erimental), 44 (Placebo)	Total events: 91 (Favours exp
			df = 1 (P = 0.44); $l^2 = 0.0\%$	Heterogeneity: $Chi^2 \approx 0.60$,
			B0 (P < 0.00001)	Test for overall effect: $Z = 4.1$
				2 Painful diabetic neuropathy
73.2 %	-	79/151	89/153	A0081071 2007
26.8 %		32/97	50/81	Lesser 2004
100.0 %	•	248	234	Subtotal (95% CI)
			perimental), III (Placebo)	Total events: 139 (Favours ex
			df = 1 (P = 0.01); l ² =86%	Heterogeneity: Chi ² = 6.98,
			II (P = 0.0019)	Test for overall effect: $Z = 3$.
				3 Fibromyalgia
21.2 %		34/184	59/183	A0081100 2008
34.8 %		56/184	76/183	Amold 2008
22.7 %		36/131	51/134	Crofford 2005
21.3 %		34/184	80/185	Mease 2008
100.0 %	•	683	685	Subtotal (95% CI)
			perimental), 160 (Placebo)	Total events: 266 (Favours e>
			df = 3 (P = 0.08); $I^2 = 56\%$	Heterogeneity: Chi ² = 6.78,
			DI (P < 0.00001)	Test for overall effect: $Z = 6.0$
% % % % %	372. 100.0 9 732 268 100.0 9 212 348 227 213	 372 100.0 9 732 268 100.0 9 100.0 9 212 348 227 213 	1693 - 372 183 - 372 183 - 100.0 9 79/151 732 32/97 - 268 248 - 100.0 9 34/184 - 21/2 56/184 - 348 36/131 - 227 34/184 - 21/3	4098 1693 - 372 186 183 - 100.0 9 r= 1 (P = 0.44); P = 0.0% 89/153 79/151 - 732 50/8 3297 - 26.8 234 248 - 100.0 9 r= 1 (P = 0.01); P = 86% 11 (P = 0.01); P = 86% 11 (P = 0.01); P = 86% 51/13 34/184 - 21.2 76/183 56/184 - 34.8 51/134 36/131 - 22.7 80/185 34/184 - 21.3 90/185 34/184 - 21.3 100.0 9 r= 1 (P = 0.06); P = 56%

_

Analysis 2.2 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 2 At least 50% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 2 At least 50% pain relief

Study or subgroup	Pregabalin 300 mg n/N	Placebo n/N	Risk Ratio M-H.Fixed,95% Cl	Weight	Risk Ratio M-H.Fixed,95% C
	1914	17/15	1-1-FT,FTXEU,7376 CJ		11PH, HXEU, 7578 C
Postherpetic neuralgia					
A0081120 2008	32/89	15/98		31.0 %	2.35 [1.37, 4.04
Sabatowski 2004	21/76	8/81		16.8 %	2.80 [1.32, 5.93
Stacey 2008	35/88	17/90		36.5 %	2.11 [1.28, 3.47
van Seventer 2006	26/98	7/93		15.6 %	3.52 [1.61, 7.73
Subtotal (95% CI)	351	362	•	100.0 %	2.52 [1.86, 3.42
fotal events: 114 (Pregabalin	300 mg), 47 (Placebo)				
-leterogeneity: Chi ² = 1.34, c	df = 3 (P = 0.72); I ² =0.0%				
lest for overall effect: Z = 5.9	€4 (P < 0.00001)				
2 Painful diabetic neuropathy					
A0081071 2007	62/153	53/151	+	49.1 %	1.15 [0.86, 1.54
Lesser 2004	37/81	17/97		14.2 %	2.61 [1.59, 4.27
Rosenstock 2004	30/76	10/70		9.6 %	2.76 [1.46, 5.23
Tolle 2008	33/99	29/96		27.1 %	1.10 [0.73, 1.67
Subtotal (95% CI)	409	414	•	100.0 %	1.50 [1.23, 1.83
fotal events: 162 (Pregabalin	300 mg), 109 (Placebo)				
-leterogeneity: Chi ² = 13.63,	df = 3 (P = 0.003); l ² =78%				
Test for overall effect: Z = 3.9	98 (P = 0.000070)				
3 Fibromyalgia					
A0081100 2008	32/183	17/184		17.2 %	1.89 [1.09, 3.29
Arnold 2008	44/183	28/184		28.3 %	1.58 [1.03, 2.42
Crofford 2005	25/134	17/131		17.4 %	1.44 [0.82, 2.53
Mease 2008	46/185	37/190		37.0 %	1.28 [0.87, 1.87
Subtotal (95% CI)	685	689	•	100.0 %	1.50 [1.19, 1.89
fotal events: 147 (Pregabalin	300 mg), 99 (Placebo)				
-leterogeneity: Chi ² = 1.44, c	$df = 3 (P = 0.70); l^2 = 0.0\%$				
lest for overall effect: Z = 3.4	\$2 (P = 0.00062)				

Analysis 2.3 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 3 Much or very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 3 Much or very much improved

Study or subgroup	Pregabalin 300 mg n/N	Placebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Rati M-H,Fixed,95% (
1 Postherpetic neuralgia					
Sabatowski 2004	29/76	11/81		40.9 %	2.81 [1.51, 5.22
van Seventer 2006	27/98	15/93		59.1 %	1.71 [0.97, 3.00
Subtotal (95% CI)	174	174		100.0 %	2.16 [1.43, 3.27
Total events: 56 (Pregabalin 3	100 mg), 26 (Placebo)				
Heterogeneity: Chi ² = 1.36, d	df = 1 (P = 0.24); $l^2 = 26\%$				
Test for overall effect: $Z = 3.6$	64 (P = 0.00027)				
2 Painful diabetic neuropathy					
Lesser 2004	44/79	23/85		40.5 %	2.06 [1.38, 3.07
Tolle 2008	42/99	32/96		59.5 %	1.27 [0.88, 1.83
Subtotal (95% CI)	178	181		100.0 %	1.59 [1.22, 2.08
Total events: 86 (Pregabalin 3	100 mg), 55 (Placebo)				
Heterogeneity: Chi ² = 3.03, d	df = 1 (P = 0.08); $I^2 = 67\%$				
Test for overall effect: $Z \approx 3.4$	40 (P = 0.00067)				
3 Fibromyalgia					
A0081100 2008	58/183	50/184		26.3 %	1.17 [0.85, 1.60
Arnold 2008	51/183	39/184		20.6 %	1.31 [0.91, 1.89
Crofford 2005	60/134	34/131		18.2 %	1.73 [1.22, 2.44
Mease 2008	80/185	67/190		34.9 %	1.23 [0.95, 1.58
Subtotal (95% CI)	685	689	-	100.0 %	1.32 [1.13, 1.54
Total events: 249 (Pregabalin	300 mg), 190 (Placebo)				
Heterogeneity: Chi ² = 3.22, d	df = 3 (P = 0.36); I ² =7%				
Test for overall effect: $Z = 3.4$	49 (P = 0.00048)				
			0.5 0.7 1 1.5 2		
			avours placebo Favours pregab	10 C	

Analysis 2.4 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 4 Very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 4 Very much improved

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
I Fibromyalgia					
A0081100 2008	13/183	7/184		9.7 %	1.87 [0.76, 4.57
Arnold 2008	18/183	12/184		16.6 %	1.51 [0.75, 3.04]
Crofford 2005	56/134	32/131		44.9 %	1.71 [1.19, 2.46
Mease 2008	28/175	21/178		28.9 %	1.36 [0.80, 2.29
Subtotal (95% CI)	675	677	-	100.0 %	1.59 [1.22, 2.07]
Total events: 115 (Pregabalin),	72 (Placebo)				
Heterogeneity: Chi ² = 0.65, d	$f = 3 (P = 0.88); I^2 = 0$	0.0%			
Test for overall effect: Z = 3.4	4 (P = 0.00057)				
			0.5 0.7 1 1.5 2		
			Favours placebo Favours pregab	alin	

Analysis 2.5 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 5Withdrawal - lack of efficacy

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 5 Withdrawal - lack of efficacy

Study or subgroup	Pregabalin 300 mg n/N	Placebo n/N	Risk Ratio M-H.Fixed.95% CI	Weight	Risk Ra M-H,Fixed,95%
I Postherpetic neuralgia					
A0081120 2008	1/98	6/98	•	4.9 %	0.17 [0.02, 1.3
Sabatowski 2004	1/76	7/81	·-	5.5 %	0.15 [0.02, 1.2
Stacey 2008	1/88	5/90	*	4.0 %	0.20 [0.02, 1.7;
van Seventer 2006	13/98	22/93		18.4 %	0.56 [0.30, 1.05
Subtotal (95% CI)	360	362	-	32.9 %	0.39 [0.23, 0.67
Total events: 16 (Pregabalin 3	0.00	502		52.7 70	0.57 [0.25, 0.07
Heterogeneity: Chi ² = 3.08,					
Test for overall effect: Z = 3.	, ,.				
2 Painful diabetic neuropathy	1				
Rosenstock 2004	1/76	3/70	• • • • • • • • • • • • • • • • • • • •	2.6 %	0.31 [0.03, 2.88
Tolle 2008	5/99	11/96	******	9.1 %	0.44 [0.16, 1.2
Subtotal (95% CI)	175	166		11.7 %	0.41 [0.16, 1.04
Total events: 6 (Pregabalin 30	0 mg), 14 (Placebo)				. ,
Heterogeneity: Chi ² = 0.08,					
Test for overall effect: Z = 1.					
3 Fibromvalgia					
A0081100 2008	6/183	8/184		6.5 %	0.75 [0.27, 2.13
Arnold 2008	8/183	20/184		16.3 %	0.40 [0.18, 0.85
Crofford 2005	6/134	18/131		14.9 %	0.33 [0.13, 0.80
Mease 2008	9/185	22/190	unanana 📕 mananan	17.7 %	0.42 [0.20, 0.89
Subtotal (95% CI)	685	689	+	55.4 %	0.43 [0.28, 0.65
Total events: 29 (Pregabalin 3	00 mg), 68 (Placebo)				
Heterogeneity: Chi ² = 1.53,	df = 3 (P = 0.68); $I^2 = 0.0\%$				
Test for overall effect: Z = 3.	94 (P = 0.000080)				
Total (95% CI)	1220	1217	•	100.0 %	0.41 [0.30, 0.57
Total events: 51 (Presshalin 3	00 mg), 122 (Placebo)				
	$df = 9 (P = 0.87); I^2 = 0.0\%$				
Heterogeneity: $Chi^2 \approx 4.60$,					

0.1 0.2 0.5 I 2 5 I0 Favours pregabalin Favours placebo

Analysis 2.6 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 6 Somnolence

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 6 Somnolence

Study or subgroup	Pregabalin 300 mg	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Postherpetic neuralgia					
A0081120 2008	22/89	9/98		12.4 %	2.69 [1.31, 5.53]
Sabatowski 2004	18/76	6/81		8.4 %	3.20 [1.34, 7.63]
Stacey 2008	17/88	2/90	•	2.9 %	8.69 [2.07, 36.52]
van Seventer 2006	11/98	4/93		5.9 %	2.61 [0.86, 7.91]
Subtotal (95% CI)	351	362	+	29.6 %	3.40 [2.13, 5.41]
Total events: 68 (Pregabalin 3	800 mg), 21 (Placebo)				
Heterogeneity: Chi ² = 2.28,	df = 3 (P = 0.52); $l^2 = 0.0\%$				
Test for overall effect: Z = 5.	15 (P < 0.00001)				
2 Painful diabetic neuropathy					
A0081071 2007	29/153	8/151		11.6 %	3.58 [1.69, 7.57]
Lesser 2004	19/81	4/97		5.3 %	5.69 [2.02, 16.05]
Rosenstock 2004	15/76	2/70		3.0 %	6.91 [1.64, 29.13]
Tolle 2008	4/99	1/96		1.5 %	3.88 [0.44, 34.08]
Subtotal (95% CI)	409	414	-	21.4 %	4.59 [2.67, 7.87]
Total events: 67 (Pregabalin 3	800 mg), 15 (Placebo)				
Heterogeneity: Chi ² = 0.92,	df = 3 (P = 0.82); I ² =0.0%				
Test for overall effect: Z = 5.	53 (P < 0.00001)				
3 Fibromyalgia					
A0081100 2008	37/183	11/184		15.9 %	3.38 [1.78, 6.42]
Arnold 2008	23/183	7/184		10.1 %	3.30 [1.45, 7.51]
Crofford 2005	37/134	6/131		8.8 %	6.03 [2.63, 13.80]
Mease 2008	39/185	10/190		14.3 %	4.01 [2.06, 7.79]
Subtotal (95% CI)	685	689	+	49.0 %	4.02 [2.80, 5.77]
Total events: 136 (Pregabalin	300 mg), 34 (Placebo)				
Heterogeneity: Chi ² = 1.42,	df = 3 (P = 0.70); I ² =0.0%				
Test for overall effect: $Z = 7$.	56 (P < 0.00001)				
Total (95% CI)	1445	1465	•	100.0 %	3.96 [3.08, 5.09]
Total events: 271 (Pregabalin	300 mg), 70 (Placebo)				
Heterogeneity: Chi ² = 5.55,	df = 11 (P = 0.90); $1^2 = 0.0\%$				
Test for overall effect: Z = 10	0.70 (P < 0.00001)				
Test for subgroup differences	c Chi ² = 0.0, df = 2 (P = 0.0)	, l ² ≕0.0%			

Favours pregabalin Favours placebo

Analysis 2.7 Comparison 2 Pregabalin 300 mg daily versus placebo, **Outcome 7 Dizziness**

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 7 Dizziness

Study or subgroup	Pregabalin 300 mg n/N	Placebo n/N	Risk Ratio	Weight	Risk Ratio
Mark and the second	n/n	B/IN	M-H,Fixed,95% CI		M-H,Fixed,95% C
1 Postherpetic neuralgia A0081100 2008	27/89	7/98		5.3 %	4.25 [1.95, 9.27]
Sabatowski 2004	21/76	12/81		9.3 %	1.87 [0.99, 3.52]
	27/88	6/90		4.7 %	
Stacey 2008					4.60 [2.00, 10.60]
van Seventer 2006	32/98	9/93		7.4 %	3.37 [1.70, 6.68]
Subtotal (95% CI)	351	362	•	26.7 %	3.24 [2.27, 4.64]
Total events: 107 (Pregabalin 3					
Heterogeneity: Chi ² = 4.05, d					
Test for overall effect: $Z = 6.4$	5 (P < 0.00001)				
2 Painful diabetic neuropathy A0081071 2007	36/153	5/151		4.0 %	7.11 [2.87, 17.62]
Lesser 2004	22/81	5/97		3.6 %	5.27 [2.09, 13.29]
		8/70			
Rosenstock 2004	27/76			6.7 %	3.11 [1.51, 6.38]
Tolle 2008	9/99	2/96	******	1.6 %	4.36 [0.97, 19.68]
Subtotal (95% CI)	409	414	+	15.9 %	4.74 [3.00, 7.49]
Total events: 94 (Pregabalin 30 Heterogeneity: $Chi^2 = 2.15$, d Test for overall effect: $Z = 6.6$ 3 Fibromyalgia	f = 3 (P = 0.54); l ² =0.0% 7 (P < 0.00001)				
A0081100 2008	68/183	28/184	-	22.3 %	2.44 [1.65, 3.61]
Arnold 2008	51/183	14/184		11.1 %	3.66 [2.10, 6.38]
Crofford 2005	42/134	14/131		11.3 %	2.93 [1.68, 5.11]
Mease 2008	60/185	16/190		12.6 %	3.85 [2.31, 6.43]
Subtotal (95% CI) Total events: 221 (Pregabalin 3 Heterogeneity: Chi ² = 2.50, dl Test for overall effect: Z = 9.0	$f = 3 (P = 0.47); I^2 = 0.0\%$	689	•	57.4 %	3.09 [2.42, 3.94]
Total (95% CI)	1445	1465	•	100.0 %	3.39 [2.82, 4.08
Total events: 422 (Pregabalin 3					
Heterogeneity: Chi ² = 11.11,					
Test for overall effect: $Z = 13.0$	01 (P < 0.00001) Chi ² = 0.0, df = 2 (P = 0.0)	8 -0.00			

0.1 0.2 0.5 1 2 5 10 Favours pregabalin Favours placebo

Analysis 2.8 Comparison 2 Pregabalin 300 mg daily versus placebo, Outcome 8Withdrawal - adverse event

Review: Pregabalin for acute and chronic pain in adults Comparison: 2 Pregabalin 300 mg daily versus placebo Outcome: 8 Withdrawal - adverse event

Study or subgroup	Pregabalin 300 mg	Placebo	Risk Ratio	Weight	Risk Rati
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% (
l Postherpetic neuralgia					
A0081120 2008	16/89	5/98		4.2 %	3.52 [1.35, 9.22
Sabatowski 2004	12/76	8/81		6.8 %	1.60 [0.69, 3.70
Stacey 2008	17/88	5/90		4.3 %	3.48 [1.34, 9.02
van Seventer 2006	15/98	5/93		4.5 %	2.85 [1.08, 7.52
Subtotal (95% CI)	351	362	+	19.8 %	2.70 [1.71, 4.27
Total events: 60 (Pregabalin)	300 mg), 23 (Placebo)				
Heterogeneity: Chi ² = 2.08,	df = 3 (P = 0.56); I ² =0.0%				
Test for overall effect: Z = 4.	25 (P = 0.000022)				
2 Painful diabetic neuropathy	r				
A0081071 2007	24/153	12/151		10.6 %	1.97 [1.02, 3.80
Lesser 2004	3/81	3/97		2.4 %	1.20 [0.25, 5.77
Rosenstock 2004	8/76	2/70		1.8 %	3.68 [0.81, 16.76
Tolle 2008	11/99	3/96		2.7 %	3.56 [1.02, 12.35
Subtotal (95% CI)	409	414	-	17.4 %	2.29 [1.38, 3.80
Total events: 46 (Pregabalin :				17.1 70	2.2) [1.50, 5.00
Heterogeneity: Chi ² = 1.71,	df = 3 (P = 0.64); 1 ² = 0.0%				
Test for overall effect: $Z = 3$.	20 (P = 0.0014)				
	20 (P = 0.0014)				
Test for overall effect: Z = 3. 3 Fibromyalgia A0081100 2008	20 (P = 0.0014) 36/183	23/184	-	20.1 %	1.57 [0.97, 2.55
3 Fibromyalgia	,	23/184 20/184		20.1 %	
3 Fibromyalgia A0081100 2008	36/183				1.56 [0.92, 2.63
3 Fibromyalgia A0081100 2008 Arnold 2008	36/183 31/183	20/184	+ + -+	17.5 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27
3 Fibromyalgia A008 I 100 2008 Arnold 2008 Crofford 2005	36/183 31/183 10/134	20/184 10/131	+ + -+ +	17.5 % 8.9 %	1.57 [0.97, 2.55 1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18 1.57 [1.19, 2.07
3 Fibromyalgia A008 I 100 2008 Arnold 2008 Crofford 2005 Mease 2008	36/183 31/183 10/134 35/185 685	20/184 10/131 19/190	+ + + +	17.5 % 8.9 % 16.4 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18
3 Fibromyalgia A0081100 2008 Arnold 2008 Crofford 2005 Mease 2008 Subtotal (95% CI)	36/183 31/183 10/134 35/185 685 300 mg), 72 (Placebo)	20/184 10/131 19/190	+ + +	17.5 % 8.9 % 16.4 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18
3 Fibromyalgia A0081100 2008 Armold 2008 Crofford 2005 Mease 2008 Subtotal (95% CI) Total events: 112 (Pregabalin	36/183 31/183 10/134 35/185 685 300 mg), 72 (Placebo) df = 3 (P = 0.64); I ² = 0.0%	20/184 10/131 19/190	+ + •	17.5 % 8.9 % 16.4 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18
3 Fibromyalgia A0081100 2008 Arnold 2008 Crofford 2005 Mease 2008 Subtotal (95% CI) Total events: 112 (Pregabalin Heterogeneity: Chi ² = 1.71,	36/183 31/183 10/134 35/185 685 300 mg), 72 (Placebo) df = 3 (P = 0.64); I ² = 0.0%	20/184 10/131 19/190	+ + + •	17.5 % 8.9 % 16.4 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18
3 Fibromyalgia A0081100 2008 Arnold 2008 Crofford 2005 Mease 2008 Subtotal (95% CI) Total events: 112 (Pregabalin Heterogeneity: Chi = 1.71, Test for overall effect Z = 3.	36/183 31/183 10/134 35/185 685 300 mg), 72 (Placebo) df = 3 (P = 0.64); P = 0.0% 20 (P = 0.0014) 1445	20/184 10/131 19/190 689	+ + + •	17.5 % 8.9 % 16.4 % 62.8 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18 1.57 [1.19, 2.07
3 Fibromyalgia A008 100 2008 Arnold 2008 Crofford 2005 Mease 2008 Subtotal (95% CI) Total events: 112 (Pregabalin Heterogeneity: Chi ² = 1.71, Test for overall effect 2 = 3. Total events: 118 (Pregabalin Total events: 218 (Pregabalin	36/183 31/183 10/134 35/185 685 300 mg), 72 (Placebo) df = 3 (P = 0.64); P = 0.0% 20 (P = 0.0014) 1445	20/184 10/131 19/190 689	+ + + •	17.5 % 8.9 % 16.4 % 62.8 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18 1.57 [1.19, 2.07
3 Fibromyalgia A008 100 2008 Arnold 2008 Crofford 2005 Mease 2008 Subtotal (95% CI) Total events: 112 (Pregabalin Heterogeneity: Chi ² = 1.71, Test for overall effect 2 = 3. Total events: 118 (Pregabalin Total events: 218 (Pregabalin	36/183 31/183 10/134 35/185 685 300 mg), 72 (Placebo) df = 3 (P = 0.64); P = 0.0% 20 (P = 0.0014) 1445 300 mg), 115 (Macebo) df = 11 (P = 0.57); P = 0.0%	20/184 10/131 19/190 689	+ + + + + +	17.5 % 8.9 % 16.4 % 62.8 %	1.56 [0.92, 2.63 0.98 [0.42, 2.27 1.89 [1.12, 3.18 1.57 [1.19, 2.07

0.1 0.2 0.5 1 2 5

Favours pregabalin Favours placebo

Analysis 3.1 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 1 At least 30% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 1 At least 30% pain relief

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
I Fibromyalgia					
A0081100 2008	60/182	34/184		17.6 %	1.78 [1.24, 2.58
Arnold 2008	94/190	56/184		29.5 %	1.63 [1.25, 2.11
Crofford 2005	64/132	36/131		18.8 %	1.76 [1.27, 2.45
Mease 2008	79/183	67/190		34.1 %	1.22 [0.95, 1.58
Subtotal (95% CI)	687	689	•	100.0 %	1.54 [1.33, 1.79
Total events: 297 (Pregabalin),	193 (Placebo)				
Heterogeneity: Chi ² = 4.57, d	f = 3 (P = 0.21); I ² = 3	34%			
Test for overall effect: $Z = 5.8$	0 (P < 0.00001)				
			0.2 0.5 1 2 5		
			Favours placebo Favours pregabali		

Analysis 3.2 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 2 At least 50% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 2 At least 50% pain relief

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
I Fibromyalgia					
A0081100 2008	33/182	17/184		17.1 %	1.96 [1.13, 3.39
Arnold 2008	52/190	28/184		28.8 %	1.80 [1.19, 2.72
Crofford 2005	38/132	17/131	********	17.3 %	2.22 [1.32, 3.72
Mease 2008	46/183	37/190		36.8 %	1.29 [0.88, 1.89
Subtotal (95% CI)	687	689	•	100.0 %	1.71 [1.37, 2.14
Total events: 169 (Experiment	al), 99 (Control)				
Heterogeneity: Chi ² = 3.35, d	$f = 3 (P = 0.34); I^2 = 10!$	%			
Test for overall effect: Z = 4.7	I (P < 0.00001)				
			0.2 0.5 1 2 5		
			Favours placebo Favours pregabain		

Analysis 3.3 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 3 Much or very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 3 Much or very much improved

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Ratic
	n/N	n/N	M-H,Fixed,95% CI	6	M-H,Fixed,95% C
I Fibromyalgia					
A0081100 2008	66/182	50/184		26.3 %	1.33 [0.98, 1.81
Amold 2008	80/190	39/184		20.9 %	1.99 [1.44, 2.75]
Crofford 2005	69/132	34/131		18.0 %	2.01 [1.45, 2.81
Mease 2008	75/183	67/190		34.7 %	1.16 [0.90, 1.51
Subtotal (95% CI)	687	689	•	100.0 %	1.53 [1.32, 1.78]
Total events: 290 (Experimen	ital), 190 (Control)				
Heterogeneity: Chi ² = 10.21,	df = 3 (P = 0.02); I ² =7	1%			
Test for overall effect: $Z = 5.0$	50 (P < 0.00001)				
			0.5 0.7 1 1.5 2		
			Favours placebo Favours pregabalir	1	

Analysis 3.4 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 4 Very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 4 Very much improved

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
I Fibromyalgia					
A0081100 2008	16/182	7/184		9.7 %	2.31 [0.97, 5.48
Arnold 2008	25/190	12/184		16.9 %	2.02 [1.05, 3.89
Crofford 2005	65/132	32/131		44.6 %	2.02 [1.42, 2.85
Mease 2008	26/173	21/178		28.8 %	1.27 [0.75, 2.18
Subtotal (95% CI)	677	677	•	100.0 %	1.83 [1.42, 2.37]
Total events: 132 (Pregabalin),	, 72 (Placebo)				
Heterogeneity: Chi ² = 2.42, d	$If = 3 (P = 0.49); I^2 = 0$	0.0%			
Test for overall effect: Z = 4.6	3 (P < 0.00001)				
			0.2 0.5 1 2 5		
			Favours placebo Favours pregabalir		

Analysis 3.5 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 5Withdrawal - lack of efficacy

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 5 Withdrawal - lack of efficacy

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Rati
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
I Fibromyalgia					1999 - Sana ang Pelanggan Sang Sang Sang Sang Sang Sang San
A0081100 2008	3/182	8/184		11.7 %	0.38 [0.10, 1.41
Arnold 2008	6/190	20/184		29.9 %	0.29 [0.12, 0.71
Crofford 2005	8/132	18/131		26.6 %	0.44 [0.20, 0.98
Mease 2008	6/183	22/190		31.8 %	0.28 [0.12, 0.68
Subtotal (95% CI)	687	689	+	100.0 %	0.34 [0.21, 0.54
Total events: 23 (Experiment	al), 68 (Control)				
Heterogeneity: Chi ² = 0.72,	df = 3 (P = 0.87); $ ^2 = 0.0$	%			
Test for overall effect: $Z = 4$.	62 (P < 0.00001)				
			0.1 0.2 0.5 1 2 5 10		
			Favours pregabalin Favours placebo		

Analysis 3.6 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 6 Somnolence

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 6 Somnolence

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
1 Fibromyalgia					
A0081100 2008	44/183	10/190		30.0 %	4.57 [2.37, 8.80
Arnold 2008	37/190	7/184		21.7 %	5.12 [2.34, 11.19]
Crofford 2005	37/132	6/131		18.4 %	6.12 [2.67, 14.01
Mease 2008	44/183	10/190		30.0 %	4.57 [2.37, 8.80
Subtotal (95% CI)	688	695	•	100.0 %	4.97 [3.47, 7.12]
Total events: 162 (Experiment	tal), 33 (Control)				
Heterogeneity: $Chi^2 \approx 0.38$, c	$ff = 3 (P = 0.95); I^2 = 0.00$	%			
Test for overall effect: Z = 8.7	'5 (P < 0.00001)				
			0.1 0.2 0.5 1 2 5 10		
			Favours pregabalin Favours placebo		

Analysis 3.7 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 7 Dizziness

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 7 Dizziness

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Rati
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
I Fibromyalgia					
A0081100 2008	76/182	28/184		38.8 %	2.74 [1.87, 4.02
Arnold 2008	71/190	14/184		19.8 %	4.91 [2.87, 8.39
Crofford 2005	65/132	14/131		19.6 %	4.61 [2.73, 7.78
Mease 2008	80/183	16/190		21.9 %	5.19 [3.16, 8.53
Subtotal (95% CI)	687	689	•	100.0 %	4.07 [3.22, 5.15
Total events: 292 (Experimen	tal), 72 (Control)				
Heterogeneity: Chi ² = 5.71, c	$f = 3 (P = 0.13); 1^2 = 47!$	6			
Test for overall effect: $Z = 11$.70 (P < 0.00001)				
			0.1 0.2 0.5 1 2 5 10		
			Favours pregabalin Favours placebo		

Analysis 3.8 Comparison 3 Pregabalin 450 mg daily versus placebo, Outcome 8Withdrawal - adverse event

Review: Pregabalin for acute and chronic pain in adults Comparison: 3 Pregabalin 450 mg daily versus placebo Outcome: 8 Withdrawal - adverse event

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
I Fibromyalgia					
A0081100 2008	36/183	23/184		31.9 %	1.57 [0.97, 2.55
Arnold 2008	43/190	20/184		28.2 %	2.08 [1.28, 3.40
Crofford 2005	17/132	10/131		14.0 %	1.69 [0.80, 3.55
Mease 2008	41/183	19/190		25.9 %	2.24 [1.35, 3.71
Subtotal (95% CI)	688	689	•	100.0 %	1.91 [1.46, 2.48]
Total events: 137 (Experiment	tal), 72 (Control)				
Heterogeneity: Chi ² = 1.23, d	If = 3 (P = 0.75); I ² =0.0	%			
Test for overall effect: Z = 4.7	8 (P < 0.00001)				
			0.1 0.2 0.5 1 2 5 10		
			Favours pregabalin Favours placebo		

Analysis 4.1 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 1 At least 30% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 1 At least 30% pain relief

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Rati
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% (
I Postherpetic neuralgia					
Dworkin 2003	56/89	21/84		33.0 %	2.52 [1.68, 3.77
Stacey 2008	64/91	28/90		43.0 %	2.26 [1.62, 3.16
van Seventer 2006	47/90	16/93		24.0 %	3.04 [1.86, 4.94
Subtotal (95% CI)	270	267	•	100.0 %	2.53 [2.01, 3.18
Total events: 167 (Pregabalin),	65 (Placebo)				
Heterogeneity: Chi ² = 0.97, d	$f = 2 (P = 0.62); I^2 = 0$	0.0%			
Test for overall effect: $Z = 7.9$	4 (P < 0.00001)				
2 Painful diabetic neuropathy					
A0081071 2007	94/152	79/151	-	53.9 %	1.18 [0.97, 1.44
Freynhagen 2005	171/273	24/65		26.3 %	1.70 [1.22, 2.36
Lesser 2004	53/81	32/97		19.8 %	1.98 [1.43, 2.74
Subtotal (95% CI)	506	313	•	100.0 %	1.48 [1.27, 1.72
Total events: 318 (Pregabalin),	135 (Placebo)				
Heterogeneity: $Chi^2 = 8.75$, d	f = 2 (P = 0.01); I ² =7	7%			
Heterogeneity: $Chi^2 = 8.75$, d Test for overall effect: Z = 5.0		7%			
0		7%			
Test for overall effect: $Z = 5.0$		9/67		100.0 %	3.13 [1.60, 6.10
Test for overall effect: $Z = 5.0$ 3 Central neuropathic pain	0 (P < 0.00001)		-	100.0 % 100.0 %	-
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006	0 (P < 0.00001) 29/69 69	9/67	-		3.13 [1.60, 6.10 3.13 [1.60, 6.10
Test for overall effect: Z = 5.00 3 Central neuropathic pain Siddall 2006 Subtotal (95% CI)	0 (P < 0.00001) 29/69 69	9/67	-		-
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtotal (95% CI) Total events: 29 (Pregabalin), 5	0 (P < 0.00001) 29/69 69 9 (Placebo)	9/67	-		
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtotal (95% CI) Total events: 29 (Pregabalin), 5 Heterogeneity: not applicable	0 (P < 0.00001) 29/69 69 9 (Placebo)	9/67	-		-
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtotal (95% CI) Total events: 29 (Pregabalin), 9 Heterogeneity: not applicable Test for overall effect: Z = 3.3	0 (P < 0.00001) 29/69 69 9 (Placebo)	9/67	-		3.13 [1.60, 6.10
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtotal (95% CI) Total events: 29 (Pregabalin), 5 Heterogeneity: not applicable Test for overall effect: Z = 3.3 4 Fibromyalgia	0 (P < 0.00001) 29/69 69 9 (Placebo) 5 (P = 0.00082)	9/67 67	÷	100.0 %	3.13 [1.60, 6.10
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtotal (95% CI) Total events: 29 (Pregabalin), 5 Heterogeneity: not applicable Test for overall effect: Z = 3.3 4 Fibromyalgia A008 I 100 2008	0 (P < 0.00001) 29/69 69 9 (Placebo) 5 (P = 0.00082) 49/186	9/67 67 34/184		100.0 % 21.7 %	3.13 [1.60, 6.10 1.43 [0.97, 2.10 1.54 [1.18, 20]
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtoat (95% CL) Total events: 29 (Pregabalin), 5. Heterogeneity: not applicable Test for overall effect: Z = 3.3 A0061100 2008 Arnold 2008 Mease 2008	0 (P < 0.00001) 29/69 €9 9 (Placebo) 5 (P = 0.00082) 49/186 88/188	9/67 67 34/184 56/184	÷	100.0 % 21.7 % 35.9 %	3.13 [1.60, 6.10 1.43 [0.97, 2.11 1.54 [1.18, 2.0 1.25 [0.98, 1.6
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddal 2006 Subtotal (95% CI) Total events: 2 2 (Pregabalin), 5 Heterogeneity: not applicable Test for overall effect: Z = 3.3 4 Fibromyalgia AO08 (100 2008 Arnold 2008 Mease 2008 Subtotal (95% CI) Total events: 221 (Pregabalin),	0 (P < 0.0001) 29/69 69 9 (Placebo) 5 (P = 0.00082) 49/186 88/188 84/190 564 157 (Placebo)	9/67 67 34/184 56/184 67/190 558		100.0 % 21.7 % 35.9 % 42.5 %	3.13 [1.60, 6.10 1.43 [0.97, 2.11 1.54 [1.18, 2.0 1.25 [0.98, 1.6
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddall 2006 Subtotal (95% CL) Total events: 29 (Pregabalin), 5 Heterogeneity: not applicable Test for overall effect: Z = 3.3 A0061100 2008 Amold 2008 Mease 2008 Subtotal (95% CL)	0 (P < 0.0001) 29/69 69 9 (Placebo) 5 (P = 0.00082) 49/186 88/188 84/190 564 157 (Placebo)	9/67 67 34/184 56/184 67/190 558	- - -	100.0 % 21.7 % 35.9 % 42.5 %	3.13 [1.60, 6.10 1.43 [0.97, 2.10 1.54 [1.18, 20 1.25 [0.98, 1.6
Test for overall effect: Z = 5.0 3 Central neuropathic pain Siddal 2006 Subtotal (95% CI) Total events: 2 2 (Pregabalin), 5 Heterogeneity: not applicable Test for overall effect: Z = 3.3 4 Fibromyalgia AO08 (100 2008 Arnold 2008 Mease 2008 Subtotal (95% CI) Total events: 221 (Pregabalin),	29/69 69 9 (Placebo) 5 (P = 0.00082) 49/186 88/188 84/190 564 157 (Placebo) f = 2 (P = 0.54); P =C	9/67 67 34/184 56/184 67/190 558	÷ • •	100.0 % 21.7 % 35.9 % 42.5 %	-

Analysis 4.2 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 2 At least 50% pain relief

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 2 At least 50% pain relief

Study or subgroup	Pregabalin n/N	Placebo n/N	Risk Ratio M-H.Fixed,95% CI	Weight	Risk Ratio M-H.Fixed.95% C
	n/IN	n/N	M-H,Fixed,95% CI		M-H/Hxed/A2% C
I Postherpetic neuralgia A0081120 2008	30/97	15/98		26.5 %	2.02 [1.16, 3.51
Dworkin 2003	45/89	17/84	ananan a shaana	31.0 %	2.50 [1.56, 4.00
Stacey 2008	42/91	17/90		30.3 %	2.44 [1.51, 3.96
van Seventer 2006	34/90	7/93		12.2 %	5.02 [2.35, 10.73
Subtotal (95% CI)	367	365	•	100.0 %	2.66 [2.04, 3.48
Total events: 151 (Pregabalin),	56 (Placebo)				
Heterogeneity: Chi ² = 3.82, d	f = 3 (P = 0.28); l ² = 2	22%			
Test for overall effect: Z = 7.1	5 (P < 0.00001)				
2 Painful diabetic neuropathy					
A0081071 2007	55/152	53/151	+	30.7 %	1.03 [0.76, 1.40
Arezzo 2008	40/82	20/85		11.3 %	2.07 [1.33, 3.23
Freynhagen 2005	137/273	32/130		25.0 %	2.04 [1.48, 2.82
Lesser 2004	39/81	17/97		8.9 %	2.75 [1.69, 4.47
Richter 2005	32/82	13/95		6.9 %	2.85 [1.61, 5.06
Tolle 2008	46/101	29/96		17.1 %	1.51 [1.04, 2.19
Subtotal (95% CI)	771	654	•	100.0 %	1.76 [1.51, 2.06
Total events: 349 (Pregabalin),		0,71		10010 /0	1,01,191,100
Heterogeneity: Chi ² = 19.93,		=75%			
Test for overall effect: $Z = 7.0$		10/0			
3 Central neuropathic pain	(, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
Siddall 2006	15/69	5/67	·····•	83.5 %	2.91 [1.12, 7.57
Vranken 2008	7/20	1/20	· · · · ·	16.5 %	7.00 [0.95, 51.80
Subtotal (95% CI)	89	87		100.0 %	3.59 [1.53, 8.42
Total events: 22 (Pregabalin), 6		67		100.0 %	5.57 [1.55, 0.42
Heterogeneity: $Chi^2 \approx 0.61$, d		0.00			
Test for overall effect: $Z = 2.9$.		1.076			
	3 (P = 0.0034)				
4 Fibromyalgia	20/10/	170.04		207.0	1 12 1 0 02 2 02
A0081100 2008	28/186	17/184		20.7 %	1.63 [0.92, 2.87
Arnold 2008	57/188	28/184		34.3 %	1.99 [1.33, 2.98
Mease 2008	51/190	37/190	+	44.9 %	1.38 [0.95, 2.0
Subtotal (95% CI)	564	558	+	100.0 %	1.64 [1.28, 2.10
fotal events: 136 (Pregabalin),					
Heterogeneity: Chi ² = 1.73, df		0.0%			
-					
Test for overall effect: $Z = 3.94$					

Analysis 4.3 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 3 Much or very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 3 Much or very much improved

	Pregabalin	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	M-H,Fixed,95% C
I Postherpetic neuralgia					
van Seventer 2006	33/90	15/93		100.0 %	2.27 [1.33, 3.89
Subtotal (95% CI)	90	93		100.0 %	2.27 [1.33, 3.89]
Total events: 33 (Pregabalin), 1	5 (Placebo)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 3.00$) (P = 0.0027)				
2 Painful diabetic neuropathy					
Arezzo 2008	52/82	36/85		24.7 %	1.50 [1.11, 2.02
Freynhagen 2005	144/273	40/130		37.9 %	1.71 [1.29, 2.27
Lesser 2004	54/78	23/95		14.5 %	2.86 [1.95, 4.20
Tolle 2008	51/101	32/96		22.9 %	1.51 [1.08, 2.13
Subtotal (95% CI)	534	406	-	100.0 %	1.78 [1.52, 2.09
Total events: 301 (Pregabalin),					
Heterogeneity: Chi ² = 8.04, df	'= 3 (P = 0.05); F =€	53%			
Test for overall effect: $Z = 7.05$	5 (P < 0.00001)				
3 Fibromyalgia					
A0081100 2008	66/190	67/190		38.7 %	0.99 [0.75, 1.30
Amold 2008	78/188	39/185		22.7 %	1.97 [1.42, 2.73
Mease 2008	87/190	67/190	*******	38.7 %	1.30 [1.01, 1.66
Subtotal (95% CI)	568	565	•	100.0 %	1.33 [1.13, 1.56
Total events: 231 (Pregabalin),	173 (Placebo)				
Heterogeneity: Chi ² = 10.18, d	$f = 2 (P = 0.01); I^2 =$	80%			
Test for overall effect: $Z = 3.50$	0 (P = 0.00046)				
			0.5 0.7 I I.5 2		
		F	avours placebo Favours pregabal	n	

Analysis 4.4 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 4 Very much improved

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 4 Very much improved

.

Study or subgroup	Pregabalin n/N	Placebo n/N		Risk Ratio ked,95% Cl	Weight	Risk Ratic M-H,Fixed,95% C
I Fibromyalgia						
A0081100 2008	20/186	7/184			17.6 %	2.83 [1.22, 6.52]
Arnold 2008	19/188	12/184	-	••••••	30.3 %	1.55 [0.77, 3.10
Mease 2008	27/175	21/178			52.1 %	1.31 [0.77, 2.22
Subtotal (95% CI)	549	546			100.0 %	1.65 [1.13, 2.39]
Total events: 66 (Pregabalin),	40 (Placebo)					
Heterogeneity: Chi ² = 2.36, c	$If = 2 (P = 0.31); I^2 = 1$	5%				
Test for overall effect: Z = 2.6	2 (P = 0.0087)					
			0.5 0.7	1 1.5 2		
			Favours placebo	Favours pregabalin		

_

Analysis 4.5 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 5Withdrawal - lack of efficacy

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 5 Withdrawal - lack of efficacy

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Rati
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
Postherpetic neuralgia					
A0081120 2008	3/97	6/98		3.3 %	0.51 [0.13, 1.96
Dworkin 2003	0/89	6/84	••••••	3.7 %	0.07 [0.00, 1.27
Stacey 2008	1/91	4/90	•	2.2 %	0.25 [0.03, 2.17
van Seventer 2006	6/90	22/93		12.1 %	0.28 [0.12, 0.66
Subtotal (95% CI)	367	365	+	21.4 %	0.28 [0.14, 0.53
Fotal events: 10 (Pregabalin), 38	3 (Placebo)				
Heterogeneity: Chi ² = 1.61, df	= 3 (P = 0.66); I ² = 0	0.0%			
Test for overall effect: $Z \approx 3.84$	(P = 0.00012)				
Painful diabetic neuropathy					
Arezzo 2008	4/82	5/85		2.7 %	0.83 [0.23, 2.98
Freynhagen 2005	13/273	38/130		28.7 %	0.16 [0.09, 0.30
Richter 2005	1/82	1/85		0.5 %	1.04 [0.07, 16.30
Tolle 2008	3/101	11/96		6.3 %	0.26 [0.07, 0.90
Subtotal (95% CI)	538	396	•	38.3 %	0.24 [0.15, 0.38
Fotal events: 21 (Pregabalin), 5		070		5015 10	0121 (012), 0150
Heterogeneity: $Chi^2 = 6.34$, df		392			
Test for overall effect: $Z = 6.03$		576			
3 Central neuropathic pain	(1 < 0.00001)				
Siddall 2006	5/70	20/67		11.4 %	0.24 [0.10, 0.60
Vranken 2008	0/20	1/20	•	0.8 %	0.33 [0.01, 7.72
Subtotal (95% CI)	90	87	-	12.2 %	0.25 [0.10, 0.59
Fotal events: 5 (Pregabalin), 21					
Heterogeneity: $Chi^2 = 0.04$, df		1.0%			
Test for overall effect: $Z = 3.12$	(P = 0.0018)				
Fibromyalgia					
A0081100 2008	5/186	8/184		4.5 %	0.62 [0.21, 1.85
Arnold 2008	6/188	20/184		11.3 %	0.29 [0.12, 0.71
Mease 2008	3/190	22/190	•	12.3 %	0.14 [0.04, 0.45
Subtotal (95% CI)	564	558	•	28.1 %	0.28 [0.15, 0.50
fotal events: 14 (Pregabalin), 50					
leterogeneity: Chi ² = 3.43, df		2%			
Test for overall effect: $Z = 4.33$					
	1559	1406	•	100.0 %	0.26 [0.19, 0.35
Total (95% CI)	54 (Placebo)				
fotal events: 50 (Pregabalin), 1					
fotal events: 50 (Pregabalin), 16 Heterogeneity: Chi ² = 11.88, d		=0.0%			
fotal events: 50 (Pregabalin), 1 Heterogeneity: Chi ² = 11.88, d fest for overall effect: Z = 8.83	(P < 0.00001)				
fotal events: 50 (Pregabalin), 16 Heterogeneity: Chi ² = 11.88, d	(P < 0.00001)				

Analysis 4.6 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 6 Somnolence

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 6 Somnolence

I Postherpetic neuralgia $\Delta OB 12 2038$ 3797 9796 Dworkin 2003 2269 664 7.3% $3.46 [1.48. 6]$ Stacey 2008 1091 2790 2.4% $455 [1.11, 21$ van Seventer 2006 2390 493 47% $594 [2.14, 16. 5]$ Subtocal (95% CI) 367 365 24.9% $4.36 [2.79, 6.8]$ Trail events 20 (Progabalin), 21 (Photebo) Heterogenetic, Cu ² = 0.68, d = 3 (P = 0.89); P = 0.000. Text Text for overall effect Z = 6.46 (P < 0.00001) 2 2 handi dabetic neuropathy $A008 1071 2007$ 257152 87151 95% $3100 [1.45, 6.8]$ Arezzo 208 11.82 565 58% $228 [0.83, 6.]$ $102 [1.45, 6.8]$ Freynhagen 2005 32.073 $0/130$ 0.8% $3108 [1.92, 503.]$ $108 [1.92, 503.]$ Liesser 2004 2292 497 43% $651 [2.34, 18.]$ 102% 73% $463 [2.05, 10.]$ Subtocal (95% CI) 772 644 25.1 % 5.04 [3.18, 8.0] 106% $100 (50. 1]$ 106% $100 (50. 1]$ $106 $	Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Rati
A0081120 2008 3797 998 Image: constraint of the second		n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
Dworkin 2003 2289 6494 Stacey 2008 1091 290 van Seventer 2006 2390 493 Subtoral (95% CI) 367 365 Total enters 20 (Fragbalan), 21 (Placebo) 47% 594 [2:14, 16] Hetergenery, CVP = 0.05, df = 3 [P = 0.05k] 4.36 [2:79, 6.8 Ter for owall effect, Z = 6.4 (P < 0.0001)						
Sacey 208 1091 290 443 455 [11, 2] van Seventer 206 2390 493 47% 554 [214, 16] Subtotal (95% CI) 367 365 24.9 % 4.36 [2.79, 6.8 Total events 92 (Pregbalain), 21 (Placebo) Heterogenety, Ch ² = 0.68, 0° = 0.008; 1° End to event effect. $Z = 6.46$ ($P < 0.00001$) 2 Panful diabetic neuropathy A0081071 2007 257152 87151 95 % 3.10 [145, 6. Arezo 2008 11/62 5/65 58 % 2.28 [0.83, 6. Freynhagen 2005 32.27.73 07130 0.8 % 31.068 [192, 503, Lesser 2004 2.2/82 4.977 4.3 % 6.51 [2.34, 18, Rether 2005 18/82 3/85 3.5 % 6.21 [2.34, 18, Rether 2005 18/82 3/85 3.5 % 6.21 [142, 128, 7.00 [0.57, 59, Subtotal (95% CI) 772 644 4. Total events 30 (Pregbalain), 21 (Placebo) Heterogenetic, Ch ² = 0.87 ($P = 0.003$); $P = 17%$ Total events 30 (Pregbalain), 15 (Placebo) Heterogenetic, Ch ² = 8.98, df = 1 ($P = 0.003$; $P = 17\%$ Total events 30 (Pregbalain), 15 (Placebo) Heterogenetic, Ch ² = 8.98, df = 1 ($P = 0.003$; $P = 17\%$ Total events 30 (Pregbalain), 27 (Placebo) Heterogenetic, Ch ² = 0.33 ($P = 0.003$; $P = 17\%$ Total events 30 (Pregbalain), 27 (Placebo) Heterogenetic, Ch ² = 2.94 ($P = 0.003$; $P = 10\%$ Total events 49 (Pregbalain), 27 (Placebo) Heterogenetic, Ch ² = 2.94 ($P = 0.003$; $P = 0.03$;	A0081120 2008	37/97	9/98		10.6 %	4.15 [2.12, 8.13
van Seventer 2006 $23/90$ $4/93$ 4.7% 5.44 [2.14, 16. Subtotal (95% CI) 367 365 24.9% 4.36 [2.79, 6.8 Total events: 92 (Pregulatin), 21 (Placebo) Heterogeneity, Ch ² = 0.08; h ² = 0.09;	Dworkin 2003	22/89	6/84		7.3 %	3.46 [1.48, 8.11
Subtotal (95% CI) 367 365 Total events: 92 (Pregabalin), 21 (Placebo) Heterogenety: $Ch^2 = 0.68$, $(l = 2, (l = 0.03); l = 0.05)$; Ers for overall effect: Z = 644 (l $(l = 0.000)$) 2 Painful dabetic neuropathy AOBI (071 2007 25/152 8/151 Preynhagen 2005 32/273 0/130 Lesser 2004 2282 4/97 Richter 2005 18/82 3/85 Total events: 105 18/82 3/85 Subtotal (95% CI) 772 644 Total events: 138 (Pregabalin), 21 (Placebo) 4/43 5.04 [3.18, 8.0 Heterogenetic, Ch ² = 605, df = 5 (l = 0.000); l ² = 17%. 5.04 [3.18, 8.0 5.04 [3.18, 8.0 Subtotal (95% CI) 9 87 7.3 % 4.63 [2.05, 10 Variken 2008 9/20 9/20 10.6 % 1.00 [0.50, 1: Subtotal (95% CI) 9 87 17.9 % 2.47 [1.47, 4.1 Heterogenetic, Ch ² = 8.9, df = 1 (l ² = 0.003); l ² = 19%. 11.8 % 5.30 [2.78, 10. Total events: 138 (Pregabalin), 15 (Placebo) 448 5.73 [2.44, 12. 4.36 5.73 [2.44, 12. Heterogenetic, Ch ² = 8.9, df = 1 (l ² = 0.003); l ² = 19%.	Stacey 2008	10/91	2/90		2.4 %	4.95 [1.11, 21.94
Total events: 10 (Pregulatin), 21 (Placebo) Heterogeneity: Ch ² = 0.86, df = 3 (P = 0.89); P = 0.0% Test for overall effect: Z = 6.46 (P < 0.00001) Zondi databetic neuropathy AO081071 2007 25/152 8/151 Arezzo 2008 11/82 5/85 Freynhagen 2005 32/273 0/130 Lesser 2004 22/82 4/97 Hitetrogeneity: Ch ² = 0.05; P = 10%; Total events: 116 (Pregulatin), 21 (Placebo) Heterogeneity: Ch ² = 6.65, df = 5 (P = 0.30); P = 17%; Test for overall effect: Z = 6.47 (P < 0.00001) 3 Central neuropathic pain Siddal 2006 29/70 6/67 Vranken 2008 9/20 9/20 Vranken 2008 9/20 9/20 Vranken 2008 9/20 9/20 Notal events: 8 (Pregulatin), 15 (Placebo) Heterogeneity: Ch ² = 0.98, df = 1 (P = 0.003); P = 9%; Test for overall effect: Z = 4.41 (P = 0.003); P = 9%; Test for overall effect: Z = 8.41 (P = 0.003); P = 9%; Test for overall effect: Z = 8.41 (P = 0.003); P = 9%; Test for overall effect: Z = 8.41 (P = 0.003); P = 9%; Test for overall effect: Z = 8.41 (P = 0.003); P = 9%; Test for overall effect: Z = 8.42 (P < 0.00001) Arnold 2008 41/188 7/184 Mease 2008 53/190 10/190 Fotal events: 147 (Pregulatin), 15 (Placebo) Heterogeneity: Ch ² = 0.03, fr = 2 (P = 0.9%); P = 0.0%; Test for overall effect: Z = 8.42 (P < 0.00001) Total (95% CL) 568 564 Fotal events: 147 (Pregulatin), 27 (Placebo) Heterogeneity: Ch ² = 2.576, df = 14 (P = 0.03); P = 0.0%; Test for overall effect: Z = 8.42 (P < 0.00001) Total (95% CL) 1777 1660 Total events: 30 (Placebo) Heterogeneity: Ch ² = 2.576, df = 14 (P = 0.03); P = 0.0%; Test for overall effect: Z = 8.42 (P < 0.00001) Total events: 30 (Placebo) Heterogeneity: Ch ² = 2.576, df = 14 (P = 0.03); P = 0.0%; Test for overall effect: Z = 8.42 (P < 0.00001) Total (95% CL) 278 (D,	van Seventer 2006	23/90	4/93		4.7 %	5.94 [2.14, 16.50
Total events: 92 (Pregabalin), 21 (Placebo) Heterogeneity: Ch ² = 0.8, df = 2 ($P = 0.8$); $P = 0.0\%$ Test for overall effect: Z = 6.46 ($P < 0.00001$) 2 Painful dabetic neuropathy A08 (071 2007 25/152 8/151 \rightarrow 95 % 3.10 [145, 6 Arezzo 2008 11/82 5/85 58% 2.28 [0.8], 6 Freynhagen 2005 32/273 0/130 \rightarrow 0.8 % 31.08 [1.92, 503. Lesser 2004 22/82 4/97 \rightarrow 43 % 6.51 [2.34, 18, Richter 2005 18/82 3/85 3.5 % 6.22 [1.90, 20. Tole 2008 8/101 11/96 12 % 7.60 [0.97, 59. Subtotal (95% CI) 772 644 \rightarrow 25.1 % 5.04 [3.18, 8.0 Total events: 116 (Pregabalin), 21 (Placebo) Heterogeneity: Ch ² = 6.65, df = 5 ($P = 0.00$); $P = 17\%$. Test for overall effect: Z = 6.47 ($P = 0.00001$) 3 Central neuropathic pain Siddal 2006 29/70 6/67 7.3 % 4.63 [2.05, 10. Vranken 2008 9/20 9/20 10.6 % 1.00 [0.50, 11. Subtotal (95% CI) 90 87 Total events: 140 (Pregabalin), 15 (Placebo) Heterogeneity: Ch ² = 8.98, df = 1 ($P = 0.003$); $P = 99\%$ Test for overall effect: Z = 3.41 ($P = 0.0036$; $P = 99\%$ Test for overall effect: Z = 8.42 ($P < 0.00006$) 4 Heterogeneity: Ch ² = 0.03 df = 2 ($P = 0.033$; $P = 99\%$ Test for overall effect: Z = 8.42 ($P < 0.00006$) 4 Heterogeneity: Ch ² = 8.98, df = 1 ($P = 0.0036$; $P = 99\%$ Test for overall effect: Z = 8.42 ($P < 0.00006$) 4 Heterogeneity: Ch ² = 2.576, df = 14 ($P = 0.033$; $P = 90\%$ Total events: 310 (D190 \rightarrow 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 \rightarrow 32.0 % 5.41 [3.65, 8.0 Heterogeneity: Ch ² = 2.576, df = 14 ($P = 0.033$; $P = 40\%$.	Subtotal (95% CI)	367	365	•	24.9 %	4.36 [2.79, 6.82
Test for overall effect: $Z = 6.46$ ($P < 0.00001$) 2 Panifel diabetic neuropathy A0081071 2007 25/152 8/151 $95.\%$ 3.10 [1.45, 6. Avezzo 2008 11/82 5/85 $58.\%$ 2.28 [0.83, 6. Freynhagen 2005 32/273 0/130 0.8% 31.08 [1.92, 503. Lesser 2004 22.962 4/97 4.3% 6.51 [2.34, 18. Richter 2005 18/82 3/85 $35.\%$ 6.22 [1.90, 20. Tole 2008 8/101 1/96 $12.\%$ 7.60 [0.97, 59. Subtrat (95% CI) 772 644 25.1% 5.04 [3.18, 8.0 Heteragenety: Ch ² = 65, df = 5 ($P = 0.30$); $P = 17\%$. Test for overall effect: $Z = 6.87$ ($P < 0.00001$) 3 Central neuropathic pain Action 2008 9/20 9/20 10.6 % 1.00 [0.50, 1: Subtrat (95% CI) 90 87 Total events: 38 (Pregubalin), 15 (Placebo) Heteragenety: Ch ² = 8.98, df = 1 ($P = 0.003$); $P = 89\%$ Test for overall effect: $Z = 8.41$ ($P = 0.0036$); $P = 89\%$ Total events: 38 (Pregubalin), 15 (Placebo) Heteragenety: Ch ² = 0.98, df = 1 ($P = 0.003$); $P = 89\%$ Total events: 38 (Pregubalin), 15 (Placebo) Heteragenety: Ch ² = 0.98, df = 1 ($P = 0.003$); $P = 89\%$ Total events: 38 (Pregubalin), 15 (Placebo) Heteragenety: Ch ² = 0.39, df = 1 ($P = 0.0036$); $P = 89\%$ Total events: 38 (Pregubalin), 27 (Placebo) Heteragenety: Ch ² = 0.03, df = 2 ($P = 0.093$); $P = 89\%$ Total events: 417 (Pregubalin), 27 (Placebo) Heteragenety: Ch ² = 0.03, df = 2 ($P = 0.093$); $P = 0.0\%$. Test for overall effect: $Z = 8.42$ ($P < 0.00006$) 4 11.8 % 5.30 (2.78, 10. 5 Subtrat (95% CI) 568 564 5 32.0 % 5.41 [3.65, 8.0] 5 31/90 10/190 5 31/90 10/19	Total events: 92 (Pregabalin), 2	I (Placebo)				
2 Painful diabetic neuropathy $\Delta 081071 2007$ 25/152 $B'151$ Arezzo 2008 11/82 5/85 5.8 % 2.28 [0.83, 6] Freynhagen 2005 32/273 0/130 0.8 % 31.06 [1.92, 503, 508 % 2.28 [0.83, 6] Lesser 2004 22/82 4.977 4.3 % 6.51 [2.34, 18, 6] Richter 2005 18/82 3/85 3.5 % 6.22 [1.90, 20, 7] Tole 2008 8/101 1.96 1.2 % 7.60 [0.97, 59] Subtotal (95% CI) 772 644 6.1 2 % 7.60 [0.97, 59] Subtotal (95% CI) 772 644 6.5, df = 5 (P = 0.30); l ² = 17%. 7.3 % 4.63 [2.05, 10] Yanken 2008 29/70 6/67 7.3 % 4.63 [2.05, 10] 10.0 [0.5, 1]: Subtotal (95% CI) 90 87 7.3 % 4.63 [2.05, 10] 10.0 [0.5, 1]: Subtotal (95% CI) 90 87 7.3 % 4.63 [2.05, 10] 10.0 [0.5, 1]: A0081100 2008 53/190 10/190 11.8 % 5.30 [2.78, 10] Arnold 2008 41/188 7/184 8.4 % 5.73 [2.64, 12]	Heterogeneity: $Chi^2 = 0.68$, df	= 3 (P = 0.88); I ² =0	0.0%			
A0881071 2007 $25/152$ $8/151$ 95% $3.10 [1.45, 6.0]$ Avezo 2008 11.82 5/85 5.8% $2.28 [0.83, 6.0]$ Freynhagen 2005 $32/273$ $0/130$ 0.8% $31.08 [1.92, 503.0]$ Lesser 2004 22.922 4.97 4.3% $6.51 [2.34, 18.0]$ Richter 2005 $18/82$ 3.85 3.5% $6.22 [1.90, 20.0]$ Tole 2008 $8/101$ 1.96 1.2% $7.60 [0.97, 59.0]$ Subtotal (95% CI) 772 644 6.67 7.3% $4.63 [2.05, 10.0]$ Total events: $116 (Pregabalin), 21 (Placebo)$ Heterogeneity: Ch ² = $6.96, d^2 = 1.09, 20.0$ 10.6% $100 [0.50, 11.0]$ Subtotal (95% CI) 90 87 7.3% $4.63 [2.05, 10.0]$ 10.6% Subtotal (95% CI) 90 87 7.3% $4.63 [2.05, 10.0]$ 11.8% $5.30 [2.78, 10.0]$ Arould 2008 $41/188$ $7/184$ 4.4% $5.73 [2.64, 12.0]$ 4.4% $5.73 [2.64, 12.0]$ Mease 2008 $53/190$ $10/190$ 11.8% $5.30 [2.78, 10.0]$ $4.53 [3.62, 5.6.0]$	Test for overall effect: $Z = 6.46$	(P < 0.00001)				
Arezzo 2008 11/82 5/85 5.8 % 2.28 [0.83, 6. Freynhagen 2005 32/273 0/130 0.8 % 31.08 [1.92, 503. Lesser 2004 2.2962 4.97 4.3 % 6.51 [2.34, 18. Richter 2005 1.862 3.85 3.5 % 6.22 [1.90, 20. Tolle 2008 8.1/01 1.96 1.2 % 7.60 [0.97, 59. Subtocal (95% CI) 772 644 644 25.1 % 5.04 [3.18, 8.0 Heterogenety: Ch ² = 6.05, df = 5 (P = 0.30); P = 17%. Test for overall effect: Z = 6.87 (P < 0.00001)						
Freynhagen 2005 $32/273$ $0/130$ 0.8 % 31.08 [1.92, 503. Lesser 2004 22.92 497 4.3 % 651 [2.34, 18. Rehter 2005 $18/82$ 385 35 % 622 [1.90, 20. Tolle 2008 $8/101$ $1/96$ $12.\%$ 760 [0.97, 59. Subtotal (95% CI) 772 644 4 25.1 % 5.04 [$3.18, 8.0$ Heterogenety. Ch ² = 605, df = 5 (P = 0.30); P = 17%. Test for overall effect: Z = 6.87 (P < 0.00001)	A0081071 2007	25/152	8/151		9.5 %	3.10 [1.45, 6.66
Lesser 2004 22/82 4/97 Rether 2005 18/82 3/85 Tole 2008 8/101 1/96 Subtotal (95% CI) 772 644 Total events: 116 (Progubalin), 21 (Placebo) Heterogenety: $Ch^2 = 657, (P < 0.0001)$ 3 Central neuropathic pain Siddall 2006 29/70 6/67 Vranken 2008 9/20 9/20 Subtotal (95% CI) 90 87 Total events: 87 (P < 0.0005) 4 Heterogenety: $Ch^2 = 898, df = 1 (P = 0.003); P = 89%$ Test for overall effect: Z = 3.41 (P = 0.0036) 4 Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); P = 89%$ Test for overall effect: Z = 3.41 (P = 0.0036); 4 Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 2.376, 10$ Subtotal (05% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Heterogenety: $Ch^2 = 2.576, df = 14 (P = 0.0031; P = 60%;$ Test for overall effect: Z = 8.42 (P < 0.00001) Total (05% CI) 1797 1660 Total events: 37 (Progubalin), 84 (Placebo) Heterogenety: $Ch^2 = 2.576, df = 14 (P = 0.031; P = 466%$	Arezzo 2008	11/82	5/85		5.8 %	2.28 [0.83, 6.28
Lesser 2004 22/82 4/97 Rether 2005 18/82 3/85 Tole 2008 8/101 1/96 Subtotal (95% CI) 772 644 Total events: 116 (Progubalin), 21 (Placebo) Heterogenety: $Ch^2 = 657, (P < 0.0001)$ 3 Central neuropathic pain Siddall 2006 29/70 6/67 Vranken 2008 9/20 9/20 Subtotal (95% CI) 90 87 Total events: 87 (P < 0.0005) 4 Heterogenety: $Ch^2 = 898, df = 1 (P = 0.003); P = 89%$ Test for overall effect: Z = 3.41 (P = 0.0036) 4 Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); P = 89%$ Test for overall effect: Z = 3.41 (P = 0.0036); 4 Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 898, df = 1 (P = 0.0036); 4$ Heterogenety: $Ch^2 = 2.376, 10$ Subtotal (05% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Heterogenety: $Ch^2 = 2.576, df = 14 (P = 0.0031; P = 60%;$ Test for overall effect: Z = 8.42 (P < 0.00001) Total (05% CI) 1797 1660 Total events: 37 (Progubalin), 84 (Placebo) Heterogenety: $Ch^2 = 2.576, df = 14 (P = 0.031; P = 466%$	Emunhanan 2005	22072	0/120	I	0.9 %	21.00 (1.02 502 50
Richter 2005 $18/82$ $3/85$ 35% 622 [19, 20. Tole 2008 $8/101$ $1/96$ 12% 760 [097, 59. Subtotal (95% CI) 772 644 25.1% 5.04 [097, 59. Total events: 116 (Progsbalin), 21 (Placebo) Heterogenety. Ch ² = 605, 61 = 5 (P = 030); P = 17%. Test for overall effect Z = 687 (P < 0.00001)						
Tolle 2008 $8/101$ $1/96$ Subtotal (95% CI) 772 644 Total events: 116 (Pregubalin), 21 (Placebo) $= 655, 646 = 25.1 \%$ 5.04 [3.18, 8.0 Heterogeneity: Ch ² = 605, 61 = 5 (P = 0.0001) $= 656, 70 = 606, 71 = 30\%$ $= 667, 73 \%$ $= 655, 100 = 050, 12 = 17\%$ Test for overall effect: Z = 6.87 (P < 0.00001)						
Subtotal (95% CI) 772 644 Total events: 116 (Pregubalin), 21 (Placebo) $= 656, d^{-5} (p = 0.30); l^{2} = 17\%$. Test for overall effect: Z = 6.87 ($p < 0.00001$) $= 356, d^{-5} (p < 0.0001)$ 3 Central neuropathic pain Siddall 2006 2970 3 Central neuropathic pain Siddall 2005 2970 Subtotal (95% CI) 90 87 Total events: 36 (Pregubalin), 15 (Placebo) 87 Heterogeneity: Chi ² = 898, df = 1 ($p = 0.003); l^{2}$ = 89% 17.9 % 2.47 [1.47, 4.1 Total events: 38 (Pregubalin), 15 (Placebo) 11.8 % 5.30 [2.78, 10. Heterogeneity: Chi ² = 898, df = 1 ($p = 0.003); l^{2}$ = 89% 11.8 % 5.30 [2.78, 10. Arnold 2008 531/90 10/190 11.8 % 5.30 [2.78, 10. Arnold 2008 531/90 10/190 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Feat events: 147 (Pregubalin), 27 (Placebo) Heterogeneity: Chi ² = 2.842 ($p < 0.00001$) 4.53 [3.62, 5.6 Total events: 37 (Pregubalin), 24 (Placebo) 1660 4.00.0 % 4.53 [3.62, 5.6 Total events: 37 (Pregubalin), 24 (Placebo) 4664	Richter 2005	18/82	3/85		3.5 %	6.22 [1.90, 20.32
Total events: 116 (Pregulatin), 21 (Placebo) Heterogenety: $Ch^2 = 605, cf = 5 (p = 0.30); l^2 = 17\%$. Test for overall effect: Z = 6.87 ($p < 0.00001$) 3 Central neuropathic pain Siddall 2006 2970 90 970 Vranken 2008 9720 90 87 Total events: 38 (Pregulatin), 15 (Placebo) Heterogeneity: $Ch^2 = 898, df = 1 (P = 0.003); P = 89%$ Test for overall effect: Z = 3.41 ($P = 0.0036; P = 89\%$ Heterogeneity: $Ch^2 = 898, df = 1 (P = 0.003); P = 89%$ Test for overall effect: Z = 3.41 ($P = 0.0036; P = 89\%$ Heterogeneity: $Ch^2 = 898, df = 1 (P = 0.0036; P = 89%$ Test for overall effect: Z = 3.41 ($P = 0.0036; P = 89\%$ Heterogeneity: $Ch^2 = 9.95, r^2 = 0.056; P = 0.$	Tolle 2008	8/101	1/96		1.2 %	7.60 [0.97, 59.66
Heterogeneity: $Ch^2 = 605$, $df = 5$ ($p = 0.30$); $l^2 = 17\%$ Test for overall effect: $Z = 648$ ($p < 0.00001$) 3 Gotdall 2006 29/70 6/67 7.3 % 4.63 [2.05, 10. Vranken 2008 9/20 9/20 10.6 % 1.00 [0.50, 1: Subtotal (95% CI) 90 87 7 7.3 % 4.63 [2.05, 10. Total events: 38 (Pregabalin), 15 (Placebo) Heterogeneity: $Ch^2 = 8.98$, $df = 1$ ($p = 0.003$); $l^2 = 89\%$ Test for overall effect: $Z = 3.41$ ($p = 0.003$); $l^2 = 89\%$ Historomyalga A0081 100 2008 53/190 10/190 11.8 % 5.30 [2.78, 10. Arnold 2008 41/188 7/184 84 % 5.73 [2.64, 12. Mease 2008 53/190 10/190 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Total events: 147 (Pregabalin), 27 (Placebo) Heterogeneity: $Ch^2 = 0.33$, $df = 2$ ($p = 0.99$); $l^2 = 0.0\%$ Test for overall effect: $Z = 8.42$ ($p < 0.00001$) Total (95% CI) 1797 1660 Total events: $Ch^2 = 25.76$, $df = 14$ ($p = 0.03$; $l^2 = -46\%$	Subtotal (95% CI)	772	644	+	25.1 %	5.04 [3.18, 8.00
Test for overall effect: $Z = 4.87$ ($P < 0.00001$) 3 Central neuropathic pain Siddull 2006 29/70 6/67 7.3 % 4.63 [2.05, 10. Vranken 2008 9/20 9/20 10.6 % 1.00 [0.50, 1: Subtoal (95% CI) 90 87 Total events: 36 (Pregubalin), 15 (Placebo) Heterogeneity: Ch ² = 8.98, df = 1 ($P = 0.033$); $P = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.0036$); $H = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.0036$); $H = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.0036$); $H = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.0036$); $H = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.0036$); $H = 80\%$ Arnold 2008 53/190 10/190 $-$ 11.8 % 5.30 [2.78, 10. Subtoal (95% CI) 568 564 $-$ 32.0 % 5.41 [3.65, 8.0 Total events: 317 (Pregubalin), 27 (Placebo) Heterogeneity: Ch ² = 2.576, df = 14 ($P = 0.03$); $P = 46\%$						
3 Central neuropathic pain Siddall 2006 29/70 6/67 7.3 % 4.63 [2.05, 10. Vranken 2008 9/20 9/20 10.6 % 1.00 [0.50, 1: Subtotal (95% CI) 90 87 7.7.9 % 2.47 [1.47, 4.1 Total events: 36 (Pregubain), 15 (Placebo) Heterogeneity: Chi ² = 898, df = 1 (P = 0.003); P = 89% Test for overall effect: Z = 3.41 (P = 0.003); P = 89% Test for overall effect: Z = 3.41 (P = 0.003); P = 89% Aoo81 100 2008 53/190 10/190 11.8 % 5.30 [2.78, 10. Amoid 2008 41/188 7/184 44 % 5.73 [2.64, 12. Mease 2008 53/190 10/190 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Total events: 3/7 (Pregubain), 27 (Placebo) Test for overall effect: Z = 8.42 (P < 0.00001) Total (95% CI) 1797 1660 Total events: 3/7 (Pregubain), 24 (Placebo) Heterogeneity: Chi ² = 25.76, df = 14 (P = 0.03); P = 46%	0 1		17%			
Siddall 2006 29/70 6/67		(P < 0.00001)				
Vranken 2008 9/20 9/20 10.6 % 1.00 [0.50, 12] Subtotal (95% CI) 90 87 17.9 % 2.47 [1.47, 4.1 Total events: 38 (Pregubalin), 15 (Placebo) 164 cm (2003); β = 89%, df = 1 (β = 0.003); β = 89% 17.9 % 2.47 [1.47, 4.1 Total events: 38 (Pregubalin), 15 (Placebo) 11.8 % 5.30 [2.78, 10. 11.8 % 5.30 [2.78, 10. Ac0081100 2008 53/190 10/190 I1.8 % 5.30 [2.78, 10. 11.8 % 5.30 [2.78, 10. Arnold 2008 41/188 7/184 II.8 % 5.30 [2.78, 10. 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Total events: 147 (Pregubalin), 27 (Placebo) 1660 32.0 % 5.41 [3.62, 5.6 Total events: 37 (Pregubalin), 27 (Placebo) 100.0 % 4.53 [3.62, 5.6 100.0 % 4.53 [3.62, 5.6 Total events: 37 (Pregubalin), 21 (Placebo) 100.0 % 4.53 [3.62, 5.6 5.6 Total events: 37 (Pregubalin), 12 (Placebo) 100.0 % 4.53 [3.62, 5.6 5.6						
Subtotal (95% CI) 90 87 Total events: 38 (Pregubalin), 15 (Placebo) 17.9% $2.47 [1.47, 4.1]$ Heterogeneity: $Ch^2 = 8.98$, $df = 1 (P = 0.033); P = 89\%$ 17.9% $2.47 [1.47, 4.1]$ Test for overall effect: $Z = 3.41 (P = 0.00066)$ 11.8% $5.30 [2.78, 10.]$ Arould 2008 $53/190$ $10/190$ 11.8% $5.30 [2.78, 10.]$ Arould 2008 $41/188$ $7/184$ 84% $5.73 [2.64, 12.]$ Mease 2008 $53/190$ $10/190$ 11.8% $5.30 [2.78, 10.]$ Subtotal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0] Total events: 30 (Pregubalin), 27 (Placebo) 11.8% $5.30 [2.78, 10.]$ 5.60 [1.60 [Siddall 2006	29/70	6/67		7.3 %	4.63 [2.05, 10.43
Total events: 38 (Pregubalin), 15 (Placebo) Heterogeneity: $Ch^2 = 8.98$, df = 1 ($P = 0.003$); $P = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.00066$) Hormonigation A0081100 2008 53/190 Arnold 2008 41/188 Mease 2008 53/190 Subtoral (95% CI) 568 Stabtoral (95% CI) 568 Total events: 147 (Pregubalin), 27 (Placebo) Heterogeneity: $Ch^2 = 0.03$, df = 2 ($P = 0.99$); $P = 0.0\%$. Test for overall effect: $Z = 8.42$ ($P < 0.00001$) Total events: 147 (Pregubalin), 24 (Placebo) Heterogeneity: $Ch^2 = 25.76$, df = 14 ($P = 0.03$; $P = 46\%$	Vranken 2008	9/20	9/20		10.6 %	1.00 [0.50, 1.98
Heterogeneity: $Chi^2 = 8.98$, $df = 1$ ($P = 0.003$); $P = 89\%$ Test for overall effect: $Z = 3.41$ ($P = 0.0006$) 4 A0081100 2008 53/190 10/190 Amold 2008 41/188 7/184 Mease 2008 53/190 10/190 Heterogeneity: $Chi^2 = 25.76$, $df = 14$ ($P = 0.03$); $P = 0.0\%$ Test for overall effect: $Z = 8.42$ ($P < 0.00001$) Total (95% CI) 1797 1660 Total events 37 (Strepshalin), 24 (Placebo) Heterogeneity: $Chi^2 = 25.76$, $df = 14$ ($P = 0.03$); $P = 46\%$	Subtotal (95% CI)	90	87	+	17.9 %	2.47 [1.47, 4.15
Test for overall effect: $Z = 3.41$ ($P = 0.00066$) 4 Fbromyalgia A0081100 2008 53/190 10/190 4 mold 2008 41/188 7/184 Mease 2008 53/190 10/190 4 11.8 $\%$ 5.30 [2.78, 10. Subtoal (95% CL) 568 564 50al events: 1/2 (Pregabalin), 27 (Placebo) Heterogeneity: Chi ² = 0.03, df = 2 ($P = 0.99$); $I^{2} = 0.0\%$ Test for overall effect: $Z = 8.42$ ($P < 0.00001$) Total (95% CL) 1797 1660 Total events: 1/2 ($P = 2.576$, df = 14 ($P = 0.03$); $I^{2} = 46\%$						
4 Fibromysigia $A0081100\ 2008$ 53/190 10/190 II.8 % 5.30 [2.78, 10. Arnold 2008 41/188 7/184 84 % 5.73 [2.64, 12. Mease 2008 53/190 10/190 II.8 % 5.30 [2.78, 10. Stabtocal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Total events: 147 (Pregabalin), 82 (P ecobo) II.8 % 5.30 [2.78, 10. 5.41 [3.65, 5.0 Test for overall effect: Z = 8.42 (P < 0.00001)	0		-89%			
A0081100 2008 53/190 10/190 → 11.8 % 5.30 [2.78, 10. Arnold 2008 41/188 7/184 → 8.4 % 5.73 [2.64, 12. Mease 2008 53/190 10/190 → 11.8 % 5.30 [2.78, 10. Subtrati (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Total events 30 (2.78, 10. → 32.0 % 5.41 [3.65, 8.0 Test for overall effect: Z = 8.42 (P < 0.00001)		(P = 0.00066)				
Arnold 2008 41/188 7/184 ▲ 84 % 5.73 [2.64, 12. Mease 2008 53/190 10/190 ↓ 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 → 32.0 % 5.41 [3.65, 8.0 Total events: 1747 (Pregabalin), 27 (Placebo) ↓ ↓ 12.8 % 5.41 [3.65, 8.0 Heterogeneity: Chi ² = 0.03, df = 2 (P = 0.99); P = 0.0%. ↓ ↓ ↓ 100.0 % 4.53 [3.62, 5.6 Total events: 393 (Pregabalin), 84 (Placebo) ↓ ↓ ↓ ↓ ↓ Heterogeneity: Chi ² = 25.76, df = 14 (P = 0.03); P = 46% ↓ ↓ ↓ ↓ ↓	1.0					
Mease 2008 53/190 10/190 → 11.8 % 5.30 [2.78, 10. Subtotal (95% CI) 568 564 32.0 % 5.41 [3.65, 8.0 Total events: 147 (Pregabalin), 27 (Placebo) → 10.0 % 5.41 [3.65, 8.0 Heterogeneity: Ch ² = 0.03, df = 2 (P = 0.99); P = 0.0%. → 100.0 % 4.53 [3.62, 5.6 Total (95% CI) 1797 1660 → 100.0 % 4.53 [3.62, 5.6 Heterogeneity: Ch ² = 25.76, df = 14 (P = 0.03); P = 46% → 4.53 [3.62, 5.6 →	A0081100 2008	53/190	10/190		11.8 %	5.30 [2.78, 10.10
Subtoral (95% CI) 568 564 Total events: 147 (Progabalin), 27 (Placebo) Heterogeneity: Chi ² = 0.03, df = 2 (P = 0.99); l ² = 0.0%. Test for overall effect: Z = 8.42 (P < 0.00001)	Arnold 2008	41/188	7/184		8.4 %	5.73 [2.64, 12.45
Total events: 147 (Pregubalin), 27 (Placebo) Heterogeneity: Ch ² = 0.03, df = 2 (P = 0.99); l ² = 0.0%. Test for overall effect: Z = 8.42 (P < 0.00001) Total (95% CI) 1797 1660 ◆ 100.0 % 4.53 [3.62, 5.6 Placeterus 393 (Pregabalin), 84 (Placebo) Heterogeneity: Ch ² = 25.76, df = 14 (P = 0.03); l ² = 46%	Mease 2008	53/190	10/190		11.8 %	5.30 [2.78, 10.10
Heterogeneity: Ch ² = 0.03, df = 2 (P = 0.99); l ² = 0.0%. Text for overall effect: Z = 8.42 (P < 0.00001) Total (95% CI) 1797 1660 ◆ 100.0 % 4.53 [3.62, 5.6 Total events 393 (Pregabalin), 84 (Piacebo) Heterogeneity: Ch ² = 25.76, df = 14 (P = 0.03); l ² = 46%			564	•	32.0 %	5.41 [3.65, 8.02
Test for overall effect: Z = 8.42 (P < 0.00001) Total (95% CI) 1797 1660 ◆ 100.0 % 4.53 [3.62, 5.6 Total events 39 (Pestable) A (Picatebo) Heterogeneity: Chi ² = 25.76, df = 14 (P = 0.03); I ² = 46%						
Total (95% CI) 1797 1660 100.0 % 4.53 [3.62, 5.6 Total events: 393 (Pregabalin). 84 (Placebo) Heterogeneity: Chi² = 25.76. df = 14 (P = 0.03); P² = 46% 100.0 % 4.53 [3.62, 5.6			0.0%			
Total events 393 (Pregatalin), 84 (Placebo) Haterogeneity: Chi ² = 25.76, df = 14 (P = 0.03); I ² =46%			1660		100.0.0/	1
Heterogeneity: $Chi^2 = 25.76$, df = 14 (P = 0.03); l ² = 46%			1660	•	100.0 %	4.53 [3.62, 5.67
			=46%			
Test for overall effect: $Z = 13.16$ (P < 0.00001)	Heterogeneity: Chi ² = 25.76, d					

Analysis 4.7 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 7 Dizziness

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 7 Dizziness

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Rati
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% C
1 Postherpetic neuralgia					
A0081120 2008	48/97	7/98		5.4 %	6.93 [3.30, 14.54
Dworkin 2003	25/89	10/84	******	8.0 %	2.36 [1.21, 4.61
Stacey 2008	22/91	6/90		4.7 %	3.63 [1.54, 8.52
van Seventer 2006	33/90	9/93		6.9 %	3.79 [1.92, 7.46
Subtotal (95% CI)	367	365	•	24.9 %	3.98 [2.78, 5.70
Total events: 128 (Pregabalin),	32 (Placebo)				
Heterogeneity: $Chi^2 = 4.55$, df	$f = 3 (P = 0.21); I^2 =$	34%			
Test for overall effect: $Z = 7.54$	4 (P < 0.00001)				
2 Painful diabetic neuropathy					
A0081071 2007	56/152	5/151		3.9 %	11.13 [4.58, 27.00
Arezzo 2008	27/82	5/85		3.8 %	5.60 [2.27, 13.83
Freynhagen 2005	65/273	6/130		6.3 %	5.16 [2.30, 11.59
Lesser 2004	32/82	5/97		3.5 %	7.57 [3.09, 18.54
Richter 2005	31/82	2/85		1.5 %	16.07 [3.97, 64.98
Tolle 2008	14/101	2/96		1.6 %	6.65 [1.55, 28.51
Subtotal (95% CI)	772	644	-	20.6 %	7.70 [5.17, 11.45
Total events: 225 (Pregabalin),	25 (Placebo)				
Heterogeneity: Chi ² = 3.18, di	$f = 5 (P = 0.67); I^2 =$	0.0%			
Test for overall effect: Z = 10.0					
3 Central neuropathic pain					
Siddall 2006	17/70	6/67		4.7 %	2.71 [1.14, 6.46
Vranken 2008	7/20	6/20		4.6 %	1.17 [0.48, 2.86
Subtotal (95% CI)	90	87	-	9.4 %	1.95 [1.05, 3.63
Total events: 24 (Pregabalin), 1	2 (Placebo)				
Heterogeneity: Chi ² = 1.81, df	f = 1 (P = 0.18); I ² =	45%			
Test for overall effect: $Z = 2.10$	0 (P = 0.035)				
4 Fibromyalgia					
A0081100 2008	93/186	28/184		21.8 %	3.29 [2.27, 4.76
Amold 2008	79/188	14/184		11.0 %	5.52 [3.25, 9.39
Mease 2008	88/190	16/190		12.4 %	5.50 [3.36, 9.01
Subtotal (95% CI)	564	558	+	45.1 %	4.44 [3.42, 5.75
fotal events: 260 (Pregabalin),	58 (Placebo)				
Heterogeneity: $Chi^2 = 3.91$, df	= 2 (P = 0.14); l ² =	19%			
est for overall effect: $Z = 11.2$					
Total (95% CI)	1793	1654	•	100.0 %	4.76 [3.99, 5.69
fotal events: 637 (Pregabalin),					
Heterogeneity: $Chi^2 = 29.40$, c		=52%			
Test for overall effect: $Z \approx 17.2$					
est for overall effect: Z = 17.2 est for subgroup differences: ($Chi^2 = 0.0, df = 3 (P)$	= 0.0), 1° =0.0%			

Analysis 4.8 Comparison 4 Pregabalin 600 mg daily versus placebo, Outcome 8Withdrawal - adverse event

Review: Pregabalin for acute and chronic pain in adults Comparison: 4 Pregabalin 600 mg daily versus placebo Outcome: 8 Withdrawal - adverse event

	Pregabalin	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% C
I Postherpetic neuralgia				1212121	
A0081120 2008	20/97	5/98		3.6 %	4.04 [1.58, 10.33
Dworkin 2003	28/89	4/84		3.0 %	6.61 [2.42, 18.04
Stacey 2008	4/91	5/90		3.6 %	0.79 [0.22, 2.85
van Seventer 2006	19/90	5/93		3.5 %	3.93 [1.53, 10.07
Subtotal (95% CI)	367	365	+	13.7 %	3.71 [2.28, 6.03]
Total events: 71 (Pregabalin), 1					
Heterogeneity: $Chi^2 = 6.89$, df		6%			
Test for overall effect: $Z = 5.28$	8 (P < 0.00001)				
2 Painful diabetic neuropathy					
A0081071 2007	36/152	12/151		8.7 %	2.98 [1.61, 5.50
Arezzo 2008	14/82	10/85	-+	7.1 %	1.45 [0.68, 3.08
Freynhagen 2005	57/273	10/130		9.8 %	2.71 [1.43, 5.14
Lesser 2004	10/82	3/97	+	2.0 %	3.94 [1.12, 13.85
Richter 2005	7/82	4/85		2.8 %	1.81 [0.55, 5.97
Tolle 2008	13/101	3/96		2.2 %	4.12 [1.21, 14.01
Subtotal (95% CI)	772	644	+	32.6 %	2.60 [1.86, 3.63
Test for overall effect: Z = 5.62 3 Central neuropathic pain	! (P < 0.00001)			6.6 %	1.60 [0.75, 3.40
	15.000			0.0 %	1.60 [0.75, 3.40
Siddall 2006	15/70	9/67			
Siddall 2006 Vranken 2008	3/20	3/20		2.2 %	
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabalin), 1 Heterogeneity: Chi ² = 0.30, df Test for overall effect: Z = 1.09	3/20 90 2 (Placebo) = 1 (P = 0.58); 1 ² = 0	3/20 87	-		
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabalin), 1 Heterogeneity: Chi ² = 0.30, df Test for overall effect: Z = 1.09	3/20 90 2 (Placebo) = 1 (P = 0.58); 1 ² = 0	3/20 87		2.2 %	1.45 [0.74, 2.83
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabalin), 1: Heterogeneity: Chi ² = 0.30, df Test for overall effect: Z = 1.09 4 Fibromyalgia	3/20 90 2 (Placebo) = I (P = 0.58); I ² = 0 6 (P = 0.28)	3/20 87	-	2.2 % 8.8 %	1.45 [0.74, 2.83 202 [1.28, 3.19
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabalin), 1 Heterogeneity: Chi ² = 0.30, df Test for overall effect: Z = 1.09 4 Fibromyalgia A0081100 2008	3/20 90 2 (Placebo) = 1 (P = 0.58); I ² =0 9 (P = 0.28) 47/186	3/20 87 1.0% 23/184		2.2 % 8.8 % 16.7 %	1.45 [0.74, 2.83 2.02 [1.28, 3.19 2.45 [1.52, 3.94
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabalin), 11 Heterogeneity: Ch ² = 0.30, d1 Heterogeneity: Ch ² = 0.09 4 Fibromyalgia A0081 100 2008 Arnold 2008 Mease 2008	3/20 90 2 (Placebo) = 1 (P = 0.58); I ² = 0 9 (P = 0.28) 47/186 50/188	3/20 87 10% 23/184 20/184	+ + +	2.2 % 8.8 % 16.7 % 14.6 %	1.45 [0.74, 2.83 2.02 [1.28, 3.19 2.45 [1.52, 3.94 3.26 [2.03, 5.24
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabain), 1 Heteroageneity: Ch ² = 0.30, df Ent for overall effect: Z = 1.09 4 Fibromyalgia AO081100 2008 Mease 2008 Subtotal (95% CI) Total events: 159 (Pregabain), Heteroageneity: Ch ² = 2.07, df	3/20 90 2 (Placebo) = 1 (P = 0.58); l ² = C (P = 0.28) 47/186 50/188 62/190 564 62 (Placebo) = 2 (P = 0.36); l ² = 3	3/20 87 23/184 20/184 19/190 558	* * *	2.2 % 8.8 % 16.7 % 14.6 % 13.7 %	1.45 [0.74, 2.83] 2.02 [1.28, 3.19 2.45 [1.52, 3.94 3.26 [2.03, 5.24
Siddall 2006 Vranken 2008 Subtotal (95% CI) Total events: 18 (Pregabalin), 1 Heterogeneity: Chi ² = 0.30, df Test for overall effect: Z = 1.09 4 Fibromyalgia A0081100 2008 Arnold 2008	3/20 90 2 (Flacebo) = 1 (P = 0.58); l ² = 0 (P = 0.28) 47/186 50/188 62/190 564 62 (Placebo) = 2 (P = 0.36); l ² = 3 (P < 0.0001) 1793 135 (Placebo) 1793 135 (Placebo) 1793 136 (Placebo) 1793 137 (Placebo) 1793 137 (Placebo) 1793 137 (Placebo) 1793 137 (Placebo) 1793 137 (Placebo) 1793 137 (Placebo) 1793 137 (Placebo) 1793 179 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1793 1795 1	3/20 87 23/184 20/184 19/190 558 % 1654 =20%	•	2.2 % 8.8 % 16.7 % 14.6 % 13.7 %	1.00 [023, 4.37 1.45 [0.74, 2.83] 202 [1.28, 3.19 245 [1.52, 394 3.26 [203, 5.24 2.54 [1.94, 3.32] 2.62 [2.18, 3.16]

Analysis 5.1 Comparison 5 Participants with at least one adverse event, Outcome 1 At least one adverse event

Review: Pregabalin for acute and chronic pain in adults Comparison: 5 Participants with at least one adverse event Outcome: 1 At least one adverse event

Study or subgroup	Pregabalin n/N	Piacebo n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% C
I Pregabalin 150 mg					
A0081120 2008	65/87	62/98		36.6 %	1.18 [0.97, 1.43
Crofford 2005	103/132	101/132	-	63.4 %	1.02 [0.89, 1.16
Subtotal (95% CI)	219	230	•	100.0 %	1.08 [0.97, 1.20
Total events: 168 (Pregabalin),					
Heterogeneity: $Chi^2 = 1.54$, df Test for overall effect: $Z = 1.35$		35%			
2 Pregabalin 300 mg	((0.10)				
A0081071 2007	124/153	98/151		14.3 %	1.25 [1.09, 1.44
A0081100 2008	155/183	135/184		19.6 %	1.15 [1.04, 1.28
A0081120 2008	78/89	62/98		8.6 %	1.39 [1.17, 1.64
Arnold 2008	148/183	132/184		19.1 %	1.13 [1.01, 1.26
Crofford 2005	118/134	101/132		14.8 %	1.15 [1.03, 1.29
Mease 2008	165/185	144/190		20.6 %	1.18 [1.07, 1.29
Rosenstock 2004	47/76	20/70		3.0 %	2.16 [1.44, 3.26
Subtotal (95% CI)	1003	1009	•	100.0 %	1.22 [1.16, 1.28
Total events: 835 (Pregabalin),	692 (Placebo)				
Heterogeneity: $Chi^2 = 14.00$, c		-57%			
Test for overall effect: $Z = 7.83$	8 (P < 0.00001)				
3 Pregabalin 450 mg A0081100 2008	164/182	135/184		26.3 %	1.23 [1.11, 1.36
Arnold 2008	167/190	132/184		26.2 %	1.23 [1.10, 1.36
Crofford 2005	121/134	101/132		19.9 %	1.18 [1.06, 1.32
Mease 2008	168/183	144/190	-	27.6 %	1.10 [1.06, 1.32
Subtotal (95% CI) Total events: 620 (Pregabalin),	689	690	•	100.0 %	1.21 [1.15, 1.28]
Heterogeneity: $Chi^2 \approx 0.34$, df		0.0%			
Test for overall effect: $Z = 7.50$	0 (P < 0.00001)				
4 Pregabalin 600 mg					
A0081071 2007	123/152	98/151		12.4 %	1.25 [1.08, 1.43
A0081100 2008	171/186	135/184		17.1 %	1.25 [1.14, 1.38
A0081120 2008	90/97	62/98		7.8 %	1.47 [1.25, 1.72
Amold 2008	165/188	132/184		16.8 %	1.22 [1.10, 1.36
Crofford 2005	121/132	101/132		12.7 %	
					1.20 [1.08, 1.33
Freynhagen 2005	169/273	18/65		3.7 %	2.24 [1.49, 3.35
Mease 2008	179/190	144/190		18.1 %	1.24 [1.14, 1.36
Siddall 2006	67/70	50/67		6.4 %	1.28 [1.11, 1.49
Stacey 2008	66/91	39/90		4.9 %	1.67 [1.28, 2.19
Subtotal (95% CI)	1379	1161	•	100.0 %	1.31 [1.25, 1.38
Total events: 1151 (Pregabalin) Heterogeneity: Chi ² = 19.26, c		-58%			
Test for overall effect: $Z = 11.6$.5.63.5			

-

Analysis 6.1 Comparison 6 Participants with at least one serious adverse event, Outcome 1 At least one serious adverse event

Review: Pregabalin for acute and chronic pain in adults Comparison: 6 Participants with at least one serious adverse event Outcome: 1 At least one serious adverse event

Study or subgroup	Pregabalin	Placebo	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
I Pregabalin 150 mg A0081120 2008	2/87	6/98		52.9 %	0.38 [0.08, 1.81]
Sabatowski 2004	4/81	3/81		28.1 %	1.33 [0.31, 5.77]
Tolle 2008	5/99	2/96		19.0 %	2.42 [0.48, 12.20]
Subtotal (95% CI)	267	275	-	100.0 %	1.03 [0.45, 2.38]
Total events: 11 (Pregabalin), 1 Heterogeneity: Chi ² = 2.78, df					
Heterogeneity: $Ch^2 = 2.78$, df Test for overall effect: $Z = 0.08$		(876			
2 Pregabalin 300 mg	(
A0081071 2007	14/153	6/151		22.5 %	2.30 [0.91, 5.83]
A0081100 2008	2/183	4/184	••	14.9 %	0.50 [0.09, 2.71]
A0081120 2008	5/89	6/98		21.3 %	0.92 [0.29, 2.90]
Arnold 2008	2/183	2/184		7.4 %	1.01 [0.14, 7.06]
Lesser 2004	0/81	3/97		11.9 %	0.17 [0.01, 3.26]
Sabatowski 2004	1/76	3/81	·	10.8 %	0.36 [0.04, 3.34]
Stacey 2008	1/88	1/90		3.7 %	1.02 [0.06, 16.10]
Tolle 2008	4/99	2/96		7.6 %	1.94 [0.36, 10.34]
Subtotal (95% CI)	952	981	-	100.0 %	1.11 [0.66, 1.85]
Total events: 29 (Pregabalin), 2					
Heterogeneity: $Chi^2 = 6.31$, df Test for overall effect: $Z = 0.36$		0.0%			
3 Pregabalin 450 mg	((= 0.70)				
A0081100 2008	8/182	4/184		66.2 %	2.02 [0.62, 6.60]
Amold 2008	2/190	2/184		33.8 %	0.97 [0.14, 6.80]
Subtotal (95% CI)	372	368		100.0 %	1.67 [0.61, 4.52]
Total events: 10 (Pregabalin), 6		000			10, (001, 191)
Heterogeneity: $Chi^2 = 0.40$, df	$= 1 (P = 0.53); I^2 = 0$	0.0%			
Test for overall effect: $Z = 1.00$) (P = 0.32)				
4 Pregabalin 600 mg A0081071 2007	14/152	6/151		18.1 %	2.32 [0.92, 5.87]
A0081071 2007	14/152	6/151		18.1 %	2.32 [0.72, 3.87]
A0081100 2008	4/186	4/184		12.1 %	0.99 [0.25, 3.90
A0081120 2008	0/97	6/98		19.5 %	0.08 [0.00, 1.36
Arezzo 2008	4/82	8/85		23.7 %	0.52 [0.16, 1.66
Arnold 2008	2/188	2/184		6.1 %	0.98 [0.14, 6.87
Lesser 2004	4/82	3/97		8.3 %	1.58 [0.36, 6.84
Siddall 2006	3/70	1/67		3.1 %	2.87 [0.31, 26.92
Stacey 2008	1/91	1/90	·	3.0 %	0.99 [0.06, 15.57
Tolle 2008	6/101	2/96		6.2 %	2.85 [0.59, 13.78
Subtotal (95% CI)	1049	1052	-	100.0 %	1.16 [0.74, 1.83
Total events: 38 (Pregabalin), 3					
	= 8 (P = 0.30); 2 = 1	6%			
Heterogeneity: Chi ² = 9.54, df					
Heterogeneity: $Chi^2 = 9.54$, df Test for overall effect: $Z = 0.65$	(P = 0.52)				

Appendix 1. PubMed search strategy

- 1. Exp PAIN/
- 2. pain*

- 3. Exp ANALGESIA/
- 4. analges*
- 5. neuralgi* or sciatica or headache* or colic* or toothache* OR earache* OR dysmenorrhea OR dysmenorrhoea OR arthralgi* OR neuropath*
- 6. OR/1-5
- 7. pregabalin OR lyrica
- 8. 6 AND 7 with Limits: 'Randomized controlled trial' and 'Human'

Search repeated without limits above, but limited to 'Published in the last 90 days'

Appendix 2. EMBASE (via OVID) search strategy

- 1. exp Pain/
- 2. exp Analgesia/
- 3. pain*.ti,ab.
- 4. analgesi*.ti,ab.
- 5. (neuralgi* or sciatica or headache* or colic* or toothache* OR earache* OR dysmenorrhea OR dysmenorrhoea OR arthralgi* OR arthriti* OR neuropath*).ti,ab.
- 6. OR/1-5
- 7. (pregabalin OR lyrica).ti,ab.
- 8. clinical trials.sh.
- 9. controlled clinical trials.sh.
- 10. double-blind procedure.sh.
- **11.** (clin* adj25 trial*).ab.
- 12. ((doubl* or trebl* or tripl*) adj25 (blind* or mask*)).ab.
- 13. placebo*.ab.
- 14. random*.ab.
- 15. OR/8-14
- 16. 6 AND 7 AND 15

Appendix 3. CENTRAL search strategy

- 1. exp MeSH descriptor Pain
- 2. exp MeSH descriptor Analgesia
- 3. pain*:ti,ab.kw
- 4. analgesi*:ti,ab.kw

Moore et al.

- 5. (neuralgi* or sciatica or headache* or colic* or toothache* OR earache* OR dysmenorrhea OR dysmenorrhoea OR arthralgi* OR arthriti* OR neuropath*):ti,ab.kw
- 6. OR/1-5
- 7. (pregabalin OR lyrica):ti,ab.kw
- 8. Randomized Controlled Trial.pt
- 9. MESH descriptor Double-Blind Method
- 10. ((double or treble or triple) adj25 (blind* or mask*)):ti,ab,kw
- 11. placebo*:ti,ab,kw
- 12. random*:ti,ab,kw
- **13.** OR/8-12
- 14. 6 AND 7 AND 13

WHAT'S NEW

Last assessed as up-to-date: 10 May 2009.

Date	Event	Description
24 September 2010	Amended	Contact details updated.

HISTORY

Protocol first published: Issue 2, 2008

Review first published: Issue 3, 2009

Date	Event	Description
25 August 2009	Amended	Minor amendment to Analysis 2.2. Results and conclusions unchanged
10 November 2008	Amended	Published protocol converted to new review format.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The main difference is that the final review has given particular weight to efficacy criteria defined by the IMMPACT study group (Dworkin 2008), and published after the protocol was written. A risk of bias table was completed. A post hoc sensitivity analysis for trial duration 8 weeks was carried out, based on increasing indications that trial duration affects efficacy estimates (Moore 2009)

References to studies included in this review

- A0081071 2007 {unpublished data only} . Anon. A randomized double-blind, placebo-controlled, parallel-group, multi-center trial of pregabalin versus placebo in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. PhRMA Clinical Study Synopsis 19 December 2007.
- A0081100 2008 {unpublished data only} . Anon. A 14-week, randomized, double-blind, placebocontrolled trial of pregabalin twice daily in patients with fibromyalgia. PhRMA Web Synopsis 7– March-2008.
- A0081120 2008 {unpublished data only} . Anon. A 13-week, randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety of pregabalin (CI-1008) in the treatment of postherpetic neuralgia. PhRMA Web Synopsis 1–September–2008.
- Agarwal 2008 {published data only} . Agarwal A, Gautam S, Gupta D, Agarwal S, Singh PK, Singh U. Evaluation of a single preoperative dose of pregabalin for attenuation of postoperative pain after laparoscopic cholecystectomy. British Journal of Anaesthetics. 2008; 101(5):700–4. [DOI: 10.1093/bja/aen244].
- Arezzo 2008 {published data only} . Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a doubleblind placebo-controlled trial. BMC Neurology. 2008; 8:33. [DOI: 10.1186/1471-2377-8-33]. [PubMed: 18796160]
- Arnold 2008 {published data only} . Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia. The Journal of Pain. 2008; 9(9):792–805.
 [DOI: 10.1016/j.jpain.2008.03.013]. [PubMed: 18524684]
- Crofford 2005 {published data only} . Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Pregabalin 1008-105 Study Group. et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatism. 2005; 52(4):1264–73. [DOI: 10.1002/art.20983]. [PubMed: 15818684]
- Crofford 2008 {published data only} . Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008; 136(3):419–31. [DOI: 10.1016/j.pain.2008.02.027]. [PubMed: 18400400]
- Dworkin 2003 {published data only} . Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003; 60:1274–83. [PubMed: 12707429]
- Freynhagen 2005 {published data only} . Freyhagen R, Busche P, Konrad C, Balkenohl M. Effectiveness and time to onset of pregabalin in patients with neuropathic pain. Schmerz. 2006; 20:285–92. [PubMed: 16205904]
- *Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005; 115:254–63. [DOI: 10.1016/j.pain.2005.02.032]. [PubMed: 15911152]
- Hill 2001 {published data only} . Hill CM, Balkenohl M, Thomas DW, Walker R, Mathé H, Murray G. Pregabalin in patients with postoperative dental pain. European Journal of Pain. 2001; 5(2):119–24. [PubMed: 11465977]
- Jokela 2008a {published data only} . Jokela R, Ahonen J, Tallgren M, Haanpää M, Korttila K. A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy. Pain. 2008; 134(1-2):106–12. [DOI: 10.1016/j.pain.2007.04.002]. [PubMed: 17507163]
- Jokela 2008b {published data only} . Jokela R, Ahonen J, Tallgren M, Haanpää M, Korttila K. Premedication with pregabalin 75 or 150 mg with ibuprofen to control pain after day-case gynaecological laparoscopic surgery. British Journal of Anaesthesia. 2008; 100(6):834–40. [DOI: 10.1093/bja/aen098]. [PubMed: 18448418]

- Lesser 2004 {published data only} . Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004; 63:2104–10. [PubMed: 15596757]
- Mathiesen 2009 {published data only} . Mathiesen O, Rasmussen ML, Dierking G, Lech K, Hilsted KL, Fomsgaard JS, et al. Pregabalin and dexamethasone in combination with paracetamol for postoperative pain control after abdominal hysterectomy. A randomized clinical trial. Acta Anaesthesiologica Scandinavica. 2009; 53(2):227–35. [DOI: 10.1093/bja/aen215]. [PubMed: 19076108]
- Mease 2008 {published data only} . Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. The Journal of Rheumatology. 2008; 35(3):502–14. [PubMed: 18278830]
- Paech 2007 {published data only} . Paech MJ, Goy R, Chua S, Scott K, Christmas T, Doherty DA. A randomized, placebo-controlled trial of preoperative oral pregabalin for postoperative pain relief after minor gynecological surgery. Anesthesia and Analgesia. 2007; 105(5):1449–53. [DOI: 10.1213/01.ane.0000286227.13306.d7]. [PubMed: 17959981]
- Richter 2005 {published data only} . Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. The Journal of Pain. 2005; 6(4):253–60. [DOI: 10.1016/ j.jpain.2004.12.007]. [PubMed: 15820913]
- Rosenstock 2004 {published data only} . Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebocontrolled trial. Pain. 2004; 110:628–38. [DOI: 10.1016/j.pain.2004.05.001]. [PubMed: 15288403]
- Sabatowski 2004 {published data only} . Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, 1008-045 Study Group. et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004; 109:26–35. [DOI: 10.1016/j.pain.2004.01.001]. [PubMed: 15082123]
- Siddall 2006 {published data only} . Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebocontrolled trial. Neurology. 2006; 67:1792–800. [PubMed: 17130411]
- Stacey 2008 {published data only} . Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. Journal of Pain. 2008; 9(11):1006–17. [DOI: 10.1016/j.pain.2008.05.014]. [PubMed: 18640074]
- Tolle 2008 {published data only} . Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP
 Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. European Journal of Pain. 2008; 12(2):203–13. [DOI: 10.1016/j.ejpain. 2007.05.003]. [PubMed: 17631400]
- van Seventer 2006 {published data only} . van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Current Medical Research and Opinion. 2006; 22(2):375–84. [PubMed: 16466610]
- Vranken 2008 {published data only} . Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008; 136(1-2):150–7. [DOI: 10.1016/j.pain.2007.06.033]. [PubMed: 17703885]

References to studies excluded from this review

Reuben 2006 {published data only} . Reuben SS, Buvanendran A, Kroin JS, Raghunathan K. The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery.
Anesthesia and Analgesia. 2006; 103(5):1271–7. [DOI: 10.1213/01.ane.0000237279.08847.2d].
[PubMed: 17056968]

Additional references

- Attal 2006 . Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, EFNS Task Force. et al. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology. 2006; 13:1153–69. [DOI: 10.1111/j.1468-1331.2006.01511.x]. [PubMed: 17038030]
- Dahl 2004 . Dahl JB, Mathiesen O, Miniche S. 'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiologica Scandinavica. 2004; 48(9):1130–6. [DOI: 10.1111/j. 1399-6576.2004.00484.x]. [PubMed: 15352959]
- Dworkin 2008 Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. The Journal of Pain. 2008; 9(2):105–21. [DOI: 10.1016/j.jpain. 2007.09.005]. [PubMed: 18055266]
- Edwards 1999 . Edwards JE, McQuay HJ, Moore RA, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. Journal of Pain and Symptom Management. 1999; 18(6):427–37. [DOI: 10.1016/S0885-3924(99)00093-7]. [PubMed: 10641469]
- Edwards 2004 . Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain. 2004; 111(3):286–96. [DOI: 10.1016/j.pain.2004.07.004]. [PubMed: 15363872]
- EMC 2007 . Electronic Medicines Compendium. [Accessed 1 September 2007] http:// emc.medicines.org.uk/http://emc.medicines.org.uk/
- Fricker 2004 . Fricker, J. [1 September 2007, 2004] Pain in Europe. A report. Accessed on line at www.painineurope.com
- Hempenstall 2005 . Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLOS Medicine. 2005; 2(7):e164. [PubMed: 16013891]
- Ioannidis 2001 . Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. The Journal of the American Medical Association. 2001; 285(4): 437–43.
- Jacox 1994 . Jacox, A.; Carr, DB.; Payne, R.; Agency for Health Care Policy and Research. Management of cancer pain. Clinical Practice Guideline No. 9. US Department of Health and Human Services, Public Health Service; Rockville, Maryland: 1994.
- Jadad 1996 . Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials. 1996; 17(1):1–12. [PubMed: 8721797]
- Loke 2001 . Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials a systematic survey. BMC Clinical Pharmacology. 2001; 1:3. [DOI: 10.1186/1472-6904-1-3]. [PubMed: 11591227]
- McQuay 1995 . McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995; 311:1047–52. [PubMed: 7580659]
- McQuay 1998 . McQuay, H.; Moore, R. An evidence-based resource for pain relief. Oxford University Press; Oxford: 1998.
- McQuay 2008a . McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain. 2008; 135(3):217–20. [DOI: 10.1016/j.pain.2008.01.014]. [PubMed: 18258369]
- McQuay 2008b . McQuay HJ, Poon KH, Derry S, Moore RA. Acute pain: combination treatments and how we measure their efficacy. British Journal of Anaesthesia. 2008; 101(1):69–76. [DOI: 10.1093/bja/aen108]. [PubMed: 18503059]
- Moher 1999 . Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999; 354:1896–900. [PubMed: 10584742]
- Monks 1994 . Monks, R. Psychotropic drugs. In: Wall, PD.; Melzack, R., editors. Textbook of Pain. Churchill Livingstone: 1994. p. 963-89.

- Moore 1998 . Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everythinglarge amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998; 78(3):209–16. [DOI: 10.1016/ S0304-3959(98)00140-7]. [PubMed: 9870574]
- Moore 2005 . Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain. 2005; 116(3):322– 31. [DOI: 10.1016/j.pain.2005.05.001]. [PubMed: 15979792]
- Moore 2008 . Moore, RA.; Barden, J.; Derry, S.; McQuay, HJ. Managing potential publication bias. In: McQuay, HJ.; Kalso, E.; Moore, RA., editors. Systematic reviews in pain research: methodology refined. IASP Press; Seattle: 2008. p. 15-23.[ISBN: 978–0–931092–69–5]
- Moore 2009 . Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases. Apr 12.2009 [Epub ahead of print]. [DOI: 10.1136/ard.2009.107805].
- Moulin 2007 . Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Canadian Pain Society. et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Research & Management: The Journal of the Canadian Pain Society. 2007; 12(1):13–21.
- Rappaport 1994 . Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self-sustaining discharge in the trigeminal ganglion. Pain. 1994; 56:127–38. [PubMed: 8008402]
- Straube 2008 . Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology. 2008; 66(2):266–75. [DOI: 10.1111/j.1365-2125.2008.03200.x]. [PubMed: 18489611]
- Sultan 2008 . Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology. 2008; 8:29. [DOI: 10.1186/1471-2377-8-29]. [PubMed: 18673529]
- Tiippana 2007 . Tiippana EM, Hamunen K, Kontinen VK, Kalso E. Do surgical patients benefit from perioperative gabapentin/pregabalin? A systematic review of efficacy and safety. Anesthesia and Analgesia. 2007; 104(6):1545–56. [PubMed: 17513656]
- Wiffen 2005a . Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; (3) [DOI: 10.1002/14651858.CD001133.pub2].
- Wiffen 2005b . Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; (3) [DOI: 10.1002/14651858.CD005451].
- Wiffen 2005c . Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005; (3) [DOI: 10.1002/14651858.CD005452].
- Zaccara 2008 . Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure. 2008; 17(5):405–21. [DOI: 10.1016/j.seizure.2007.12.003]. [PubMed: 18262442]
- * Indicates the major publication for the study

Europe PMC Funders Author Manuscripts

PLAIN LANGUAGE SUMMARY

Pregabalin for acute and chronic pain in adults

Pregabalin relieves pain caused by damage to nerves, either from injury or disease. Antiepileptics (such as pregabalin) are medicines used for treating epilepsy, but are also effective for treating pain. The type of pain that responds well to pregabalin treatment is neuropathic pain (pain caused by damage to nerves). This includes postherpetic neuralgia (persistent pain in an area previously affected by shingles) and painful complications of diabetes, as well as fibromyalgia. Only a minority of patients with these types of pain will have a substantial benefit, and somewhat more will have moderate benefit. With pregabalin daily doses of 300 mg to 600 mg, the patient global impression of change rating of much or very much improved was about 35% in postherpetic neuralgia, 50% in painful diabetic neuropathy, and 40% in fibromyalgia. There is no evidence that pregabalin is effective in acute conditions where pain is already established, and in chronic conditions in which nerve damage is not the prime source of the pain, such as arthritis.




Figure 1. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies

	Adequate sequence generation?	Allocation concealment?	Blinding?
A0081071 2007	?	?	•
A0081100 2008	?	?	•
A0081120 2008	?	?	?
Agarwal 2008	•	•	•
Arezzo 2008	•	•	•
Arnold 2008	•	•	?
Crofford 2005	•	?	?
Crofford 2008	?	•	•
Dworkin 2003	•	•	•
Freynhagen 2005	?	?	•
Hill 2001	?	?	?
Jokela 2008a	•	•	•
Jokela 2008b	•	•	•
Lesser 2004	•	•	•
Mathiesen 2009	•	•	•
Mease 2008	?	?	?
Paech 2007	•	•	•
Richter 2005	•	?	•
Rosenstock 2004	•	?	?
Sabatowski 2004	•	?	•
Siddall 2006	•	?	•
Stacey 2008	?	?	•
Tolle 2008	?	?	?
van Seventer 2006	?	?	?
Vranken 2008	•	?	•

Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study




Figure 3. Percentage of participants with at least 50% pain relief with placebo or four daily pregabalin doses at trial end in four painful conditions